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The most abundant bifidobacteria found in breastfed infant feces are able to metabolize human milk 
oligosaccharides (HMO), by cleaving the α-glycosidic bonds of fucoses and sialic acids, as well as the 
β-glycosidic bonds in the HMO core. The whey obtained from cow’s milk contains complex 
oligosaccharides, also called bovine milk oligosaccharides (BMO), especially 3’-sialyllactose (3’SL). 
BMO are structurally very similar to HMO and share some common properties. Because they are of 
bovine origin, Bifidobacterium crudilactis FR/62/b/3 and Bifidobacterium mongoliense FR/49/f/2, two 
bifidobacterial strains isolated from a raw cow’s milk cheese, could encode the enzymes necessary to 
digest them. In addition, the fermentation of carbohydrates by bifidobacteria could produce some 
metabolites able to modulate the virulence of intestinal pathogens. Because in vivo experimentations 
are difficult and limited by obvious ethical reasons, some in vitro digestive models have been 
developed. Among all models, the simulator of the human intestinal microbial ecosystem (SHIME®) 
represents all parts of digestive tract and seems particularly adapted to evaluate the interactions 
between the pre/probiotics and the microbiota of young children. 
 
This research was divided into three main axes:  
-Ability of B. crudilactis FR/62/b/3 and B. mongoliense FR/49/f/2 to metabolize BMO (genome 
analysis: study 2; BMO fermentation: studies 1 and 2). 
-Virulence gene expression analysis of intestinal pathogens after contact with cell-free spent media 
(CFSM; containing potential antivirulent metabolites) obtained from BMO fermentation by 
B. crudilactis FR/62/b/3 and B. mongoliense FR/49/f/2 (studies 1 and 2). 
-Challenges in a toddler SHIME® model inoculated with prebiotic (3’SL), probiotic (B. crudilactis 
FR/62/b/3), synbiotic (3’SL+B. crudilactis FR/62/b/3) and CFSM (metabolites): impact on the 
microbiota (study 3).  
 
Genome analysis revealed that B. mongoliense DSM 21395 has a more sophisticated enzymatic 
pathway for BMO digestion compared to B. crudilactis LMG 23609. B. crudilactis FR/62/b/3 and 
B. mongoliense FR/49/f/2 were able to grow on media supplemented with BMO or 3’SL as the main 
source of carbohydrates. The CFSM issued from the fermentation of 3’SL by these two bifidobacteria 
significantly down-regulated the virulence gene expression of enterohaemorrhagic Escherichia coli 
(EHEC) O157:H7 and Salmonella enterica serotype Typhimurium, respectively. Those obtained from 
fermentation of BMO (in whey) by B. mongoliense FR/49/f/2 significantly down-regulated the 
virulence gene expression of EHEC O157:H7. Finally, the synbiotic combination of 3’SL and 
B. crudilactis FR/62/b/3 tested in the toddler SHIME® model, in which specific bacterial populations 
proper to each colon are developed, tended to a bifidogenic effect. 
  
In conclusion, the glycobiome of B. mongoliense DSM 21395 seemed more adapted to BMO digestion 
to that of B. crudilactis DSM 23609. However, the synbiotic combination of 3’SL and B. crudilactis 
FR/62/b/3 led to interesting in vitro results by decreasing the virulence gene expression of intestinal 
pathogens and by having a bifidogenic effect on the microbiota implemented in the gastrointestinal 
system. In addition, the toddler SHIME® model developed in this work shares both infant and adult 
microbiota properties and seems appropriate to study the interactions between the pre/probiotics and 





Les bifidobactéries retrouvées majoritairement dans les matières fécales des enfants allaités possèdent 
un arsenal enzymatique permettant la digestion des oligosaccharides du lait maternel (HMO), en 
clivant notamment les liaisons α-glycosidiques des fucoses et acides sialiques, mais aussi les liaisons 
β-glycosidiques présentes au cœur de ces HMO. Le lactosérum contient les oligosaccharides 
complexes issus du lait de vache (BMO), et notamment le 3’-sialyllactose (3’SL). Les BMO sont 
structurellement très proches des HMO et partagent donc des propriétés communes. Parce qu’elles 
sont d’origine bovine, Bifidobacterium crudilactis FR/62/b/3 et Bifidobacterium mongoliense 
FR/49/f/2 deux bifidobacteries issues d’un fromage au lait cru de vache, sont susceptibles de posséder 
l’arsenal enzymatique nécessaire à leur digestion. De plus, la fermentation d’hydrates de carbone par 
des bifidobactéries pourrait produire des métabolites capables de moduler la virulence de pathogènes 
intestinaux. Les études in vivo étant difficiles et limitées par des raisons éthiques évidentes, des 
modèles digestifs in vitro ont été développés. Parmi tous les modèles, le simulateur de l’écosystème 
microbien intestinal humain (SHIME®) représente toutes les parties du tube digestif et semble 
particulièrement adapté à l’étude des interactions entre les pré/probiotiques et le microbiote du jeune 
enfant.  
 
Cette recherche est divisée en trois axes principaux : 
-La capacité de B. crudilactis FR/62/b/3 et B. mongoliense FR/49/f/2 à métaboliser les BMO (analyse 
du génome : étude 2 ; fermentation des BMO : études 1 et 2). 
-L’analyse de l’expression des gènes de virulence de bactéries pathogènes intestinales après contact 
avec les surnageants de culture filtrés (CFSM ; contenant des potentiels métabolites antivirulents) 
obtenus à partir de la fermentation des BMO par B. crudilactis FR/62/b/3 et B. mongoliense FR/49/f/2 
(études 1 et 2). 
-Les expérimentations dans le modèle SHIME® du jeune enfant inoculé avec un prébiotique (3’SL), un 
probiotique (B. crudilactis FR/62/b/3), un synbiotique (3’SL+B. crudilactis FR/62/b/3) et le CFSM 
(métabolites) : impact sur le microbiote (étude 3). 
 
L’analyse des génomes a révélé que B. mongoliense DSM 21395 possède un arsenal enzymatique plus 
sophistiqué et plus adapté à la digestion des BMO que celui de B. crudilactis LMG 23609. 
B. crudilactis FR/62/b/3 et B. mongoliense FR/49/f/2 était capable de croître dans un milieu 
supplémenté avec des BMO ou du 3’SL, comme source principale d’hydrates de carbone. Les 
surnageants de culture filtrés issus de la fermentation du 3’SL par B. crudilactis FR/62/b/3 et 
B. mongoliense FR/49/f/2 sous-exprimaient significativement l’expression des gènes de virulence 
d’Escherichia coli enterohémorrhagique (EHEC) O157:H7 et de Salmonella enterica serotype 
  
Typhimurium, respectivement. Ceux issus de la fermentation de BMO (contenus dans le lactosérum) 
par B. mongoliense FR/49/f/2 sous-régulaient significativement l’expression des gènes de virulence 
d’EHEC O157:H7. Finalement, la combinaison synbiotique du 3’SL et de B. crudilactis FR/62/b/3 
testée à l’aide du modèle SHIME® du jeune enfant, dans lequel des populations bactériennes propres à 
chaque colon se sont développées, tendait vers un effet bifidogénique. 
 
En conclusion, le glycobiome de B. mongoliense DSM 21395 semblait plus adaptée à la digestion des 
BMO que celui de B. crudilactis LMG 23609. Cependant, la combinaison synbiotique du 3’SL et de 
B. crudilactis FR/62/b/3 a montré d’intéressant résultats in vitro en diminuant l’expression des gènes 
de virulence de bactéries pathogènes intestinales et en ayant un effet bifidogenique sur le microbiote 
implanté dans le modèle digestif. De plus, le modèle SHIME® du jeune enfant développé pour cette 
étude, partage des propriétés de l’adulte et de l’enfant et semble approprié à l’étude des interactions 
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According to the Food and Agriculture Organization (FAO) and the World Health Organization 
(WHO), an exclusive breastfeeding is recommended until the age of 6 months-old and can be 
continued with appropriate complementary food up to 2 years-old (Ballard and Morrow, 2013). 
However, when breastfeeding is not (or no longer) possible, infants may be fed with commercial 
formulas containing prebiotics or probiotics trying to match as much as possible the health benefits of 
human milk (Chichlowski et al., 2011). 
 
Within food or in the form of dietary supplements, probiotics are considered as microorganisms 
beneficial to health by modulating gut microbiota (Lee et al., 2018). The most commercialized strains 
belong to the genera Lactobacillus and Bifidobacterium, and, for example, they are able to prevent or 
treat digestive disorders in infants (Patel and DuPont, 2015).  
 
 Often associated with the term “probiotic”, the term “prebiotic” considers non-digestible compounds 
changing favorably the microbiota and conferring health benefits to the host (Roberfroid et al., 2010). 
Therefore, some oligosaccharides, such as fructo-oligosaccharides and galacto-oligosaccharides, are 
added to infant formula in order to favorably modulate microbiota by improving bifidobacterial 
growth, also called bifidogenic effect (Vandenplas et al., 2015).  
 
Interestingly, the combination of both prebiotic and probiotic, called “synbiotic”, provides combined 
benefits by improving the survival and activity of probiotic strains. Therefore, a supplementation with 
bifidobacterial strains associated with prebiotic oligosaccharides in formula could positively 
contribute to the neonate, infant or child health (Patel and DuPont, 2015) and impact, at longer term, 
adult health (Milani et al., 2017). 
 
Beneficial effects of breastmilk are notably due to its high quantities of human milk oligosaccharides 
(HMO). These complex prebiotics are metabolized by bifidobacteria associated to breastfed child 
microbiota, such as Bifidobacterium bifidum or Bifidobacterium longum subsp. infantis, able to 
synthetize galactosidases, hexosaminidases, sialidases or fucosidases (Arboleya et al., 2016; Milani et 
al., 2017). Because of their structural similarity, bovine milk oligosaccharides (BMO) could be 
considered as analogous to HMO and share common properties (Chichlowski et al., 2011). 
Bifidobacterium crudilactis FR/62/b/3 and Bifidobacterium mongoliense FR/49/f/2, two strains of 
bovine origin, could easily consume them and secrete enzymes necessary to their degradation (Milani 
et al., 2015). In addition, the synbiotic combination of BMO with Bifidobacterium animalis subsp. 
lactis added to commercial formulations is already known for its strong bifidogenic effect in infant 
microbiota (Cooper et al., 2016) and fermentation of oligosaccharides by bifidobacteria could also 
 2 
produce some antivirulent metabolites against intestinal pathogenic bacteria (Bayoumi and Griffiths, 
2012; Mundi et al., 2013). Therefore, supplementation of BMO in formulas would make powder milk 
closer to maternal milk and fermentation of BMO by bifidobacteria of bovine origin could contribute 
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The gut microbiota 
 
A world inside us 
 
According to Cani and Delzenne (2011), we are only 10% human and composed of 90% with 
microbes. With up to 2,000 species, our digestive microbiota contains 1014 bacterial cells, which 
represents 10 times the number of cells constituting the human body. However, these estimates may 
vary depending on whether or not red blood cells are considered. Finally, Sender et al. (2015) have 
revised the number of human versus microbial cells and obtained a ratio 1:1. At least 160 species, 
issued from a consortium of 1,000 to 1,150 prevalent bacterial species, are present in each individual 
and largely shared.  A core of microbial species can be common to each individual, but with very 
variable abundances (Qin et al., 2010; Nova et al., 2016).  
 
Ninety percent of adult microbiota species belong to the phyla Firmicutes and Bacteroidetes, followed 
by Actinobacteria and Proteobacteria (Cani and Delzenne, 2011; Ottman et al., 2012). However, at 
species and strain taxonomic level, the diversity is very high in adult life, and is characterized by an 
important interindividual variability (Arboleya et al., 2016). 
 
In term of the function of associated microbial species and their functional potential, the intestinal 
community can be categorized in three groups called “enterotypes”: enterotype I is dominated by the 
genus Bacteroides, enterotype II by the genus Prevotella and enterotype III, the most frequently 
encountered, by the genus Ruminococcus (Arumugam et al., 2011). In addition, enterotype I could be 
associated with individuals who consume more fibers and enterotype II with individuals who consume 
more proteins and fat (De Filippo et al., 2010). However, this enterotype concept is controversial. 
Even if the microbial composition is stable in the short and long term, some environmental changes 
such as diet can impact species abundances, and an individual can harbor different enterotypes over 
time (Rajilić-Stojanović et al., 2012). In addition, enterotypes may not exist at all (Yang et al., 2012) 
and their number varies when different methods are employed even on the same samples (Cheng and 
Ning, 2019). 
 
The adult microbiota is relatively stable, and a core of 40 bacterial species, corresponding to 75% of 
the microbiota in term of abundance, persists for at least 1 year. Over 5 years, 60% of all bacterial 
strains are able to persist in individuals (Donaldson et al., 2016). The microbial ecosystems are unique 
and specific to their host and, despite highly different bacterial compositions, they can share the same 
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metabolic functions. Therefore, instead of sharing a core microbiome, it would be better to consider 
that we share a functional core microbiome (Lozupone et al., 2012). 
 
The composition of the gut microbiota is influenced by early colonization, host genetics, lifestyle, 
health/disease and medication, but diet is decisive in shaping the microbiota (Graf et al., 2015). In 
addition, the early colonizers have a crucial role in long-term establishment of the microbiota 
(Donaldson et al., 2016). Diet modifications can contribute to 57% of variations in microbiota, while 
genetics can contribute to only 12% (Baothman et al. 2016). Interestingly, only 17% of genes are 
shared between the feces of genetically identical twins (Turnbaugh et al., 2010).  
 
A diversified microbial composition is associated with a healthy microbiota, also called eubiosis. The 
opposite is dysbiosis, characterized by a poor microbial diversity with an imbalance between 
commensal and pathogenic bacteria. Dysbiosis can be associated with metabolic and inflammatory 
disease such as obesity, colorectal cancer and inflammatory bowel disease (IBD) encompassing 
ulcerative colitis (UC) and Crohn’s disease (CD). For example, despite the same diet, obese or type 2 
diabetes patients have fewer Bacteroidetes and more Firmicutes than lean patients. Faecalibacterium 
prausnitzii is less abundant in patients suffering from CD, and IBD is associated with a reduction of 
Firmicutes and Bacteroidetes with an increase of Proteobacteria (Belizário and Napolitano, 2015; 
Castaner et al., 2018). In addition, a dysbiosis state is also known to have a negative impact on host 
wellbeing (Guinane and Cotter, 2013).  
 
It is however important to specify that a “high gut microbial richness does not per se imply a healthy 
gut microbial ecosystem”. For example, the colonic transit time in humans influences microbial 
composition, diversity and metabolism, a long colonic transit time resulting in higher richness and 
protein catabolism (Roager et al., 2016). 
 
During antibiotic treatment, fecal diversity is lower but is restored after a recovery period. Some 
disappeared species are recovered about 1 month after the end of the treatment. However, the 
microbial composition will be permanently affected, and some bacterial groups will not reappear even 
after several years. The impact of antibiotic treatments depends on the host but can lead to harmful 
long-term effects on health (Lozupone et al., 2012; Rajilić-Stojanović et al., 2012; Graf et al., 2015; 
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Microbiota composition depends on digestive localization 
 
The composition of the bacterial community is influenced by physiological variations along the length 
of the small intestine and colons. In adults, the small intestine is more acidic and contains a high level 
of oxygen. This proximal gastrointestinal part is dominated by facultative anaerobic and bile acidity-
tolerant bacteria, such as the Lactobacillaceae and Enterobacteriaceae families (Donaldson et al., 
2016). Lactobacillus spp. is one the most predominant species found in the small intestine, but the 
Streptococcus and Veillonella genera are also very abundant (Figure 1) (Rajilić-Stojanović and de 
Vos, 2014). The colons exhibit a high diversity and are dominated by the Bacteroidaceae, 
Prevotellaceae, Rikenellaceae, Lachnospiraceae and Ruminococcaceae families (Figure 1) 
(Donaldson et al., 2016). Although, their proportions vary with age, diet and geographical location, 
the Bacteroides, Prevotella and Ruminococcus genera are the most abundant and associated to the 
enterotype concept as previously explained (Hillman et al., 2017). In addition, the composition of 
bacteria harbored in the mucus layer is different to that of the luminal microbiota composition and is 
dominated by butyrate-producing clostridia (Clostridium clusters IV and XIVa) and by lactobacilli 
(Venema and Van den Abbeele, 2013) (Figure 1). However, several species originally designated as 
belonging to Clostridium clusters XIVa and IV have been reclassified in new genera, meaning that 
Clostridium clusters IV and XIVa are now classified in the Ruminococcaceae and Lachnospiraceae 
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Figure 1 Main microbial populations found in lumen and mucus layer of the human gastrointestinal 
tract (adapted from Venema and Van den Abbeele, 2013; Rajilić-Stojanović and de Vos, 2014; 
Donaldson et al., 2016; Hillman et al., 2017). 
The dominant bacterial families of the small intestine and colon reflect physiological differences along the length of the gut. A gradient of 
oxygen and pH limits the bacterial density in the small intestine community, whereas the colon carries high bacterial loads. 
 
The human colon is divided into three parts: the ascending, transverse and descending colons. The 
microbial colonization process depends also on colon region specificity. The ascending colon is the 
main site of carbohydrate fermentation and the corresponding bacteria, such as Bacteroides spp. and 
Eubacterium spp, are typically involved in carbohydrate fermentation. Akkermansia muciniphila, a 
mucin degrader, is preferentially present in the transverse and descending colons. However, the mucin 
degradation process is more important in the transverse colon, where Bacteroides species, also potent 
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The role of the microbiota in host defense 
 
In addition to facilitating digestion and modulating the immunity, the microbiota is able to defend the 
host against pathogens by resisting colonization and by fermentation of non-digestible carbohydrates. 
The end-products of this fermentation, occurring mostly in the proximal colon, are short-chain fatty 
acids (SCFA) which include acetate, propionate and butyrate. In the adult colon, the concentrations of 
acetate, propionate and butyrate reach 50 to 150 mM and follow the ratio 3:1:1 (Hosseini et al., 2011; 
Rivière et al., 2016). The SCFA and lactic acids produced by microbiota inhibit the growth and 
colonization by pathogenic bacteria by creating a restrictive environment with a lower pH (Asahara et 
al., 2004). 
 
The majority of enteric bacteria produce acetate, the most abundant SCFA. Propionate is mainly 
produced by the Bacteroides using the succinate pathway, while butyrate is mainly produced by the 
Firmicutes. Bifidobacteria, by producing acetate and lactate, contribute to butyrate production using a 
cross-feeding mechanism (Rios-Covian et al., 2016). Propionate is notably considered beneficial for 
health because of its anti-inflammatory effect (Reichardt et al., 2014) but butyrate is the most studied 
SCFA because of its beneficial effects on health especially against colorectal cancer and inflammation 
(Sannasiddappa et al., 2011). The butyrate also constitutes the principal energy source for colonocytes 
and contributes to the cell growth and differentiation (Macfarlane and Macfarlane, 2011). 
 
More than 95% of SCFA produced are absorbed by the gut, contributing from 5% to 15% of the total 
caloric requirements of humans. Therefore, metabolite measurements in the feces do not reflect the 
real carbohydrate fermentation, and the in situ production of total colonic SCFA is difficult to 
determine (Hamer et al., 2008; Macfarlane and Macfarlane, 2011). 
 
Prebiotics, probiotics and synbiotics in host defense 
 
As mentioned previously, probiotics are defined as “living microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host” (FAO/WHO, 2001). A prebiotic is a selectively 
fermented ingredient allowing specific changes both in composition and/or activity in the 
gastrointestinal microbiota, and confering benefits upon host well-being and health. The synergistic 
combinations of pro- and prebiotics are called synbiotics. Prebiotics, probiotics and synbiotics have 
the same objective: allow the multiplication of healthy bacteria in intestine, which can be performed 
by adding either health-promoting bacteria or undigestible but fermentable prebiotic carbohydrates (de 
Vrese and Schrezenmeir, 2008). 
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Because of their structural composition, prebiotics reach the colons where they are fermented by 
specific bacteria into SCFA and lactic acid. Prebiotics, used as energy substrates by intestinal bacteria, 
allow an increase in SCFA concentrations and modify colonic fermentation metabolism. The 
bifidogenic effect is one of the main criteria for prebiotic classification and use of prebiotics is 
interesting for preventing food allergy and reducing atopic eczema, as well as the recurrence of 
Clostridium difficile-associated diarrhea (Patel and DuPont, 2015). These last years, successful 
attempts have been reported to make infant formula more breastmilk like by addition of fructo- (FOS) 
and galacto-oligosaccharides (GOS). This supplementation to conventional infant formula in 
quantities from 0.4 to 1 g/100 mL for feeding periods from 3 to 12 weeks results in feces 
characteristics similar to those of breast-fed babies, and in a significant increase in bifidobacteria in 
the fecal microbiota from 20% to around 60% (de Vrese and Schrezenmeir, 2008). In addition, a GOS 
prebiotic-supplemented formula promotes bifidobacteria and lactobacilli growth and inhibits clostridia 
growth, resulting in a significantly lower presence of colic (Giovannini et al., 2014). 
 
The use of probiotics, such as bifidobacteria and lactobacilli, in the intestinal environment decreases 
pathogen growth by direct competition and enhances mucosal barrier integrity by their ability to 
adhere to the epithelium and mucus. Probiotics are able to metabolize complex carbohydrates and 
therefore produce lactic acid and SCFA in higher quantities. In addition, several lactobacilli are known 
to produce bacteriocins with antimicrobial effects. The immune response may be modulated by 
probiotics via B lymphocytes and antibody production, and they are useful in the prevention and 
therapy of C. difficile infection, rotavirus diarrhea, IBD and necrotizing enterocolitis (Patel and 
DuPont, 2015). For example, the negative immune-related effects of not breastfeeding and cesarean 
delivery can be decreased by including B. animalis subsp. lactis in infant formula, resulting in 
increased concentrations of secretory, anti-rotavirus-specific and anti-poliovirus IgA (Holscher et al., 
2012). Moreover, new generation of probiotics, such as Faecalibacterium prausnitzii and 
Akkermansia muciniphila, seems promising against inflammatory diseases and obesity (Patel and 
DuPont, 2015). These strains come from human gut microbiota and may constitute an alternative to 
“classical” probiotic strategies. However, due to their stringent survival conditions, their viable 
intestinal delivery will be challenging (El Hage et al., 2017). 
 
The use of synbiotic on intestinal microbiota allows the growth of potentially protective bacteria, such 
as bifidobacteria and lactobacilli, but also the inhibition of potentially pathogenic microorganism by 
lowering the pH and by releasing SCFA (Patel and DuPont, 2015). For example, the combination of 
FOS with Lactobacillus plantarum, L. paracasei or B. bifidum is able to increase bifidobacteria and 
lactobacilli quantities and inhibits growth of pathogenic bacteria, such as Campylobacter jejuni, 
S. Enteritidis and S. Typhimurium, in vitro or in vivo in mice, piglets or humans (de Vrese and 
Schrezenmeir, 2008). In addition, a probiotic mixture containing L. acidophilus and B. lactis 
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combined with FOS is associated with a significant clinical improvement in children with atopic 
dermatitis (Gerasimov et al., 2010). Moreover, the synbiotic combination of B. lactis and FOS in 
formula decreases the incidence of constipation, regurgitation, crying and colic in formula-fed infants 




• Some microbial populations found in gut microbiota may be used as biomarkers of health 
state. For example, the presence of Bifidobacterium and Faecalibacterium genera could be 
favorable to host health. 
 
• Microbiota composition depends on digestive localization: small intestine is dominated by 
Lactobacillaceae and Enterobacteriaceae families and colons by Bacteroidaceae, 
Prevotellaceae, Rickenellaceae, Lachnospiraceae and Ruminococcaceae families. In 
addition, the ascending colon is dominated by bacteria involved in carbohydrate 
fermentation, such as Bacteroides spp. and Eubacterium spp., and the transverse and 
descending colons by bacteria involved in mucin degradation, such as 
Akkermansia muciniphila. 
 
• The production of lactic acid and SCFA (acetate, propionate and butyrate) by enteric 
bacteria exerts a protective role for host health, especially by lowering intestinal pH. 
 
• The use of prebiotic oligosaccharides, probiotic bifidobacteria or lactobacilli, but also their 
synbiotic combinations, contributes to the heath of gut microbiota and ultimately to the 
health of its host. 







Chapter 1  Literature review 
13 
The infant gut microbiota 
 
The microbiota composition changes over the years 
 
The infant gut microbiota harbors a low diversity and its structure is unstable but highly dynamic 
(Milani et al., 2017; Tanaka and Nakayama, 2017). The child microbiota evolves until 2 or 3 years 
old, becoming progressively similar to the adult microbiota (Palmer et al., 2007). 
 
For many years, scientific world thought baby were born germ free and initial microbial exposure 
started at birth with maternal vaginal or skin microbiota. However, many evidences cast doubt of this 
hypothesis and suggest that a bacterial presence already exists in amniotic fluid, umbilical cord blood, 
meconium, and placental and fetal membranes. In addition, the placenta could harbor a specific 
microbiome, mainly composed of Proteobacteria and close to oral microbiota, meaning that intestines 
of neonates are not sterile at birth. Finally, microbial exposure could start before delivery, and the first 
colonizers could derive from the maternal placenta microbiota (Hu et al., 2013; Aagaard et al., 2014). 
However, a recent contradictory study suggested that human placenta does not have a microbiome and 
this bacterial presence in placenta could be attributed to laboratory contamination or transfer during 
delivery (de Goffau et al., 2019). 
 
The first colonizers are anaerobic facultative bacteria such as Staphylococcus spp., Streptococcus spp. 
(phylum Firmicutes) and the Enterobacteriaceae family (phylum Proteobacteria). Then, anaerobic 
organisms such as Bifidobacterium spp. (phylum Actinobacteria), Clostridium spp. (phylum 
Firmicutes) and Bacteroides spp. (phylum Bacteroidetes) become predominant (Bezirtzoglou et al., 
2011).  
 
Therefore, feces from the first days of life, including meconium, are mainly composed of Firmicutes 
(Figure 2), and Proteobacteria are more represented than Bacteroidetes (Koenig et al., 2011; Nuriel-
Ohayon et al., 2016). Gradually, the Firmicutes proportion decreases and, finally, the 4-months old 
infant microbiota is dominated by Actinobacteria and Proteobacteria. At around 1 year old, the child 
microbiota becomes more similar to the adult microbiota: the phyla Firmicutes and Bacteroidetes 
make up the majority, and the proportion of Actinobacteria decreases (Figure 2) (Koenig et al., 2011; 
Guinane and Cotter, 2013; Milani et al., 2017). 
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Figure 2 Proportions of key phyla of the human microbiota composition at different stages of life 
(adapted from Claesson et al., 2011; Koenig et al., 2011; Ottman et al., 2012). 
 
In the adult microbiota, the Firmicutes and Bacteroidetes phyla represent 90% of the total population, 
with Firmicutes as the most abundant (Figure 2) (Qin et al., 2010). 
 
The gut microbiota of people over 65 years old is also different from that of young adults (Figure 2). 
The Bacteroidetes phylum becomes dominant (Guinane and Cotter, 2013) and phylum abundances can 
change to a dysbiosis state observed in the case of disease (Maynard and Weinkove, 2018). 
 
Major factors influencing the infant gut microbiota composition 
 
The mode of delivery, type of feeding and antibiotic treatments are determining factors in the 
development and maturation of the infant gut microbiota. The maternal diet, mother’s age, family 
genetics and environment, such as family lifestyle and geographical location, seem to have little 
impact (Milani et al., 2017). 
 
Mode of delivery 
Vaginally delivered infants are colonized by vaginally associated microbes such as Lactobacillus and 
Prevotella. Caesarean section (C-section)-delivered infants are colonized by microorganisms issued 
from maternal skin or the hospital environment: Proteobacteria and Firmicutes phyla are predominant 
and Actinobacteria (including bifidobacteria) appears only at day 7 to 15. In addition, the microbiota 
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complexity is reduced, with more Clostridium sensu stricto (cluster I) and C. difficile and with less 
Bifidobacterium and Bacteroides. Although differences between C-section- and vaginally delivery 
infants decrease after 4 months and disappear after 12 months, some differences may be detected until 
the age of 7 and may have an impact on health once adult (Nuriel-Ohayon et al., 2016; Milani et al., 
2017). 
 
Mode of feeding 
The infant microbiota is highly influenced by alimentation (Guinane and Cotter, 2013). Breast milk, 
rich in complex human milk oligosaccharides (HMO), improves the growth of bifidobacteria mainly 
represented by B. longum subsp. infantis or B. bifidum (Di Gioia et al., 2014). Breastfed infants also 
harbor higher levels of lactobacilli and lower levels of potential pathogens (Milani et al., 2017). The 
simple oligosaccharides (fructo-oligosaccharides, galacto-oligosaccharides or inulin) added to the 
formula of formula-fed children are less bifidogenic (Di Gioia et al., 2014). In addition, the gut 
microbiota of formula-fed children is more diversified, and Bacteroides, Clostridium and 
Enterobacteriaceae are dominant. In addition, the infants fed with formulas achieve an early 
divergence toward an adult-like microbiota composition (Younes et al., 2018). Because of these 
microbiota differences, the levels of SCFA are different in feces from breastfed versus formula-fed 
infants, this latter group harboring higher levels of propionate and butyrate (Milani et al., 2017). 
 
The core infant gut microbiota 
 
Although additional investigations have to be performed, the infant microbiota can be classified in six 
main phylogenetic groups. Group 1 is mainly composed of Enterobacteriales (Escherichia-Shigella 
spp.), group 2 of Bacteroidales (Bacteroides spp. and Prevotella) and Verrucomicrobiales, group 3 of 
Selenomonadales (Veillonella spp.) and Clostridiales (genera Pseudoflavonifractor and 
Subdoligranum and the Deltaproteobacteria Desulfovibrio), group 4 of Pasteurellales, group 5 of 
Clostridiales (Clostridium and Eubacterium) and group 6 of Clostridiales (genera Anaerostipes, 
Faecalibacterium and Ruminococcus), Lactobacillales (Enterococcus, Lactobacillus, Streptococcus) 
and Bifidobacteriales (Bifidobacterium) (Vallès et al., 2014).  
 
The impact on health of “the first 1,000 days” (Laursen et al., 2017) 
 
The weaning period increases the prevalence of species found in adults and belonging to the phyla 
Bacteroidetes and Firmicutes (Clostridium, Ruminococcus, Faecalibacterium, Roseburia and 
Anaerostipes) (Nuriel-Ohayon et al., 2016). Important changes in dietary (introduction of solid food) 
and environmental exposures and in the maturation of the immune system will strongly modulate 
infant microbiota composition. During the first year of life, the microbiome matures in function of the 
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energy sources available and a 12-months-old infant has a metagenome similar to his or her mother. 
At 4 months, microbial genes involved in sugar degradation from milk are the most abundant, while at 
12 months, the microbial genes mostly found are involved in starch or complex sugar degradation. 
Although no consensus has been found, most publications consider that microbiota diversity and 
composition are closer to those of an adult around the age of 2 or 3 years (Nuriel-Ohayon et al., 2016; 
Laursen et al., 2017; Tanaka and Nakayama, 2017). 
 
These determining years in microbiota foundation, also called the “window of opportunity”, are 
crucial and may have long-term health consequences (Nuriel-Ohayon et al., 2016, Laursen et al., 
2017). Inappropriate development of gut microbiota increases the risk of allergic diseases in 
childhood, such as atopic eczema and asthma, and, can lead to immune and metabolic disorders in 
adulthood, such as obesity and type 2 diabetes. For example, Faecalibacterium prausnitzii or the 
Bifidobacterium and Lactobacillus species are considered as “good bacteria” and their presence is 
beneficial to host health. Conversely, Enterococcus faecalis, C. difficile and Campylobacter are 





• The infant microbiota is dynamic and evolves until 2 or 3 years old. This short period, also 
called “window of opportunity”, is critical and may have long-term consequences on the 
health. 
 
• Many factors influence infant gut microbiota composition, but mode of delivery and more 
particularly mode of feeding are determining. 




History and main characteristics 
 
Tissier was the first researcher to isolate bifidobacteria from breastfed children’s feces, in 1899. 
However, they were firstly named Bacillus bifidus because of their “bifides” Y-shape and because of 
their physiology similar to that of Lactobacillus. It was necessary to wait until 1974 and the 8th edition 
of Bergey’s manual, before bifidobacteria were classified in the genus Bifidobacterium, belonging to 
the family Bifidobacteriaceae, and to the order Bifidobacteriales, one of the branches of the phylum 
Actinobacteria (Turroni et al., 2011; Di Gioia et al., 2014;, Turroni et al., 2014). 
 
Bifidobacteria are Gram-positive saccharolytic bacteria whose genome is rich in guanine and cytosine 
(G+C). The majority of bifidobacteria are strict anaerobes, but some of them, such as 
B. psychraerophilum, B. crudilactis and B. mongoliense, are microaerophilic. They present 
fermentation metabolism without gas production, are non-spore-forming and have non-motile bacteria 
(De Vuyst et al., 2013; Turroni et al., 2014). The optimal growth temperature of bifidobacterial 
species is between 37 and 41 °C. They cannot grow below 20 °C, excepted B. crudilactis, 
B. mongoliense and B. psychroaerophilum, or above 46 °C, excepted B. thermacidophilum. The 
optimal growth pH of bifidobacteria is between 6.5 and 7.0. Generally, their growth is stopped below 
4.5 and above 8.5. However, some strains, such as B. crudilactis and B. mongoliense, support acidity 
from the stomach (1.0–3.0) or fermented dairy products (4.0) (Kailasapthy and Chin, 2000; 
Delcenserie et al., 2007, 2013). 
 
This present work focuses on bifidobacteria as one of the dominant members of the infant gut 
microbiota, but Bifidobacterium species are widely distributed among different ecological niches. The 
genus Bifidobacterium is distributed in six ecological niches: nonhuman mammals, the human 
intestine, the oral cavity, social insects, birds and wastewater but have also been isolated in human 
blood. These different niches are found in hosts who love maternal care, which encourages the 
transmission of bifidobacteria to their offspring (Milani et al., 2015, 2017). 
 
Some bifidobacteria may be qualified as cosmopolitan species because they are found in different 
animals, such as B. adolescentis (dairy cattle, humans, pigs, sheep, etc), B. dentium (pigs, dairy cattle, 
sheeps, horses, etc) and B. catenulatum (pigs, domestic cats, humans, domestic dogs, sheep, etc). 
Conversely, some species are highly adapted to the digestive ecology proper to an animal, such as 
B.  cuniculi in rabbit, B. gallinarum in chickens and B. pseudolongum in cows (Lamendella et al., 
Chapter 1  Literature review 
18 
2008; Delcenserie et al., 2011; Turroni et al., 2011). In humans, certain species are commonly found 
in both the adult and infant gut, such as B. pseudocatenulatum and B. longum subsp. longum 
(Thompson et al., 2018), while others are typically found in the adult gut, such as B. adolescentis and 
B. catenulatum, or in the breastfed infant gut, such as B. bifidum, B. breve and B. longum subsp. 
infantis (Turroni et al., 2018a). 
 
The carbohydrate metabolism of bifidobacteria 
 
Bifidobacteria are unable to use glycolysis because they lack the aldolase and phosphofructokinase 
owned by homofermentative lactic acid bacteria, as well as the glucose-6-phosphate dehydrogenase 
owned by heterofermentative lactic acid bacteria. However, they have a competitive advantage by 
using the bifid shunt (also called the fructose-6-phosphate phosphoketolase pathway) to degrade 
hexose monosaccharides (glucose and fructose), which provides more energy compared to other 
carbohydrate fermentative pathways (Figure 3). More ATP is produced with the bifid shunt from 
fructose and glucose, especially due to fructose-6-phosphate phosphoketolase (F6PPK). In theory, 
from two moles of hexose monosaccharides, three moles of acetate and two moles of lactate are 
produced. However, the acetate/lactate ratio of 3:2 is rarely observed because the pyruvate is 
metabolized in formate, acetate and ethanol, and this ratio is mostly determined by the formation of 
formate and ethanol. In the colon, secondary degraders, such as butyrate-producing bacteria such as 
clostridia, are able to take advantage of the lactate and acetate provided by bifidobacteria, by 


























Figure 3 Schematic representation of the fermentation of hexoses (glucose and fructose) by 
bifidobacteria through the fructose 6-phosphate phosphoketolase pathway or bifid shunt (adapted from 










The species B. animalis species harbors the smallest genome (1.9 Mbp) and B. longum subsp. infantis 
the largest (2.8 Mbp). An average of 2,012 open reading frames (ORF) are present per bifidobacteria 
genome and, logically, B. animalis subsp. lactis and B. longum subsp. infantis possess the smallest and 
the largest number of ORF, respectively (Bottacini et al., 2014). In order to adapt to their environment, 
bifidobacterial genomes perpetually evolve by gene duplication, horizontal gene transfer (HGT), gene 
loss or chromosomal rearrangements. HGT is the main mechanism allowing the introduction of novel 
genes, leading to niche-specific adaptation. This acquisition of novel genes is supported by vectors 
such as bacteriophages or plasmids (Turroni et al., 2011). 
 
Taxonomic classification of the Bifidobacterium genus 
 
The former classifications of prokaryotes were based on their phenotypic similarities. In the late 
1960s, some genome-based methods, such as DNA–DNA hybridization (DDH), were developed to 
determine genome similarities. Strains sharing DDH values with greater than 70% similarity were 
considered as belonging to the same species. Although DDH has become the gold standard for 
prokaryotic taxonomy, this method suffers from reproducibility problems and does not provide an 
accurate measure of sequences identity. Therefore, the scientific community decided to substitute the 
DDH with other methods offering a similar resolution but also allowing the construction of databases 
for the retrieval of any information. The use of the 16S rRNA gene as a marker for species 
circumscription was the most promising. However, the conservative nature of this gene means it does 
not show enough resolution at taxonomic scale, and two different species can have highly similar 
sequences and be considered as belonging to the same species (Richter and Rosselló-Móra, 2009; 
Lugli et al., 2014, 2018a).  
 
The discovery of B. crudilactis FR/62/b/3 as a new species illustrates the unreliability of a taxonomic 
classification based only on the 16S rRNA gene-based sequences (Delcenserie et al., 2007). Indeed, a 
strong similarity of 16S rRNA sequences (99.8%) is shown between the strain FR/62/b/3 and 
B. psychroaerophilum LMG21775, while low DNA–DNA relatedness is observed between their DNA 
(31%).  
 
To avoid any classification mistakes, an alternative using multiple molecular markers (housekeeping 
genes) can be used (Richter and Rosselló-Móra, 2009; Lugli et al., 2014, 2018a). For example, a 
comparative analysis of 16S rRNA gene-based sequences associated to a multigenic approach 
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involving housekeeping genes (clpC, dnaJ, xfp, dnaB, rpoC and purF) allows clustering of 
bifidobacterial species in six different phylogenetic groups: B. adolescentis, B. asteroides, B. boum, 
B. longum, B. pullorum and B. pseudolongum (Turroni et al., 2011). These six groups have also been 
validated with phylogenetic trees based on either 16S rRNA gene sequences or 23S rRNA gene 
sequences. However, bifidobacterial taxa did not occupy the same positions and were not classified in 
the same groups. The B. asteroides, B. longum, B. pullorum and B. boum groups were conserved in 
both rRNA trees, contrary to B. pseudolongum and B. longum groups. In addition to the initial six 
groups, a novel 16S/23S rRNA-based group was identified, encompassing B. minimum LMG 11595, 
B. mongoliense DSM 21395, B. psychraerophilum LMG21775 and B. crudilactis LMG 23609. 
According to the delineation of bacterial groups based on the rRNA trees, 24 nodes with bootstrap 
values greater than 70% were observed from the 16S rRNA tree and 35 nodes from the 23S rRNA 
tree. Therefore, the 23S rRNA sequence-based tree seems more reliable for phylogenetic 
discrimination of the genus Bifidobacterium than the 16S rRNA sequence-based tree (Lugli et al., 
2014). 
 
Finally, the average nucleotide identity (ANI) between a given pair of genomes seems currently the 
best alternative for a new gold standard to substitute DDH. The ANI analysis is based on pairwise 
genome comparison of all shared orthologous protein-coding genes. The resulting averages reflected 
the degree of evolutionary distance between the compared genomes, and a value of 94% identity can 
represent a DDH boundary of 70% (Richter and Rosselló-Móra, 2009). ANI values ranging from 
≤ 95% to ≤ 97% confirms a subspecies bacterial assignment, while ANI values < 95% indicates that 
bacteria belong to different species. This therefore indicates that these taxa should be considered 
separate species rather than subspecies (Lugli et al., 2014). Until recently, the genus Bifidobacterium 
encompassed 59 taxa, representing 50 species and nine subspecies. A recent ANI analysis allowed 
identification of seven new species: B. anseris sp. nov. (strain Goo31D), B. criceti sp. nov. (strain 
Ham19E), B. italicum sp. nov. (strain Rab10A), B. margollesii sp. nov. (strain Uis1B), B. parmae sp. 
nov. (strain Uis4E), B. imperatoris sp. nov. (strain Tam1G) and B. vansiderenii (strain Tam10B). In 
addition, a genome-to-genome distance calculator (GGDC) analysis, which is based on in silico DDH 
of genome-to-genome comparison, was employed to validate the ANI results (Lugli et al., 2018a, 
2018b). The three putative novel species, B. aerophilum, B. avesanii and B. ramosum proposed by 
Michelini et al. (2016) were not considered in that work because they are not yet validated by the 
International Committee on Systematic Bacteriology. 
 
Currently, whole-genome sequencing associated with bioinformatic tools allows a high degree of 
strain discrimination, very useful in phylogenetic characterization, leading to a core-genome-based 
supertree. From 55 type strains genomes corresponding to each known bifidobacterium (sub)species 
and available in the public NCBI database, 26,201 clusters of orthologous genes (COGs) have been 
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identified and correspond to the pangenome of the genus Bifidobacterium. Among this pangenome, 
262 shared COGs have been characterized and represent the core bifidobacterial genome. 
Concatenation of 236 core protein sequences was used to build a Bifidobacterium phylogenomic tree 
(Figure 4a). From the same 55 type strain genomes, a phylogenetic tree was constructed (Figure 4b). 
The use of 20 amino acid sequences in the phylogenomic tree, compared to the use of the four bases in 
the phylogenetic tree, contributes to the robustness of the method. In both trees, the seven 
phylogenetic groups previously described were identified: B. adolescentis, B. asteroides, B. bifidum, 
B. boum, B. longum, B. pseudolongum and B. pullorum. However, a comparison highlighted some 
differences, especially in B. bifidum and B. longum groups (Lugli et al., 2018a). 
 
A recent genetic marker-based multi-locus sequence analysis highlighted two novel phylogenetic 
groups including the B. psychraerophilum and B. bombi groups (Mekadim et al., 2019). The 
B. crudilactis species was classified in the B. psychraerophilum group and the B. mongoliense species 
in a separate cluster.  
 
The choice of the molecular method influences the final taxonomic classification of bifidobacterial 
species, and phylogenomic tree based on core-genome seems obviously to be the most reliable.  
Interestingly, some bifidobacterium species such as B. crudilactis and B. mongoliense appear in 
separate clusters (Figures 4a and 4b) independently of the taxonomic classification method used. 
This could be explained by the fact that those bacteria present different phenotypic abilities compared 
to other bifidobacterial species. 
 
 




Figure 4 Phylogenomic (a) and phylogenetic (b) trees of the Bifidobacterium genus (Lugli et al., 
2018a). 
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Glycobiome of the Bifidobacterium genus 
 
As mentioned above, the bifidobacterial species found in the human gut depend on the age of the host 
and are mostly influenced by food intake. This distribution of bifidobacteria throughout life is in 
accordance with their genomes, particularly with the genes involved in carbohydrate metabolism 
(carbohydrate transporters and glycoside hydrolases). For example, bifidobacteria mainly found in the 
breastfed infant microbiota possess genes involved in HMO digestion, while bifidobacteria mainly 
found in the adult microbiota contain genes involved in the metabolism of carbohydrates of food 
origin (De Vuyst et al., 2013). Twelve percent of the bifidobacteria genome is devoted to 
carbohydrates metabolism, while only 5% is devoted to protein metabolism (Sela and Mills, 2010).  
 
In the Bifidobacterium core genome, all the genes involved in the bifid shunt are present and are 
therefore shared by all the bifidobacterial species. As explained previously, the bifid shunt is the main 
competitive advantage responsible for their high ecological success. Study of the Bifidobacterium 
pangenome associated with the Carbohydrate-Active enZymes (CAZy) system, has highlighted one of 
the most important predicted enzyme arsenals for carbohydrate metabolism existing among the gut 
commensals. Indeed, the Bifidobacterium glycobiome consists of 3,385 genes encoding predicted 
CAZy, including 57 glycosyl hydrolases (GH), 13 glycosyltransferases (GT) and seven carbohydrate 
esterases (CE) families (Turroni et al., 2018a). 
 
The GH13 family, representing α-amylases, is the GH family most often observed in the 
bifidobacterial glycobiome and is involved in the breakdown of complex glycans, such as starch and 
glycogen, carbohydrates mostly found in the adult human diet. In function of host glycan breakdown, 
the bifidobacterial glycobiome encompasses GH families belonging to GH33 and GH34, representing 
exo-sialidases, GH29 and GH30, representing fucosidases and GH20, including hexosaminidase and 
lacto-N-biosidase activity. The bifidobacterial glycobiome also contains a wide set of genes encoding 
GH families GH3, GH43 and GH51, involved in the degradation of plant oligosaccharides. Three 
groups have been identified depending on the predicted GH (Table 1). The group GHP/A includes 
bifidobacteria with important array of predicted GH43, representing enzymes involved in the 
degradation of complex plant glycans such as xylans and arabinoxylans, mostly associated with a 
vegetarian or omnivorous diet. The group GHP/C includes bifidobacteria isolated from social insects, 
where the GH13 family is poorly represented. The bifidobacteria not fitting into groups GHP/A or 
GHP/C are included in group GHP/B, where GH43 and GH3 families are underrepresented (Milani et 
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    GHP/A GHP/B GHP/C 
    Bifidobacteria associated to 
    Omnivorous diet Breastfeeding Insects 





 B. longum B. infantis B. asteroides 
 B. adolescentis B. bifidum B. bohemicum 
3, 43, 51 Xylosidase Plants oligosaccharides  + - + 
13 α-amylase Complex glycans  + + - 
20 Hexosaminidase HMO   - + - 
29, 30 Fucosidase HMO   - + - 
33, 34 Sialidase HMO    - + - 
 
Table 1 Glycobiome of the genus Bifidobacterium (adapted from Milani et al., 2014, 2015; Turroni et 
al., 2018a). 
 
Bifidobacterial species found in breastfed infant microbiota, such as B. bifidum or B. longum subsp. 
infantis, are enriched in GH families able to degrade the HMO found in human milk and belonging to 
GH33 and GH20 families. According to the Milani classification, they belong to the group GHP/B 
(Table 1) (Milani et al., 2014, 2015; Turroni et al., 2018a). 
 
Bifidobacterial species found in adult microbiota, such as B. longum subsp. longum, B. adolescentis 
and B. catenulatum, are particularly adapted to an omnivorous diet and belong to the group GHP/A. In 
addition to a high abundance of GH13, their glycobiome is rich in plant-related GH families, such as 
GH3, GH43 and GH51. However, despite a low proportion of bifidobacteria in adult microbiota, the 
functional contribution provided by their glycobiome is important and sufficient to affect the gut 
physiology (Table 1) (Milani et al., 2015). 
 
Most of the identified bifidobacterial GH, such as GH3 or GH33, are supposed to be secreted. For 
example, B. bifidum encodes genes for four secreted sialidases, essential in HMO digestion, which 
correspond to an advanced genetic adaptation to the mammalian gut. In addition, this extracellular 
activity can result in the liberation of monosaccharides or simple sugars in the gut environment, 
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Bifidobacteria strategies to digest the HMO 
 
Different strategies may be elaborated by breastfed infants’ bifidobacteria to digest HMO. As we will 
see in the part dedicated to HMO, these complex glycans are built and consolidated by specific bonds, 
which are only cleaved by specific enzymes. 
 
Genome analysis of B. longum subsp. infantis ATCC 15697, highly specialized in HMO digestion, 
highlighted genetic loci containing genes that encode enzymes involved in HMO metabolism, 
encompassing α-fucosidase, α-sialidase, β-hexosaminidase and β-galactosidase, as well as enzymes 
involved in internalization of HMO, such as extracellular solute-binding proteins (SBP) and permeases 
of ATP binding cassette (ABC) transporter systems (Sela et al., 2008; Thompson et al., 2018; Turroni 
et al., 2018a). This “selfish” behaviour does not contribute to monosaccharides or oligosaccharides 
liberation, but still releases acetate and lactate, then used by butyrate-producing bacteria (Sela et al., 
2008; Turroni et al., 2018b). 
 
Genome analysis of B. bifidum PRL2010 highlighted the genetic arsenal encompassing genes 
encoding α-sialidase, α-fucosidase, β-galactosidase, N-acetylglucosaminidase (hexosaminidase), lacto-
N-biosidase and N-acetylgalactosaminidase. N-acetylgalactosaminidase is involved in the digestion of 
O-linked glycans (glycoproteins) found in mucin. Lacto-N-biosidase and α-N-acetylgalactosaminidase 
are two unique extracellular GH present in the B. bifidum genome. Lacto-N-biosidase is able to cleave 
lacto-N-tetraose (LNT) into lacto-N-biose (LNB) and lactose. LNB is internalized inside B. bifidum 
cells by an oligosaccharide binding SBP and then digested with an intracellular LNB phosphorylase. 
B. bifidum does not use fucose or sialic acid as a carbon source. This partial extracellular digestion of 
HMO contributes to cross-feeding interactions, especially with B. breve UCC2003 when they grow in 
vitro together on sialyllactose as the sole source of carbon (Duranti et al., 2015; Thompson et al., 
2018; Turroni et al., 2018b).  
 
The molecular strategies for HMO utilization of B. infantis, B. bifidum and B. breve will be 
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Bifidobacteria of bovine origin: B. crudilactis FR/62/b/3 and 
B. mongoliense FR/49/f/2 
 
 
B. crudilactis FR/62/b/3 
B. crudilactis FR/62/b/3 (GenBank accession number: AY952449) was isolated from Saint-Marcellin, 
a raw cow’s milk cheese from Vercors (France) (Figure 5). This strain was isolated by and stored at 
the food microbiology laboratory of Professor Georges Daube (ULiège). B. crudilactis was also 
deposited in the official collection at Ghent University (Belgium) under the name LMG 23609 
(reference strain) and at the Pasteur Institute (Paris, France) under the name CNCM 1-3342. Its 
applications are protected by a patent registered under the number WO 2006/122850 (Daube et al., 
2006). Its optimal growth temperature is 39 °C, with extreme temperatures ranging from 4 to 45 °C. 
Its optimal growth pH is 4.7. The G+C content is equal to 56.4 mol%, in agreement with the G+C 
content of bifidobacterial DNA, usually between 55 and 67 mol% (Delcenserie et al., 2007). 
 
  
Figure 5 Cellular morphology of B. crudilactis after Gram coloration and classical microscopy 
(personal picture) (a) and using phase-contrast photomicrography (Mattarelli and Biavati, 2018) (b). 
 
B. crudilactis FR/62/b/3 was detected in 77% of Saint-Marcellin cheeses from l’Etoile du Vercors 
after 21 days of ripening. This bifidobacterium probably contributes to organoleptic and technologic 
characteristics of dairy products and could come from an animal feces contamination (Delcenserie et 
al., 2007, 2013). The ripening temperature of 12 °C in factory confirmed the ability of this strain to 
grow along the production chain at a lower temperature than usually observed for other bifidobacteria 
and in aerobic conditions. Also, this bifidobacterium is able to resist gastric and pancreatic juices and 
bile salts, suggesting a potential capacity to survive transit in the human intestinal tract. Therefore, 
while most bifidobacteria are unable to grow at low temperature and do not tolerate oxygen, 
B. crudilactis FR/62/b/3 may be an interesting potential probiotic (Delcenserie et al., 2013). 
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According to phenotypic tests with API kits, B. crudilactis FR/62/b/3 is positive for α-galactosidase, 
β-galactosidase, α-glucosidase, β-glucosidase, arginine arylamidase, proline arylamidase, 
phenylalanine arylamidase, leucine arylamidase, tyrosine arylamidase, glycine arylamidase and 
histidine arylamidase. B. crudilactis FR/62/b/3 is negative for urease, indole production, nitrate 
reduction, arginine dihydrolase, β-galactosidase-6-phosphate, α-arabinosidase, β-glucuronidase, β-N-
acetyl-glucosaminidase, glutamic decarboxylase acid, α-fucosidase, pyroglutamic acid arylamidase 
and glutamyl arylamidase. B. crudilactis FR/62/b/3 is able to ferment galactose, glucose, fructose, 
maltose, lactose, melibiose, sucrose, raffinose and D-turanose (Delcenserie et al., 2007). 
 
Recently, B. crudilactis was also identified in ovine cheese (Bunesova et al., 2014) and in water kefir 
(Laureys and De Vuyst, 2014). However, one bifidobacterial strain, LMG 28769T, identified from a 
household water kefir fermentation process, contained a 16S rRNA gene sequence very close to that of 
B. crudilactis (97.4% similarity) as well as of B. psychroaerophilum (97.1% similarity) and was 




B. mongoliense FR/49/f/2 
One bifidobacterial strain, FR/49/f/2 (GenBank accession number: HV688665), was also isolated from 
Saint-Marcellin cheese (Figure 6). B. mongoliense was also deposited in the official collection at the 
Pasteur Institute (Paris, France) under the name CNCM 1-3713. Its applications are protected by a 
patent registered under the number WO 2009/049932 (Daube et al., 2009). This strain was 
phylogenetically identified as B. mongoliense that was initially isolated from a traditional fermented 
mare’s milk in Mongolia (Watanabe et al., 2009; Delcenserie et al., 2013). 
 
 
Figure 6 Cellular morphology of B. mongoliense obtained using phase-contrast photomicrography 
(Mattarelli and Biavati, 2018).  
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B. mongoliense FR/49/f/2 was isolated by and stored at the microbiology laboratory of Prof. Daube 
(ULiège). Its optimal growth temperature is 33 °C, with extreme temperatures ranging from 10 to 
41 °C. Its optimal growth pH is 5 and its G+C content is equal to 61.1 mol% (Delcenserie et al., 
2013). 
 
B. mongoliense FR/49/f/2 was detected in 30% of cheeses from l’Etoile du Vercors after 21 days of 
ripening. Like B. crudilactis FR/62/b/3, this bifidobacterium is able to grow at low temperature, to 
tolerate oxygen and to resist to gastric and pancreatic acids and bile salts. Therefore, B. mongoliense 
FR/49/f/2 could also be considered as a potential probiotic (Delcenserie et al., 2013). 
 
B. mongoliense strains have recently been isolated in Parmesan cheese and can transiently colonize 
the human gut, a process that can be enhanced by cow milk consumption (Milani et al., 2019). 
 
Recently, B. mongoliense was isolated in Chinese centenarians’ feces while it was not found in that of 
younger adults (Wang et al., 2015). However, this bifidobacterium presumably found in the unique 
centenarians’ microbiota, was undetectable at any age in a more recent study (Kato et al., 2017). 
 
Glycobiome analysis of B. mongoliense DSM 21395 and B. crudilactis LMG 23609 
Mucins are glycoproteins produced by the host, covering the intestinal mucosa. They are composed of 
N-acetylglucosamine, N-acetylgalactosamine and galactose, and are decorated with fucose, sialic acid 
or sulphate groups. Like B. longum subsp. infantis and B. bifidum, B. mongoliense and B. crudilactis 
are able to metabolize these host glycans, including mucins but also HMO (Milani et al., 2015). 
 
Glycobiome analysis of B. mongoliense DSM 21395 and B. crudilactis LMG 23609 categorized these 
two strains of bovine origin in the GHP/B group, which contains the bifidobacteria associated with 
breastfeeding, such as B. longum subsp. infantis and B. bifidum (Table 1). In addition, GH arsenal 
predictions showed a GH index higher for B. mongoliense DSM 21395 than for B. crudilactis LMG 
23609, suggesting a more evolved glycobiome for B. mongoliense DSM 21395. The GH index 
represents the number of GH predicted in each genome (Milani et al., 2015). 
  






• Bifidobacterium crudilactis FR/62/b/3 and Bifidobacterium mongoliense FR/49/f/2, two 
strains of bovine origin, are able to grow below 20 °C, to support stomach acidity (1.0–3.0) 
and presence of oxygen. 
 
• The taxonomic classification of B. crudilactis and B. mongoliense in separate clusters 
suggests different phenotypic abilities compared to other bifidobacterial species. 
 
• The glycobiome analysis of B. mongoliense DSM 21395 and B. crudilactis LMG 23609 
categorized these two reference strains of bovine origin in the GHP/B group, which 
contains bifidobacteria associated with breastfeeding, able to secrete galactosidases, 
hexosaminidases, sialidases or fucosidases. These enzymes are necessary to digestion of 
complex oligosaccharides found in breastmilk, called human milk oligosaccharides 
(HMO). 
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Human breast milk 
 
“Breastfed at Tiffany’s” (Hennet and Borsig, 2016) 
 
Millions of years of evolution shaped a perfect multifunctional fluid: breast milk. This beverage 
provides infants with nutrients and vitamins, as well as bioactive factors such as immunoglobulins, 
cytokines, antimicrobials proteins and oligosaccharides. These factors contribute to enhance mucosal 
immunity, to shape the gut microbiota and to stimulate body growth (Hennet and Borsig, 2016). 
 
Breast milk is not sterile 
 
Human milk contains all the nutrition factors that the infant needs. This fluid is rich in proteins and fat 
and contains several hundred types of oligosaccharide (carbohydrate). In breast milk of healthy 
women, around 50 genera and 200 bacterial species have been identified. The classical culture 
methods highlighted 103–105 colony-forming units (CFU)/mL of viable bacteria in milk from healthy 
women. The most dominant genera found include Staphylococcus, Streptococcus, Lactococcus, 
Leuconostoc, Weissella, Enterococcus, Propionibacterium, Lactobacillus and Bifidobacterium. In 
addition, qPCR analysis highlighted the high quantities of lactobacilli and bifidobacteria, two 
beneficial bacterial species (103–104 cells/mL and 102–105 cells/mL, respectively) (Nuriel-Ohayon et 
al., 2016; Li et al., 2017; Younes et al., 2018).  
 
The microbiota of breastmilk collected from Asian mothers was investigated by using a 16S rDNA 
pyrosequencing, and bifidobacteria species such as B. adolescentis, B. dentium, B. longum and 
B. stercoris were detected (Li et al., 2017). B. longum was the predominant bifidobacterium present, 
with a prevalence of 62.3% and an abundance of 0.3%. 
 
Moreover, the milk microbiome changes during lactation. Colostrum, the first milk produced at the 
end of pregnancy and rich in antibodies, is dominated by Weissella, Leuconostoc, Staphylococcus, 
Streptococcus and Lactococcus. The milk collected between 1 and 6 months after the birth contains 
mostly oral cavity-related bacteria such as Veillonella, Leptotrichia and Prevotella, probably due to 
the interaction with the infant oral microbiome (Nuriel-Ohayon et al., 2016; Younes et al., 2018). The 
mother’s weight may influence milk composition. The milk from an obese woman exhibits lower 
diversity and different microbial composition with lower abundance of Bifidobacterium and higher 
abundances of Staphylococcus (S. aureus) and Lactobacillus compared to a normal weight mother 
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(Cabrera-Rubio et al., 2012). This dysbiosis in obese mother milk microbiota is the same as the one 
found in gut microbiota and could be due to a transfer from her gut to systemic circulation and finally 




• The human breastmilk harbors a microbiota which could be originated from infant mouth 
via a retrograde flux during sucking or from mother gut via a transfer to systemic 
circulation. 
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Human milk oligosaccharides 
 
Composition and structure 
 
After lactose (70 g/L) and lipids (40 g/L), complex oligosaccharides are the third most abundant 
component of human milk (15 g/L), followed by proteins (8 g/L) (Pacheco et al., 2015). The HMO 
concentration evolves in function of the lactation stage and can reach up to 50 g/L or more in 
colostrum (Lane et al., 2013). This diversity and abundance are unique and never seen in other 
mammals. More than 500 structures have been identified (Lane et al., 2013) but a recent study 
estimated that the total number of different neutral and acidic HMO structures exceeded 1,000 
(Ayechu-Muruzabal et al., 2018). 
 
HMO are characterized by enormous structural diversity. They can be linear or branched and are 
composed of 3 to 14 monosaccharides (Figure 7). Five monosaccharides are the building blocks of 
HMO: glucose (Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc) and 
N-acetylneuraminic acid (NeuAc). HMO are built on a lactose core (Galβ1-4Glc). In function of the 
linkage between Gal and GlcNAc, HMO are divided into type I with LNB (Galβ1-3GlcNAc) and type 
II with N-acetyllactosamine (LacNac; Galβ1-4GlcNAc). Mostly in the terminal position, Fuc or 
NeuAc, also called sialic acid, may decorate HMO (Pacheco et al., 2014). HMO are rich in type I 
oligosaccharides, and LNB is the building unit of LNT (Galβ1-3GlcNAcβ1-3Galβ1-4Glc). LacNac is 
the building unit of Lacto-N-neotetraose (LNnT; Galβ1-4GlcNAcβ1-3Galβ1-4Glc). Depending on the 
presence of sialic acid, HMO can be classified as acidic or neutral. Neutral HMO can be either 
fucosylated or non-fucosylated. Fucosylated, sialylated and non-fucosylated neutral HMO are present 
in breast milk at 35–50%, 12–14% and 42–55%, respectively. The high levels of fucosylated HMO 
and the type I predominance are considered as a specificity of human milk (Chichlowski et al., 2011; 













Figure 7 Structural diversity of HMO and corresponding glycosyl hydrolases in infant gut-associated 
bifidobacteria (adapted from Garrido et al., 2013). 
 
As mentioned previously, type 1 oligosaccharides, such as LNT, lacto-N-fucopentaose (LNFP; 
Fuc(α1–2)Gal(β1–3)GlcNAc(β1–3)Gal(β1–4)Glc) and lacto-N-difucohexaose I (LNFP I; Fuc(α1–
2)Gal(β1–3)[Fuc(α1–4)]GlcNAc(β1–3)Gal(β1–4)Glc)) are more abundant than type 2 
oligosaccharides such as LNnT. Of these two types, the most abundant oligosaccharides in HMO are 
LNT and LNnT, respectively (Chichlowski et al., 2011). 
 
Synthesis in mammary glands 
 
HMO synthesis takes place in the lactating mammary gland with specific GT, including 
galactotransferases, N-acetylglucosaminyltransferases, fucosyltransferases and sialyltransferases. Milk 
issued from different mothers does not have the same qualitative and quantitative characteristics. The 
concentrations of individual HMO change over the course of lactation, suggesting that variation of 
protective activities during breastfeeding. Moreover, the daily HMO production seems to be impacted 
by environmental exposures, such as maternal diet or medical treatment (Chichlowski et al., 2011). 
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HMO structures are linked to the Lewis Blood Group (Le) and Secretor status (Se), depending mostly 
on the expression of fucosyltransferases in mammary glands. The action of the Se gene for 
α1-2-fucosyltransferase (FUT2) attaches Fuc residues to Gal of type I HMO with α1-2 linkages. Fuc 
may also be attached by α1-4 linkage through the action of the Le gene for α1-3/4-fucosyltransferase 
(FUT3) to GlcNAc of HMO. Individuals may be classified as secretors (Se+) or non-secretors (Se–). 
Non-secretors lack a functional FUT2 enzyme and their milk contains low concentrations of 
α1-2-fucosylated HMO. In the same way, individuals may be classified as Le+ and Le–, and milk 
from an Le– woman contains low concentrations of α1-4-fucosylated HMO. Seventy percent of the 
population expresses both FUT2 and FUT3. Resulting from the combination of active or inactive 
FUT2 and FUT3, four different groups will determine the HMO profiles: Se+Le+, Se–Le+, Se+Le– 
and Se–Le– (Chichlowski et al., 2011; Pacheco et al., 2015; Milani et al., 2017).  
 
Milk issued from a Se+Le+ mother contains four dominant HMO structures: 2’-fucosyllactose (2’FL), 
LNT, LNFP and LNFP I. In addition, this milk harbors lower concentrations of undecorated and 
sialylated HMO (Thompson et al., 2018).  
 
The concentration of sialylated HMO does not seem be influenced by the Se status or the Lewis group 
of mothers. However, the milk from a Se+Le+ mother of healthy infants seems contain more sialylated 
HMO than the milk from a mother of stunted infants (Lis-Kuberka and Orczyk-Pawilowicz, 2019). 
Interestingly, the milk from preterm mothers’ harbors more sialylated HMO than the milk from full-
term mothers at most lactation stages. These oligosaccharides could contribute to the fetal brain 
development during the third trimester, after a passage through the placenta (ten Bruggencate et al., 
2014).  
 
Moreover, the HMO composition varies in function of the geographic localization. Even though the 
maternal genetic and the environmental factors are not completely understood, a recent study showed 
that the proportion of Se+ women (having a high 2’FL concentration) in the population varies from 
65% in Gambia and in Ethiopia to 98% in Peru (McGuire et al., 2017). 
 
A different status combination will determine the presence of specific fucosylated HMO in human 
milk, and indirectly the bifidobacteria population. The Se+ status is associated with a greater 
abundance of bifidobacteria. Infants fed with Se– milk present a delay in bifidobacteria colonization 
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Growth factors for bifidobacteria 
 
The human intestine does not express luminal enzymes able to cleave the α-glycosidic linkages of Fuc 
or NeuAc, or β-glycosidic linkages in the core HMO. Therefore, infants cannot degrade HMO. They 
reach the colon in an intact form and may be detected in breastfed children’s feces. Up to 1% of HMO 
are absorbed through the intestinal wall and can be detected in systemic circulation and in urine 
(Chichlowski et al., 2011). 
 
HMO do not directly nourish infants, but they enrich the microbiota with bacteria able to use them 
(Sela, 2011). The wide presence of HMO in breast milk explains the abundance of Bifidobacterium 
species in the breastfed infant microbiota, where they can represent up to 90% of the microbiome 
(Thompson et al., 2018). Because of their structural complexity, few bacteria express the enzymes 
necessary to cleave α- and β-bonds. Also, even though HMO are considered as bifidogenic, not all 
bifidobacteria possess all the enzymatic machinery to degrade them. Some species associated with the 
breastfed infant microbiota, such as B. infantis and B. bifidum, are able to metabolize a wide variety of 
HMO, with various degrees of polymerization. Conversely, bifidobacteria associated with the adult 
microbiota, such as B. adolescentis, are unable to metabolize these complex oligosaccharides (Pacheco 
et al., 2015; Thompson et al., 2018). Interestingly, some Lactobacillus (L. casei) and Bacteroides 
(B. frangilis and B. vulgatus) species are known to also consume HMO efficiently (Marcobal et al., 
2010; Bidart et al., 2014) 
 
Most bifidobacteria only cleave and metabolize specific monosaccharides of the complex HMO 
molecules. Through cross-feeding activities, the microbial population works together to digest entire 
HMO by successive degradations. As explained previously, B. longum subsp. infantis possesses the 
full HMO-degrading machinery to metabolize HMO structures intracellularly. This is evident from an 
overabundance of Family 1 SBP, part of the ABC transporters for oligosaccharides, and intracellular 
GH: α-fucosidases, α-sialidases, β-galactosidases and β-hexosaminidases (Table 1). These GH 
releases monosaccharides into the cytoplasm, which contributes to the formation of high quantities of 
acetate and lactate using the bifid shunt. These SCFA play a crucial role in intestinal physiology and 
against pathogen colonization (Thompson et al., 2018). 
 
Like B. infantis, B. bifidum is able to metabolize fucosylated and sialylated HMO and secretes 
extracellular α-fucosidases and α-sialidases. However, Fuc and NeuAc are not used as a carbon source 
by the bacteria and are available for other potential bacteria. B. bifidum harbors an extracellular lacto-
N-biosidase cleaving LNT in Lactose (Lac) and LNB. Then, LNB is internalized by a GNB/LNB 
transporter and degraded intracellularly with an LNB phosphorylase (Figure 8b). Type 2 HMO, such 
as LNnT, are sequentially and extracellularly degraded by a β-galactosidase and a 
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β-N-acetylglucosaminidase (hexosaminidase) to liberate Gal, GlcNAc and Lac. These 
monosaccharides and disaccharides are internalized into the bacteria to integrate the different 
metabolic pathways (Figure 8b) (Sakurama et al., 2013; Thompson et al., 2018; Zúñiga et al., 2018). 
 
Contrary to that by B. infantis, HMO degradation by B. bifidum results in monosaccharide availability 
and contributes to the cross-feeding mechanism. B. breve is able to digest sialic acid released by 
B. bifidum digestion (Pacheco et al., 2015), as well as LNT and LNnT with mechanisms close to those 
previously described for B. infantis and B. bifidum. This bifidobacterium contains α-fucosidases and 
α-sialidases but does not seem able to digest 2’FL, 3’-fucosyllactose (3’FL), 6’-sialyllactose (6’SL) or 
3’-sialyllactose (3’SL) (Figure 8b) (Thompson et al., 2018). 
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Figure 8 Representation of the major molecular strategies in infant-associated bifidobacteria for HMO 
utilization: B. infantis (a) and B. bifidum and B. breve (b) (adapted from Thompson et al., 2018; 
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Beneficial effects of HMO 
 
Prebiotic effect 
As explained previously, HMO enhance the growth of specific bacterial strains able to metabolize 
them, such as bifidobacteria. In addition, pathogens are less able to digest HMO, which contributes to 
prevent their development (Ayechu-Muruzabal et al., 2018). 
 
Inhibition of bacteria and viruses 
To colonize a host and lead to a disease, pathogens have to adhere to the intestinal wall.  In addition to 
a prebiotic effect, HMO allow direct blockage of viral and bacterial microorganisms by binding to 
epithelial surface receptors and by blocking the access of pathogens. Also, HMO are able to act as 
soluble receptors for viruses, such as HIV or rotavirus, and bacteria, such as Vibrio cholerae or 
enteropathogenic E. coli. Pathogen colonization can therefore be prevented by natural excretion in 
feces. Because of a large diversity in HMO structure, many decoys strategies may exist. For example, 
binding of Campylobacter jejuni to intestinal cells is impeded by fucosylated HMO, while sialylated 
HMO obstruct E. coli adhesion to enterocytes (Smilowitz et al., 2014; Hennet and Borsig, 2016; 
Ayechu-Muruzabal et al., 2018). 
 
Mucosal barrier modulation and maturation 
Bifidobacterial abundance leads to a lower gastrointestinal pH through the production of SCFA, 
especially acetate. This environmental acidification supports the function of the intestinal barrier and 
positively influences its maturation. HMO are also able to increase the differentiation of intestinal 
epithelial cells and promote mucosal barrier maturation by direct interaction between the glycans 
present at the surface and the dendritic cells (Smilowitz et al., 2014; Ayechu-Muruzabal et al., 2018). 
 
Effects on immune function and modulation of pathogen recognition 
HMO modulate the receptors involved in microbe recognition such as toll-like receptors. Also, 
dendritic cells exposed to HMO influence T cell differentiation and T cell–B cell interactions in 
secondary lymphoid organs (Ayechu-Muruzabal et al., 2018). 
 
Cerebral development  
Because some HMO contain sialic acid found in brain gangliosides, they also contribute to the 
cerebral and cognitive development of infants (Wu et al., 2011; Boquien, 2018). Interestingly, a 
supplementation with sialylated oligosaccharides during lactation seemed improve learning and 
memory in adult rats (Oliveros et al., 2018) 
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Unfortunately, all these in vitro results do not permit a full understanding of the protective mechanism 
of human breast milk against infant infections. However, the Se status of the mother, by shaping a 
complex mixture of HMO in breast milk, might be able to influence the protection against a specific 
infection. In addition, only few in vivo studies have been carried out, but they showed that HMO are 
susceptible to reduce harmful interactions with Salmonella, Shigella, Vibrio cholerae, 
enterohemorrhagic E. coli, polioviruses, rotavirus and respiratory syncytial virus in infants (Ayechu-




• The human milk oligosaccharides (HMO) are the third components of the human 
breastmilk.  
 
• HMO are synthetized in mammary glands. Their complex structure, which encompasses 
until five different monosaccharides, allows them to reach colon in intact form.  
 
• Some bifidobacteria associated to breastfed infant microbiota, such as 
Bifidobacterium bifidum or Bifidobacterium longum subsp. infantis, are able to secrete the 
enzymes necessary to digest them: galactosidases, hexosaminidases, sialidases and 
fucosidases. 
 
• HMO have bifidogenic effect and are involved in maturation and modulation of mucosal 
barrier. They are involved in infant cerebral development and also contribute to host health 
by inhibiting pathogens and by modulating immune function. 
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How to replicate the beneficial effects of 
breast milk? 
 
Food alternatives for infant feeding have been developed by companies when breastfeeding is not or 
no longer possible. HMO are not reproductible at large scale production but oligosaccharides similar 
to HMO may be added to formula, in order to mimic as much as possible, the benefits of human breast 
milk (Chichlowski et al., 2011). 
 
Fructo-oligosaccharides and galacto-oligosaccharides 
 
Fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS), known to be bifidogenic despite a 
very simple linear structure, are regularly added to formula. FOS are obtained by synthesis from 
sucrose using a fructosyl transferase or by partial hydrolysis of inulin, which is extracted from chicory 
roots (Cichorium intybus), using an endo-inulinase. FOS are composed of polymers of fructose with a 
terminal Glc and present a degree of polymerization (DP) varying from 3 to 6. GOS are obtained after 
some transglycosylation reactions and are composed of polymers of Gal with a terminal Glc. Their DP 
is higher and varies from 3 to 15 (Thompson et al., 2018). 
 
Usually added to formula following a GOS/FOS ratio of 9:1, this mix of prebiotics contributes to 
increase Bifidobacterium growth and decrease the incidence of pathogens, such as E. coli and 
enterococci. Some positive effects on transit time and stool consistency have also been observed. 
However, due to their very simple structure, some bacteria, such as Bacteroides spp. and 
Clostridium spp., are also able to metabolize them (Chichlowski et al., 2011; Scholtens et al., 2014). 
Therefore, the fecal microbiota of formula-fed infants contains a maximum of 30% of bifidobacteria 
and the predominant species are those encountered in adult feces, such as B. longum subsp. longum 
and B. adolescentis. These bifidobacteria mainly found in the adult microbiota have an enzymatic 
arsenal less sophisticated than that of bifidobacteria associated with breastfed infants, as described 
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Bovine milk oligosaccharides 
 
Interestingly, some oligosaccharides found in human milk are also present in bovine milk at lower 
levels (Table 2). However, infant formulas, which are obtained in part from bovine milk components, 
such as lactose or casein, do not contain these “bioactive” glycans beneficial to host health. Therefore, 
it would be wise to exploit analogues to HMO able to mimic their structural and functional properties 
and available on a large scale in dairy milk (Chichlowski et al., 2011). 
 
Table 2 Comparison of macronutrients and oligosaccharides in human and bovine milk (adapted from 
Thongaram, 2016). 
 
The bovine milk oligosaccharides (BMO) concentration is about 20-fold lower than the HMO 
concentration in human milk. A maximal concentration of around 1 g/L is observed in colostrum but 
decreases rapidly after 48 hours (Table 3) (Urashima et al., 2013). More than 60 BMO have been 
identified, and a significant overlap between HMO and BMO has been demonstrated (Barile et al., 
2009; Pacheco et al., 2015). 
Table 3 Total and sialylated oligosaccharides in human and bovine milk (adapted from Lane et al., 






Protein (g/l) 8 32 
Fat (g/l) 41 37 
Lactose (g/l) 70 48 
Oligosaccharides (g/l) 15 0.5 
% Fucosylated ~50-80 ~1 









Mature bovine milk 
Total oligosaccharides (g/l) 13.300-50.000 3.500-15.000 1.000 0.300-0.500 
Sialylated oligosaccharides (g/l) 1.000-3.300 0.135-2.150 0.230-1.500 0.010-0.195 
6’-sialylactose (g/l) 0.250-1.300 0.170-0.500 0.030-0.243 0.017-0.088 
3’-sialylactose (g/l) 0.090-0.350 0.090-0.350 0.354-1.250 0.030-0.119 
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Composition and structure 
BMO are structurally similar to HMO and are composed of linear or branched monosaccharides 
including Glc, Gal, GlcNAc, Fuc, NeuAc and N-glycolylneuraminic acid (NeuGc) (Figure 9). The 
majority of BMO is built from a lactose core (Glc(β1-4)Gal) but can also possess a lactosamine core 
(GlcNAc(β1-4)Gal). The lactosamine core and the presence of NeuGc are not observed in human 
milk. Contrary to HMO, which are mainly composed of type 1 components, such as LNB in LNT, 
BMO are mainly composed of type 2 structures, such as LacNac in LNnT. In addition, contrary to 
HMO, which are highly fucosylated in human milk (70%), BMO do not contain fucosylation at any 
appreciable levels. Also, while around 20% of HMO are sialylated, up to 70% of BMO contain sialic 
acid (Tables 2 and 3). NeuGc represent 5% of these sialylated BMO (Aldredge et al., 2013; Urashima 
et al., 2013).  
 
 
Figure 9 Structural diversity of BMO and corresponding glycosyl hydrolases in bifidobacteria 





Whereas 6’-sialyllactose, (NeuAc(α2-6)Gal(β1-4)Glc) is the major sialylated oligosaccharide in 
human milk, 3’SL (NeuAc(α2-3)Gal(β1-4)Glc) is predominant in bovine milk (Table 3) (ten 
Bruggencate et al., 2014). 
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With 6’-SL, 3′SL is one of the most representative oligosaccharides found in bovine milk. The 3’SL 
concentration decreases few days after the calf’s birth, but 3’SL represents half of the total 
oligosaccharides in cow colostrum, where its average concentration can reach 0.85 g/L (Table 3) 
(Nakamura et al., 2003; Urashima et al., 2013; Difilippo et al., 2016).  
 
Several hundred complex oligosaccharides coexist in human breast milk but a specific combination of 
only three oligosaccharides including the 3’SL, 6’SL and 2’FL may already bring the benefits of 
breastfeeding to formula-fed infants (Holscher et al., 2017). The 6’SL alone contributes to increase 
4.7-fold the attachment of B. infantis to HT-29 cells. Although the 3’SL alone does not increase 
B. infantis attachment to HT-29 cells, a mixture of 3’SL and 6’SL increases bifidobacteria adhesion 
10-fold (Kavanaugh et al., 2013). 
 
3’SL has anti-inflammatory properties, prevents pathogen attachment in the gut and supports the 
growth of beneficial gut bacteria such as B. longum, a bifidobacterium known to improve human 
psychological wellbeing and to support normal behaviour in stressor-exposed mice (Tarr et al., 2015). 
In addition, 3’SL is a source of sialic acid, an important compound for brain development and 
cognitive functions (Wang et al., 2003; ten Bruggencate et al., 2014).  
 
Whey 
Whey is a by-product issued from the dairy industry and obtained after casein precipitation (Dallas et 
al., 2014). Its composition, depending on the method of cheese manufacture, is rich in protein such as 
b-lactoglobulin or a-lactalbumin, in lactose and in minerals (Walzem et al., 2002). Whey permeate 
(whey stripped of its large proteins after membrane filtration) contains more than ten-fold BMO than 
bovine milk and may be considered as a potential source of prebiotics able to improve human health 
(Dallas et al., 2014; Cooper et al., 2016). In addition, the high quantities of whey produced by the 
dairy industry could easily contribute to oligosaccharide production at very large scale, increasing its 
economic value (Lee et al., 2015).  
 
Half of oligosaccharides identified in cheese whey from mature milk have an identical composition to 
HMO (Barile et al., 2009). 3’SL is the most abundant oligosaccharide found in the whey permeate and 
its concentration in whey issued from colostrum reaches 94 g/L (Lee et al., 2016).  
 
The consumption of BMO issued from whey is safe and well tolerated (Smilowitz et al., 2017) and its 
supplementation with an appropriate probiotic has a bifidogenic effect (Meli et al., 2014). 
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However, isolation of BMO from whey is extremely difficult because they are present in low 
abundance and hindered by a high concentration of lactose. The membrane technology allows the 
discrimination of molecules of different sizes by using ultra-filtration, but lactose is still present and 










• Bovine milk oligosaccharides (BMO) are close to the structural and functional properties 
of human milk oligosaccharides (HMO). 
 
• BMO are available on a large scale in dairy milk and could constitute an interesting 
analogue to HMO for supplementation of commercial formulas. 
 
• 3’-sialyllactose (3’SL) is one of the major BMO found in bovine milk. 
 
• Whey permeate contains more than ten-fold BMO than bovine milk. 
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Two food pathogens: 
E. coli serotype O157:H7 and 
S. enterica serotype Typhimurium 
 
E. coli serotype O157:H7 
 
Main characteristics and classification 
E. coli is a Gram-negative, oxidase-negative and rod-shaped bacterium, belonging to the family 
Enterobacteriaceae. E. coli is able to grow both aerobically and anaerobically and can either be motile 
or non-motile. This bacterium colonizes the gastrointestinal tract of the neonate few hours after the 
birth and belongs to the commensal members of the microbiota. However, some strains are dangerous 
pathogens causing a wide spectrum of diseases, classified in three general clinical syndromes: 
enteric/diarrheal disease, urinary tract infections and sepsis/meningitis (Kaper et al., 2004; Piérard et 
al., 2012; Croxen et al., 2013; Mainil, 2013). Diarrheal illness causes much mortality, particularly in 
children under 5 years old (Croxen et al., 2013). 
 
The pathogen strains are categorized in function of their pathogenicity in six groups: enteropathogenic 
E. coli (EPEC), enterohaemorrhagic E. coli (EHEC), enterotoxinogenic E. coli (ETEC), 
enteroaggregative E. coli (EAEC), enteroinvasive E. coli (EIEC) and diffusely adherent E. coli 
(DAEC). The pathotype of the different E. coli strains is characterized by somatic O and flagellar H 
antigens that define serogroups (O antigen only) and serotypes (O and H antigens) (Kaper et al., 2004; 
Mainil, 2013). 
 
Among the EHEC, one of the most known zoonotic E. coli is the serotype O157:H7, which leads to 
haemorrhagic colitis and haemolytic uremic syndrome (HUS) in human. These motile strains are able 
to produce Verocytotoxins, also called Shiga toxins, and to induce Attaching and Effacing (AE) 
lesions on enterocytes (Piérard et al., 2012). 
 
Epidemiology 
The first E. coli O157:H7 outbreak was reported in the United States in 1982 and was due to the 
consumption of contaminated hamburger meat from a McDonalds’s restaurant (Pacheco and 
Sperandio, 2012). 
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Although most EHEC outbreaks have been attributed to the serotype O157, an increasing number of 
human infections are caused by other serotypes, such as O26, which is often associated with raw cow 
milk consumption (Allerberger et al., 2003). 
 
In 2011, the serotype O104:H4 was responsible for an important outbreak in Germany, causing 34 
deaths and 908 HUS. Actually, the strain belonged to the EAEC but had acquired the virulence gene 
encoding the Shigatoxine (Stx) through a phage. Therefore, EAEC capacity for biofilm formation 
combined with Stx production made this strain highly pathogenic. This EAEC was identified as a non-
locus of enterocyte effacement (LEE) Stx-producing E. coli serotype O104:H4 (Pacheco and 
Sperandio, 2012). 
 
In 2017, the zoonotic report published by EFSA (EFSA and ECDC, 2018) confirmed 6,073 cases of 
EHEC infections and reported 20 deaths in the EU. Among the 6.073 cases, 123 were diagnosed in 
Belgium.  As the preceding years, the most commonly EHEC serotype was O157 (32%), and followed 
by O26, O103 and O91. However, the proportion of O157 serotypes decreases year after year, whereas 
that of non-O157 serotypes increases. Serotype O157:H7 is the most frequently reported also because 
of the HUS cases for which hospitalization was necessary. 
 
Reservoirs and sources 
E. coli O157:H7 outbreaks occur after ingestion of food or water contaminated by feces, such as beef 
meat (mainly), dairy products (raw milk, cheese, butter) and vegetables (spinach, lettuce, sprouts) 
(Pacheco and Sperandio, 2012). Contaminated bovine-derived products are at the origin of 75% of 
outbreaks. Among the cattle population, a small proportion of positive animals called “super-
shedders” are responsible for over 95% of all EHEC contaminations. In bovine ruminants, EHEC 
colonization is asymptomatic because they do not have any globotriaosylceramide 3 (Gb3) receptors, 
contrary to humans. Also, EHEC colonize the recto-anal junction in ruminants, an area impervious to 
the effects of Stx. EHEC is very resistant in the environment and can survive for more than 7 weeks in 
manure (Nguyen and Sperandio, 2012).  
 
Disease 
As mentioned previously, EHEC infection generates watery to bloody diarrhea (haemorrhagic colitis) 
with a risk of HUS development. Its infectious dose is very low, and 10–100 CFU are sufficient to 
cause disease. There is an incubation period of about 3 days before the onset of symptoms: diarrhea 
with fever, abdominal cramping or vomiting. Haemorrhagic colitis may follow these first symptoms. 
Generally, the diarrhea resolves without complications, but HUS involving thrombocytopaenia, 
haemolytic anaemia and acute renal failure may develop after 5 or 13 days. In 4% of cases, EHEC 
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infection is associated with HUS, with a mortality rate of 0.5%. However, in children under the age of 
10, the HUS rate increases to 14% and the mortality rate to 1%. Also, 20% to 40% of HUS patients 
will have long-term sequels: cardiac and gastrointestinal complications, neurological disorders, 
hypertension, chronic renal disease, cognition and behaviour changes (Kaper et al., 2004; Nguyen and 
Sperandio, 2012). 
 
Pathogenicity and virulence gene regulation 
EHEC are able to attach intimately to intestinal epithelial cells and to lead to important cytoskeletal 
changes, causing AE lesions. The microvilli of the intestine are effaced, and pedestal-like structures 
are formed. Then, the type III secretion system (T3SS) is activated and different effector proteins (Tir, 
EspF, EspG, EspH and Map) are translocated into the host cell. The ability to induce AE lesions is 
encoded by genes situated on the pathogenicity island (PI) called the locus of enterocyte effacement 
(LEE) (Kaper et al., 2004). The LEE is divided into five major operons (LEE1 to LEE5) which encode 
for T3SS, regulators, chaperones and effector proteins. The gene ler is the first gene encoded in LEE1 
and regulates expression of the entire LEE (Nguyen and Sperandio, 2012).  
 
EPEC are also able to induce AE lesions, but EHEC are more virulent because they have the gene 
encoding for Stx. The toxin reaches the systemic circulation through epithelial absorption, enabling its 
access to the kidneys. The Stx family is divided into two subgroups: Stx1 and Stx2. The Stx1 
subgroup is composed of the variants Stx1a, Stx1c and Stx1d. The Stx2 subgroup is composed of 
seven variants: Stx2a to Stx2g. These different types of variants allow targeting of different cell types. 
EHEC strains encoding Stx2 cause more severe disease than strains harboring only Stx1 or a 
combination of Stx1 and Stx2. This toxin consists of five identical B subunits and a single A subunit. 
The B subunits attach the toxin to the Gb3 receptor on the intestinal or renal cell surface. The A 
subunit cleaves ribosomal RNA and stopes proteins synthesis, leading to the cellular apoptosis and to 
an inflammatory response (Kaper et al., 2004; Pacheco and Sperandio, 2012). The genes encoding 
Stx1 (stx1) and Stx2 (stx2) are located on a prophage integrated into the chromosome. Stx1 and Stx2 
production is only possible when the phage enters its lytic phase. Then, toxins are released from lysed 
bacterial cells during the lytic cycle of the phage (Croxen et al., 2013). An SOS response has to be 
induced to produce and activate the gene recA, encoding for the recombinase A; recA activation 
initiates the lytic cycle of the phage (Pacheco and Sperandio, 2012). The use of antibiotics in cases of 
EHEC contamination has to be avoided. Indeed, through an SOS response, antibiotics stimulate the 
lytic cycle and allow large amounts of toxins to be released (Croxen et al., 2013). 
 
Quorum sensing (QS) is a mechanism of cell-to-cell communication involving the production of 
hormone-like compounds called autoinducers (AI). Thereby, the bacteria can “sense” their 
environment and communicate with their own population as well as with other bacteria. AI-1 are 
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involved in intraspecies communication, and AI-2 in both intraspecies and interspecies 
communication. AI-3 coordinate interaction between the bacteria and the host, and their presence is 
associated with recognition of host catecholamines (epinephrine and norepinephrine). QS is able to 
modulate virulence gene expression and strongly influences the genes involved in AE lesions (through 
LEE), in Stx production and in motility. The enzyme involved in AI-2 synthesis is encoded by the luxS 
gene, which is the major regulator of QS, while AI-3 synthesis is not dependent on the luxS gene. The 
genes involved in the formation of AE lesions are regulated by QS through AI-2. A high quantity of 
AI-2 in the environment activates the qseA regulator gene, which regulates expression of the ler gene. 
QS also regulates motility through qseB and qseC genes, which perceive the AI-3 signal. Then, 
QseC/B activation leads to the activation of the fliC gene involved in flagella formation. Stx gene 
expression is regulated through the SOS response and the recA gene, with qseC gene activation. Stx 
production is therefore controlled by AI-3 QS molecules.  The figure 10 represents a schematization 
of this complex process (Sperandio et al., 2001, 2002; Kaper et al., 2004; Zeinhom et al., 2012; 
Mellies and Lorenzen, 2013). 
 
 
Figure 10 Regulation of virulence regulator gene (encompassing luxS, qseA and ler genes) and 
virulence gene (encompassing fliC, stx1 and stx2 genes) expression of E. coli serotype O157:H7 
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S. enterica serotype Typhimurium 
 
Main characteristics and classification 
Salmonella are Gram-negative, non-spore-forming and rod-shaped bacteria belonging to the 
Enterobacteriaceae family. They are motile and considered as facultative anaerobes. Salmonella 
infection is one of the most common causes of food-borne illness, especially diarrheal diseases, and in 
some cases may lead to death (Fàbrega and Vila, 2013). 
 
The genus Salmonella is divided into two species: S. enterica and S. bongori. The species S. enterica 
is also divided into six subspecies: S. enterica subsp. enterica (I), S. enterica subsp. salamae (II), 
S. enterica subsp. arizonae (IIIa), S. enterica subsp. diarizonae (IIIb), S. enterica subsp. houtenae (IV) 
and S. enterica subsp. indica (VI). Before being classified as another species, S. bongori (V) was 
initially considered as another subspecies (Fàbrega and Vila, 2013). 
 
Almost all Salmonella causing disease in humans or animals belong to S. enterica subsp. enterica (I) 
and more than 2,500 serotypes have been described. Typhoid fever is caused by S. enterica serotype 
Typhi and S. enterica serotype Paratyphi A and B. They are exclusively human pathogens and may be 
lethal in 20% of cases. Nontyphoidal Salmonella infection is the one of the most common causes of 
diarrheal disease in humans but can also infect animals. The most commonly isolated serotypes are 
S. Enteritidis and S. Typhimurium (Fàbrega and Vila, 2013). 
 
Epidemiology 
Each year, 40,000 cases of Salmonella infection are reported in the United States. However, this 
number is underestimated and could be 30-fold greater or more, because of the many non-reported 
cases. Also, acute salmonellosis is responsible for the death of 400 people each year, especially in 
young children, the elderly and immunocompromised patients (Fàbrega and Vila, 2013). 
 
In 2017, the zoonotic report published by EFSA (EFSA and ECDC, 2018) confirmed 91,662 human 
salmonellosis cases in the EU and 2,298 in Belgium. A statistically significant decrease in Salmonella 
infections in EU was notified between 2008 and 2017, but no significant decrease was observed the 
last five of those years (2013–2017). However, the rate observed in 2017 was 2.9% below the rate 
observed in 2016. The five commonly reported serotypes in 2017 were S. Enteritidis, S. Typhimurium, 
monophasic S. Typhimurium, S. Infantis and then S. Newport. 
 
Reservoirs and sources 
The “carrier-state” is an important clinical particularity of Salmonella infections and corresponds to 
persistent colonization of the gut. Carriers are symptom-free, act as reservoir, and contribute to the 
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disease propagation (Fàbrega and Vila, 2013). The main reservoir of Salmonella is the gastrointestinal 
tract of animals. S. enterica serotype Typhimurium infests domestic livestock and fowl, leading to 
acute disease or asymptomatic carriage. From these animal reservoirs, bacteria may spread and 
contaminate human food (Morgan et al., 2004). 
 
Disease 
The first symptoms appear after an incubation period of 6 to 72 hours, following the ingestion of more 
than 50,000 bacteria in contaminated food or water. There is a wide spectrum of severity of illness. 
Patients present fever, cramping, abdominal pain, diarrhea with or without blood, and inflammation of 
the large bowel, and can also present nausea or vomiting. About 5% of patients (mostly young 
children, the elderly or immunocompromised individuals) will develop a bacteremia, which can lead 
to death. These patients can also develop meningitis, septic arthritis, osteomyelitis, cholangitis, 
pneumonia and endarteritis. In cases of significant fluid loss, an oral or intravenous rehydration is 
necessary. Usually, the disease resolves spontaneously in 5 or 7 days, but antibiotic treatment is 
recommended in cases of severe illness (Fàbrega and Vila, 2013). 
 
Pathogenicity and virulence gene regulation 
After adhesion to the intestinal epithelial cells, the invasion process leads to important cytoskeletal 
rearrangements. The bacteria are enveloped in large vesicles called Salmonella-containing vacuoles 
(SCV), in which Salmonella will survive and replicate. These SCV migrate to a perinuclear position in 
order to facilitate nutrient accessibility, essential for bacterial replication. Then, a fraction of these 
SCV transcytoses, and once across the intestinal cell, Salmonellae are “swallowed” by phagocytes 
(neutrophils, macrophages or dendritic cells). The migration of these infected phagocytes (mainly 
macrophages) facilitates systemic dissemination. Therefore, Salmonella can reach other organs such as 
the spleen and liver via the bloodstream (Fàbrega and Vila, 2013). 
 
The majority of the genes encoding the most important virulence factors are located within the 
Salmonella pathogenicity islands (SPI). The others are located on a virulence plasmid (pSLT) or in the 
chromosome. Five SPI have been identified: SPI-1 to SPI-5 (Fàbrega and Vila, 2013). 
 
As for E. coli O157:H7, Salmonella pathogenesis involves T3SS. Actually, there are two type of 
T3SS, T3SS-1 and T3SS-2, which are encoded by SPI-1 and SPI-2, respectively. Each SPI has its own 
mechanism of expression and regulation. Effector proteins, such as sopD, are translocated via the 
needle into the host cell by means of T3SS-1, which is therefore determinant in invasion of epithelial 
cells and contributes to the inflammatory response and intestinal fluid secretion. Once inside the SCV, 
Salmonella induces the expression of the second T3SS. T3SS-2 is involved in internalization of 
effector proteins inside the macrophages and is therefore determinant in systemic infection. All the 
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genes of SPI-1 are controlled and activated by the hilA gene, which is considered the major regulator 
of SPI-1. The gene ssrB2 is the regulator of the SPI-2 central response (Bayoumi et al., 2012; Fàbrega 
and Vila, 2013; Gart et al., 2016; Guri et al., 2016). 
 
Salmonella produces and releases the majority of AI-2 (produced by the luxS gene) during its 
exponential growth. AI-2 are exported by an unknown mechanism and accumulate extracellularly. 
Then, AI-2 are transported into the bacterial cell and negatively regulate the transcriptional repressor 
protein LsrR. The inactivation of LsrR allows SPI-1 (hilA and sopD) and flagella (fliC) gene 
transcription. AI-3 activate the two-component regulatory systems QseC/B and QseF/E. The QseC/B 
regulatory system controls especially survival in macrophages through SPI-2 genes and mostly 
contributes to systemic invasion. Conversely, the QseF/E regulatory system plays an important role 
during epithelial cells invasion through SPI-1 genes (Fàbrega and Vila, 2013; Gart et al., 2016). 
Figure 11 represents a schematization of this complex process. 
 
 
Figure 11 Regulation of virulence regulator gene (encompassing hilA and ssrB2 genes) and virulence 
gene (encompassing sopD gene) expression of S. enterica serotype Typhimurium (adapted from 
Bayoumi et al., 2012; Fàbrega and Vila, 2013; Gart et al., 2016; Guri et al., 2016). 
  
























• In addition to digestive disorders, Enterohaemorrhagic Escherichia coli (EHEC), 
encompassing the serotype O157:H7, may lead to haemorrhagic colitis and haemolytic 
uremic syndrome (HUS) in young children and elderly. EHEC possesses flagella, is 
involved in attachment and effacement (AE) lesions and is able to produce shigatoxin. 
Quorum sensing, whose luxS gene is a major regulator, is able to modulate virulence gene 
expression of fliC gene (involved in motility) and stx gene (involved in shigatoxin 
production), but also regulator gene expression of ler gene (involved in AE lesions). 
 
• In addition to digestive disorders, Salmonella enterica serotype Typhimurium may lead to 
bacteremia in young children and elderly. Invasion of intestinal cells is regulated by hilA 
gene leading to activation of sopD gene, a virulence gene coding for the sopD effector 
protein. In contrast, invasion of vacuoles, resulting in systemic disease, is controlled by 
ssrB gene, another regulator gene. 
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Prebiotic and probiotic combination 
produces bioactive metabolites influencing 
food pathogen virulence expression 
 
Probiotic bacteria are able to prevent EHEC infection in a mouse model and represent a good 
candidate for the prevention of enteric infections in humans (Gagnon et al., 2006). Indeed, probiotics 
can produce small bioactive molecules able to modulate the virulence gene expression of pathogens, 
without modulating their growth. Cell-free spent medium (CFSM) issued from Lactobacillus 
acidophilus strain La-5 contains molecules interfering with QS regulation and colonization of EHEC 
O157:H7 (Medellin-Peña et al., 2007). These molecules are also able to prevent the adherence of 
E. coli O157:H7 to epithelial cells (Medellin-Peña and Griffiths, 2009). Molecules secreted by 
B. bifidum ATCC 29521 are able to down-regulate hilA and ssrB2 genes in S. enterica serotype 
Typhimurium (Bayoumi and Griffiths, 2010) as well as genes involved in T3SS in EHEC O157:H7 
(Bayoumi and Griffiths, 2012). In addition, CFSM issued from L. acidophilus La-5 and B. longum 
NCC2705 is able to affect virulence gene expression of Campylobacter jejuni (Mundi et al., 2013). 
More recently, CFSM containing bioactive molecules issued from L. acidophilus La-5 reduced the 
attachment of C. difficile on HT-29 and Caco-2 cells but also protected cell lines from cytotoxicity and 
adherence of this nosocomial bacterium (Najarian et al., 2019). 
 
The positive effects of media supplemented with milk products on the growth of probiotics have been 
demonstrated (Champagne et al., 2014). Also, CFSM obtained from L. acidophilus La-5 grown in 
medium supplemented with dairy ingredients such as whey, presents protective effects in EHEC-
infected mice (Zeinhom et al., 2012).  
 
The released exopolysaccharides produced by probiotic bacteria can influence the virulence gene 
expression of pathogens (Kim et al., 2009; Searle et al., 2009). However, the study of Zhang et al. 
(2016) showed that both exopolysaccharides-producing and non-producing strains of 
Lactococcus lactis subsp. cremoris JFR1 are able to down-regulate Salmonella virulence gene 
expression. Therefore, these glycosidic metabolites cannot play a significant role. In addition, a recent 
study highlighted the oligopeptide transport system of Salmonella as essential for an antivirulence 
effect (Zhang et al., 2019). Indeed, milk fermented by L. lactis subsp. cremoris JFR1 seems effective 
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in vitro against the Salmonella invasion into intestinal epithelial cells, and the functional OppA 




• Fermentation of oligosaccharides by probiotic, such as some lactobacilli and bifidobacterial 
strains, could result in production of antivirulent metabolites against intestinal pathogenic 
bacteria. 
 
• These metabolites, contained in cell-free spent media (CFSM), could be of carbohydrate 
nature if they are issued from carbohydrate metabolism or peptide/protein nature if they are 
issued from protein metabolism. 
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In vitro gastrointestinal models 
 
Digestion is a complex process providing nutrients to the body and releasing molecules with a 
beneficial or deleterious effect on health. In addition, diseases, diets or drugs may have an impact on 
the microbial composition and metabolism of the human microbiota. Sampling at the extremities of 
the digestive tract is very simple; for example, it is easy to analyze an enzymatic activity in the mouth 
or to determinate the microbial composition in feces. Conversely, the other parts of the digestive tract 
are less accessible, and sampling necessitates complex investigations by using in vivo models, such as 
animals or humans. These in vivo experiments are difficult, expensive and of course limited by 
obvious ethical reasons (Williams et al., 2015; Dupont et al., 2018). 
 
In vitro models allow, in function of the system developed, complete investigation of the entire 
gastrointestinal tract. They represent an easy, quick and cost-effective means to study one or more 
parts of the digestive system. Reproducibility, choice of controlled conditions and easy sampling at the 
site of interest are the main advantages of these systems. Also, they try to mimic in vivo physiological 
conditions and take into account digestive enzymes, pH, digestion time and salt concentrations. Two 
families of models have been developed: static and dynamic systems. In addition, dynamic models 
may be either mono-compartmental (simulating one compartment of the digestive tract) or multi-
compartmental (simulating several compartments) (Minekus et al., 2014; Williams et al., 2015; 




Batch models are static systems composed of a single bioreactor (Table 4). With a basal medium 
subjected to a constant temperature in an anoxic atmosphere (N2), this mono-compartmental model 
constitutes the simplest system. The experiment runs for a short period not exceeding 72 hours 
(usually 24–48 hours), and the distal colon is usually modelled. The efficiency of some prebiotics and 
probiotics has already been tested in batch systems, but digestion being a dynamic process, they are 
usually employed before conducting more in-depth multi-compartmental experiments (Williams et al., 












Table 4 Comparison of parameters employed in various in vitro gut model systems (adapted from 
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Although static models are very far from physiological conditions, these in vitro models are non-
expensive and easy to implement. In addition, a basic static model was developed by Minekus et al. 
(2014) and the INFOGEST network standardized the methodology in order to facilitate the 
comparison of results obtained by different research groups. The harmonized method comprises three 




The enzyme α -amylase is added to liquid or minced solid meal with an electrolytes solution in order 
to mimic the process in the mouth (for a few seconds to minutes) and to reach a salivary pH close to 
the neutrality (Minekus et al., 2014; Alegria et al., 2015). 
 
Gastric phase 
The gastric phase is performed with HCL or HCL–pepsin under a fixed pH (1–2 for an adult and 4 for 
an infant). The sample is incubated for 1–3 hours at 37 °C, with agitation (Minekus et al., 2014; 
Alegria et al., 2015). 
 
Intestinal phase 
In order to reproduce intestinal digestion, the bolus has to be neutralized to a pH of 6.5–7.5 by adding 
NaOH or NaHCO3. The meal is incubated with pancreatic enzymes such as lipase, amylase and 




In recent years, some more sophisticated models have been improved to be closer to the 
physiochemical conditions found in the gastrointestinal tract. They reproduce the constant nutrient 
contribution and the release of waste products after a defined retention time. In addition, pH, 
temperature and atmospheric environment are permanently controlled (Williams et al., 2015). 
 
In order to mimic gastric digestion, some models such as the Dynamic Gastric Model (DGM) and 
Human Gastric Simulator (HGS) have been developed. The TNO (the Netherlands organization) 
intestinal model (TIM-1) is the most well-known system for studying the upper gastrointestinal tract. 
The DIDGI® also focuses on the upper parts of the digestive tract and consists of two consecutive 
compartments simulating the stomach and the small intestine. Conversely, some models focus only on 
colonic microbiota, such as the TIM-2, ARCOL (artificial colon) and PolyFermS models (Williams et 
al., 2015; Dupont et al., 2018). In addition, some dynamic models have been developed to mimic both 
the upper and lower digestive tract, such as the simulator of the human intestinal microbial ecosystem 
(SHIME®) model and the SIMulator of the GastroIntestinal tract (SIMGI®) (Barroso et al., 2015; Van 
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de Wiele et al., 2015). The list of in vitro models mentioned in this work is non-exhaustive, and only 




TIM is a multi-compartmental dynamic model mimicking the upper gastrointestinal tract and is 
particularly adapted to study microorganism survival (Table 2). TIM-1 consists of four compartments 
mimicking the stomach, duodenum, jejunum and ileum. The peristaltic movements are reproduced. 
Moreover, the pH in each module is controlled, as are enzyme secretion and activity, bile salt 
concentration, transit times and absorption capacities. Two dialysis membranes (5 kDa) are integrated 
next to the jejunum and ileum modules. TIM-2 mimics the proximal colon. In addition to peristaltic 
mixing, water and metabolites are absorbed by a membrane (50 kDa). The successive administration 
of digestive enzymes, peristaltic movements and passive absorption are the main advantages of this in 
vitro system, and this last characteristic is useful for evaluating drug assimilation in humans. However, 
the impossibility of incorporating a mucus layer in the system is probably its major inconvenience 
(Williams et al., 2015). Fermentations of carbohydrates and dietary fibre have been tested in TIM-1 
and TIM-2, and the results are in accordance with human digestion. TIM is considered as a “pioneer” 
among in vitro models, and TIM-1 has been widely used to evaluate the survival of probiotic strains 
during transit (Dupont et al., 2018). 
 
TIM-1 may also be associated with the ARCOL model, which highlights effects on gut microbiota 
composition and metabolic activity. ARCOL is a one-stage semi-continuous fermentation system 
integrating the main parameters found in the human colon: pH, temperature, supply of ileum effluents, 
retention time, anaerobiosis and passive absorption of water and fermentation metabolites. The reactor 
is inoculated with fresh feces, and a nutritive medium is sequentially introduced to mimic the ileum 
effluent composition. A stabilization period of 4 days is necessary before starting the experiment 
(Cordonnier et al., 2015). 
 
PolyFermS  
The PolyfermS model is a continuous fermentation system able to mimic the conditions of the colon 
or other intestinal compartments (Table 2). Most models are based on free-cell suspension cultures, 
which are unfortunately unstable. Indeed, some competitive bacteria can be lost during the 
experiments, and washout is important due to the short retention time. To solve these problems, the 
Lacroix team proposed the use of cell immobilization combined with a continuous fermentation 
system. Therefore, the main bacterial populations found in feces are immobilized in gel beads and are 
then released into the culture medium. The relative proportions of the major bacterial groups and 
metabolites described in infant feces are reconstituted only in the compartment mimicking the 
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SIMGI® consists of five interconnected compartments simulating the stomach, small intestine and the 
three colons (Table 2). All the physiological parameters are controlled by a computer. The gastric 
content is mixed by peristaltic movements, and the pH in ascending (AC), transverse (TC) and 
descending (DC) colons is controlled by addition of NaOH and HCl. After a fecal inoculation in the 
three colons, a colon region-specific microbial community is developed for 2 weeks of stabilization 
and provides a steady-state environment. By comparison with other systems that stimulate digestion 
and fermentation in separate modules, such as TIM-1 and TIM-2, SIMGI® simulates not only 
fermentation but also the process of digestion. The main advantage of this model is its flexible 
modulating characteristics, automated control of the physiological parameters and the reproduction of 
peristaltic movements. However, the SIMGI® model has not yet incorporated devices simulating gut 
microbiota-host interactions, and co-culture with epithelial or immune cells is currently being 
evaluated. This model also lacks devices to evaluate microbial biofilm formation and intestinal 
absorption (Barroso et al., 2015; Dupont et al., 2018). 
 
SHIME® 
Ghent University has adapted and developed the original model described by Molly et al. (1993). With 
its six reactors corresponding to the stomach, duodenum/jejunum, ileum, AC, TC and DC, the 
SHIME® model (Figure 12) is up to date one of the most complete systems for studying interactions 
between probiotics and microbiota (Table 2). In particular, experimentation for a long time period 
(several weeks) allows a thorough study of the microbiota adaptation to a specific treatment (Van den 
Abbeele et al., 2010; Dupont et al., 2018). 
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Figure 12 The simulator of the human intestinal microbial ecosystem (SHIME®) model (department 
of food sciences, Faculty of veterinary medicine, ULiège) (personal picture). 
 
SHIME® is a highly standardized system, where digestive parameters are computer-controlled, and 
leads to highly reproducible results. Like the SIMGI® model, SHIME® is very adaptable, and the pH 
of the different compartments is maintained by adding NaOH and HCl. This model integrates the 
entire gastrointestinal transit into one system and is particularly adapted for studying the digestibility 
and fermentability of prebiotic substrates in the colons, as well as the survival of pathogens or 
probiotics in the upper digestive tract. The colon compartments of the SHIME® model have to be 
inoculated with a microbiota that has been isolated from the feces of one individual (a pool of several 
feces creates disturbances in the cross-feeding processes between microorganisms that are adapted to 
their specific microbiomes). A stabilization period of 2 weeks allows adaptation of the microbial 
communities to the environmental conditions in their respective colons. Then, experiments of 1 
week’s duration can be conducted (Van de Wiele et al., 2015). 
 
As mentioned previously, colon region-specific microbial communities develop in each compartment, 
in accordance with the in vivo conditions. Genera with saccharolytic activity, such as Bacteroides and 
Eubacterium, colonize the proximal colon, and genera degrading mucin, such as Akkermansia, 
colonize the transverse and distal colons. Once these high diversified populations reach a steady state, 
the in vivo experiments may start. However, the passage from an in vivo to an in vitro environment 
results in a shift of the microbiota: an increase of the Bacteroidetes/Firmicutes ratio. Moreover, 
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Clostridium cluster IX (propionate producers) is enriched compared to Clostridium clusters IV and 
XIVa (butyrate producers) (Van den Abbeele et al., 2010). 
 
The human microbiota is dominated by Bacteroidetes and Firmicutes, such as Lactobacillus, which 
possess a mucus-binding domain. Contrary to the Firmicutes, Bacteroides spp. are less capable of 
mucosal adhesion. The mucus layer harbors a unique microbiota and extends microbial colonization 
by preventing the washout of its adherent microbes such as Lactobacillus. Therefore, the incorporation 
of a mucosal environment in the SHIME® (M-SHIME®) model, results in a better representation of 
human intestinal microbial composition by increasing the Firmicutes representation. The M-SHIME® 
model allows colonization of L. mucosae and L. rhamnosus GG, in accordance with the in vivo 
conditions (Van den Abbeele et al., 2012). On the other hand, M-SHIME® allows enrichment of 
Bacteroidetes and Proteobacteria phyla in the luminal content of the system, in accordance with the in 
vivo conditions. As mentioned previously, the Firmicutes phylum preferentially colonizes the mucin 
layer with Clostridium cluster XIVa, accounting for almost 60% of the mucin-adherent microbiota. 
These butyrate-producing bacteria are mainly represented by Roseburia intestinalis and Eubacterium 
rectale (Van den Abbeele et al., 2013a). M-SHIME® preserves the unique inter-individual differences 
among subjects and has been applied to study the differences between healthy individuals and IBD 
patients (Vermeiren et al., 2012).  
 
However, as in other in vitro models, SHIME® and M-SHIME® models cannot reproduce a real 
physiologic environment. Also, this model lacks peristaltic movements, and the food bolus is simply 
pumped and stirred until waste evacuation (Van de Wiele et al., 2015; Dupont et al., 2018). 
 
SHIME® model is an interesting tool for evaluating the metabolism of prebiotics, and the results 
observed in vitro are in accordance with those observed in vivo. The effects obtained from inulin 
administration in this model have been validated and confirmed by a clinical study (Vandenplas et al., 
2004). The same human feces inoculated in germ-free rats and in the SHIME® model, highlighted that 
similar fermentation profiles for specific microbial populations are improved by specific prebiotics, 
such as arabinoxylans and inulin (Van den Abbeele et al., 2011, 2013b). The validation of SHIME® 
for tests with probiotics was investigated by De Smet et al. (1998), by studying the effects of 
cholesterol in pigs. 
 
In order to make a direct comparison of two or more products/treatments or to perform placebo-
controlled studies, several systems in parallel may be built and started at the same time (TWIN-
SHIME to QuadSHIME) (Dupont et al., 2018). 
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In recent years, the SHIME® model has been improved and is able to simulate the microbial ecology 
of human adults, babies or the elderly. To illustrate the different possibilities of this adaptable tool, the 
Figure 13 represents a schematic representation of the toddler SHIME® model developed for this 
study. Some diseases, such as IBD or pathogen infection, may be reproduced. The model may also be 
easily adapted to simulate digestive the tract of animals, such as dogs, cats, pigs and horses (Dupont et 
al., 2018). In addition, the absence of enterocytes or immune cells can be corrected by adding Caco-2 
cells or macrophage cell line U937 (Venema et al., 2013). A Host-Microbiota Interaction (HMITM) 
module to study interactions with host cells during a long-term incubation can be integrated with the 
SHIME® model (Marzorati et al., 2014). Also, dialysis membranes can be added to mimic an 
absorptive process (Van de Wiele et al., 2015). 
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• The simulator of the human intestinal microbial ecosystem (SHIME®) is a digestive model 
mimicking both the upper and lower digestive tract, especially adapted to the study of 
interaction between pre/probiotics and microbiota. 
 
• A stabilization period of two weeks after feces inoculation allows implementation of 
specific microbial populations in ascending, transverse and descending colons. 
 
• The SHIME® model may be improved by incorporation of a mucosal environment with 
mucin beads. The absence of enterocytes may be corrected by adding Caco-2 cells or host-
microbiota interaction (HMITM) module, this latter making possible to evaluate interactions 
between microbiota and host. 
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Review: Genome of bifidobacteria and 
carbohydrates metabolism 
 
The article cited below is a review of the literature and focuses on the genomes of bifidobacteria and 
their carbohydrate metabolism.  This review highlighted the enzymatic pathways present in the 
genomes of bifidobacteria, especially species associated with the microbiota of breast-fed children, 
such as Bifidobacterium longum subsp. infantis and Bifidobacterium bifidum. Indeed, those 
bifidobacteria are able to digest complex oligosaccharides found in human milk, called HMO, and 
contribute positively to the health of the host. An important part of this article was also devoted to the 
complex oligosaccharides found in bovine milk, called BMO, which are structurally similar to HMO 
and can share common properties with them. According to their similarities with HMO, the BMO 
could be considered in the future as an interesting source of prebiotics.  
 
This review entitled “Genome of bifidobacteria and carbohydrate metabolism” was published in the 
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Abstract
In recent years, the knowledge about bifidobacteria has considerably evolved thanks to recent progress in molecular biol-
ogy. The analysis of the whole genome sequences of 48 taxa of bifidobacteria offers new perspectives for their classifica-
tion, especially to set up limit between two species. Indeed, several species are presenting a high homology and should be
reclassified. On the other hand, some subspecies are presenting a low homology and should therefore be reclassified into
different species. In addition, a better knowledge of the genome of bifidobacteria allows a better understanding of the mech-
anisms involved in complex carbohydrate metabolism. The genome of some species of bifidobacteria from human but also
from animal origin demonstrates high presence in genes involved in the metabolism of complex oligosaccharides. Those
species should be further tested to confirm their potential to metabolize complex oligosaccharides in vitro and in vivo.
Key words: bifidobacteria, genomic, complex oligosaccharides, inuline, galacto oligosaccharides, human milk oligosac-
charide, bovine milk oligosaccharide
Introduction
In 1899, Tissier was the first person to isolate bifido-
bacteria from feces of breast-fed children. Because of
their “bifides” Y-shape, and because their physiology is
similar to lactobacilli, they have first been named Bacil-
lus bifidus and then classified in the genus Lactobacillus.
It was finally in 1974 with the 8
th
 edition of Bergey’s
manual, that bifidobacteria were classified in a different
genus, the genus Bifidobacterium. This genus belongs to
the family of Bifidobacteriaceae, belonging to the order
of Bifidobacteriales and is one of the branches of the
phylum Actinobacteria. This phylum includes both
pathogens such as Mycobacterium spp. but also bacteria
beneficial to our health, such as bifidobacteria. The bacte-
ria included in this phylum have physiological and meta-
bolic properties as varied as their morphologies are
different. The genus Streptomyces is the most studied
taxon of this phylum as its metabolites have antibiotic
properties used in the pharmaceutical industry (Di Gioia
et al., 2014; Turroni et al., 2011; Turroni et al., 2014).
Bifidobacteria are Gram-positive saccharolytic bacteria
whose genome is rich in guanine and cytosine (G + C).
The vast majority of bifidobacteria are strict anaerobes,
but some of them are microaerophilic such as B. psy-
chraerophilum, B. crudilactis and B. mongoliense. They
present fermentation metabolism (De Vuyst et al., 2013;
Turroni et al., 2014) but they do not produce gas. They
are non-spore forming and non-motile bacteria (Bottacini
et al., 2014; Sela and Mills, 2010).
Bifidobacteria specifically degrade hexoses monosac-
charide (glucose and fructose) using the “fructose-6-
phosphate phosphoketolase pathway”, also called bifid
shunt. They are unable to classically ferment the hexoses
since they have neither the aldolase neither phosphofruc-
tokinase, (present in homo-fermentative lactic acid bacte-
ria) or glucose-6-phosphate dehydrogenase (present in
hetero-fermentative lactic acid bacteria). Therefore, they
are unable to ferment hexose monosaccharides through
the Emden-Meyerhof-Parnas (EMP) pathway or 6-phos-
phogluconate/phosphoketolase pathway, respectively.
However, with the bifid shunt and the production of a
specific enzyme: the fructose-6-phosphate phosphoketo-
lase (F6PPK), they are able to produce more ATP from
glucose and fructose. 
From the monosaccharides of two hexoses, there is a
formation of three moles of acetate, two moles lactate and
five moles of ATP. In theory, the acetate: lactate ratio is
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3:2. In reality, this ratio is rarely observed as pyruvate can
be metabolized in acetate, formate or even ethanol (De
Vuyst et al., 2013). If a large amount of carbohydrates is
available for the growth of bifidobacteria, a large amount
of lactate will be generated compared to acetate, formate
or ethanol. On the opposite, if the cell survival is threat-
ened, because the source of energy is less available, the
carbohydrates will be consumed slowly and lactate pro-
duction will be lower compared to a higher production of
acetate, formate and ethanol. This enables the bacteria to
produce and save more energy when a lot of substrate is
available. In the colon, the exogenous acetate produced
by bifidobacteria can be metabolised by butyrate-produc-
ing bacteria (De Vuyst et al., 2013). Therefore, the buty-
rogenic effect caused by butyrate-producing colon bac-
teria could rather be due to cross-feeding interactions
rather than direct fructan consumption. 
Bifidobacteria are also able to produce small amounts
of succinic acid, as demonstrated by Van der Meulen et
al. (2006) on 10 strains of bifidobacteria belonging to dif-
ferent species. This production seems to play a role in the
regeneration of NAD+ occurring through the production
of lactic acid or ethanol.
Excellent studies and literature reviews were recently
published about Bifidobacterium genus. The aim of this
review is to report those recent advances in molecular
biology and microbiology allowing new classification of
species inside the Bifidobacterium genus. In addition, an
update about the known metabolism involved in catabo-
lism of several complex oligosaccharides by those bacte-
ria is given.
Genotypic Characteristics and Taxonomy:
Focus on New Species
Our knowledge of bifidobacteria has considerably evol-
ved in recent years. Based on the current scientific know-
ledge, the genus Bifidobacterium consists today of 48 offi-
cial taxa representing 39 species and 9 subspecies (Lugli
et al., 2014). Forty taxa were isolated from the gastrointe-
stinal tract of mammals, birds, or insects (Arrieta et al.,
2014), and eight were isolated from sewage, fermented
milk or blood. As indicated by previous studies involved
in gastrointestinal microbiota analysis, additional bifido-
bacterial species are to be discovered in the future (Tur-
roni et al. 2012; Zoetendal et al., 2008) and further expan-
sion or refinement of the classification is to be expected.
Based on 16S rRNA sequences data from all recog-
nized species (1265 nucleotides), a tree highlighted 3 new
phylogenetic clusters groups, B. crudilactis, B. bohe-
micum and B. scardovii groups, in addition to the usual
six, representing: B. adolescentis, B. asteroides, B. boum,
B. longum, B. pullorum and B. pseudolongum (Lugli et
al., 2014; Turroni et al., 2014).
Based on 23S rRNA sequences, the analysis of the 48
taxa confirmed the classification into the six usual previ-
ously recognized groups.
However, the study of phylogeny within a specific
microbial taxon using only one molecular marker is lim-
ited today considering the tremendous progress in molec-
ular biology. In addition, 16S rRNA sequences can be of
high similarity for two different taxa. Several alternative
approaches were described using 16S rRNA gene associ-
ated with other genes. Analysis of identity levels based
on 16S rRNA and 23S rRNA sequences showed that 19
bifidobacterial pairs still present more than 97% of iden-
tify, the threshold usually considered for species separa-
tion (Lugli et al., 2014; Stackebrandt et al., 2002).  An
approach employing concatenation 16S rRNA gene with
six other housekeeping genes (clpC, dnaJ, xfp, dnaB,
rpoC and purF) for sequence analysis was described
(Ventura et al., 2006). This approach allowed a signifi-
cant increase of discrimination between taxa. Another ap-
proach according to Deletoile et al. (2010) based on con-
catenated sequences of the housekeeping genes clpC, fusA,
gyrB, ileS, purF, rplB and rpoB, and performed on 11
species allowed the classification of B. crudilactis and B.
mongoliense in two different clusters, well separated from
the other bifidobacteria clusters (Delcenserie et al., 2013).
Recent progress in molecular biology offer now the po-
ssibility to define an Average Nucleotide Identity (ANI)
using whole genome sequencing (Konstantinidis and Tie-
dje, 2005). The whole genome sequences of the 48 taxa
of bifidobacteria have been studied, and are, today, the
most complete genome analysis of those bacteria. They
allowed the identification of 18,435 bifidobacterium-spe-
cific clusters of orthologous genes (bifCOGs). Analysis
of these bifCOGs allowed the identification of 534 COGs
thereby forming the heart of the sequences encoding the
genome of bifidobacteria (core bifCOGs). With the sequ-
ences of the genomes, it was possible to identify a set of
411 genes that were then used to build a new phyloge-
netic tree for bifidobacteria, named “supertree”. That tree
highlighted 7 phylogenetic groups instead of the usual six,
with the appearance of a new cluster representing B. bifi-
dum group (Lugli et al., 2014). The ANI was also obtained
for each bifidobacterial pair and varied from 81.3% to
98.1% of identity. As suggested by Lugli et al. (2014),
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ANI could be used instead of DNA-DNA hybridization,
the gold standard, to set up the limit between two differ-
ent species. Interestingly, using ANI, the taxonomy of bi-
fidobacteria would be refined with the recognition of only
34 species of bifidobacteria instead of 39. Indeed, some
pairs presented a ANI of 97% such as B. stercoris, B.
coryneforme, B. kashiwanohense and B. saeculare com-
paring to respectively B. adolescentis, B. indicum, B. cat-
enulatum and B. gallinarum/B. pullorum). On the other
hand, the B. pseudolongum subsp. pseudolongum and B.
pseudolongum subsp. globosum pair presented an ANI
below 94% and should therefore be reclassified into two
different species. Other subspecies were confirmed with
ANI between 94 and 97% (Lugli et al., 2014).
The genome size of bifidobacteria chromosomes varies
from 1.9 to 2.8 Mbp. B. animalis has the smallest genome
and B. longum subsp. infantis has the largest. An average
of 2,012 open reading frames (ORFs) is observed per
genome. B. animalis subsp. lactis and B. longum subsp.
infantis are the species having the lowest and the most
ORF, respectively (Bottacini et al., 2014). The genome of
bifidobacteria adapts easily to new environments. Large-
scale commercial use has created new media very rich in
nutrients and, for example, B. animalis subsp. lactis has
adapted to these environments by losing genes. The
genome evolves over time through different mechanisms:
gene duplication, chromosomal rearrangements and DNA
vertical and horizontal intraspecies gene transfer (Botta-
cini et al., 2014).
The mobilome corresponds to all the mobile parts. It is
characterized by insertion sequences, bacteriophage ele-
ment, prophage-like elements or plasmides. The most
abundant and active insertion sequences are the IS30 ele-
ments. Those elements are responsible for deletions and
rearrangements into the genome and are involved in rapid
environmental adaptation of bifidobacteria, for example
an adaptation on a culture media (Lee and O’Sullivan,
2010).
Bacteriophages and prophage-like elements are
involved in lateral gene transfer. Apart from the strains of
B. longum subsp. longum and B. breve, bifidobacteria do
not contain plasmids (Bottacini et al., 2014).
Bifidobacteria are present in many ecological niches. It
is found in the human and animal intestinal tract (bovine,
rabbit, mice, chicken and insect), in the oral cavity, in
stagnant water and in food. As lactic acid bacteria, they
are often added to fermented foods, such as yoghurt.
However, the vast majority of bifidobacteria species is
only able to grow in the absence of oxygen, a condition
difficult to reproduce in industry. Some of them can sur-
vive the acidity of the stomach environment, duodenal,
bile salts and pancreatic juices but those are conditions
usually aggressive for bifidobacteria.
They are transmitted from mother to infant by direct
vertical transmission in most cases, but also indirectly by
contamination of the environment. Some bifidobacteria
have a cosmopolitan lifestyle (B. animalis, B. adolescen-
tis) while others are adapted to the digestive ecology of a
specific animal species. For example, B. cuniculi is en-
countered in rabbit, B. gallinarum in chicken and B.
pseudolongum in bovine (Turroni et al., 2011). Bifido-
bacteria adapted to a specific ecosystems can be excellent
indicators of fecal contamination and can be considered
as being more effective as currently used indicators such
as coliforms. For example, B. pseudolongum isolated from
raw milk cheese industry, indicates fecal contamination
of bovine origin and not from human origin because this
species is not encountered in the human intestinal tract
(Delcenserie et al., 2011). As mentioned earlier, the pre-
dominant species found in humans vary with age, and this
because of their genome. In a child, predominant species
are B. bifidum and B. longum subsp. infantis while in
adults it is B. adolescentis and B. longum subsp. longum.
Genes involved in carbohydrate metabolism are responsi-
ble for changing this distribution, in particular the genes
coding for carbohydrate transporters and for glycosidases,
mainly β-galactosidase and  β-fructofuranosidases (De
Vuyst et al., 2011). The majority of bifidobacteria enco-
untered in children have a genome oriented in the degra-
dation of human milk oligosaccharides (HMOs), while
those of adults have a genome oriented toward degrada-
tion of dietary carbohydrates. Degradation of complex car-
bohydrates, development of secondary metabolites and the
production of acetate and lactate through the Bifid Shunt
are based on interactions between bifidobacteria and other
microorganisms present in the intestinal tract (De Vuyst
et al., 2011). For example, Bacteroides and other gut bac-
teria secrete various glycosidases able to metabolize com-
plex sugars (Sela and Mills, 2010). Twelve percent of the
genome of bifidobacteria is dedicated to transportation of
carbohydrates or their metabolism, while 5% of the genome
is dedicated to protein metabolism (Sela and Mills, 2010).
Carbohydrate Fermentation Pattern
of Bifidobacteria
Inuline and fructooligosaccharides (FOS)
Inulin is composed of long chain of fructose. The deg-
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ree of polymerisation (DP) of the inulin is 10 on average
but can range from 3 to 60. FOS are composed of the
same fructose found in inulin, but the degree of polymer-
ization range around 4 and can vary from 2 to 8. The
higher is the degree of polymerization, the longer the fer-
mentation will be. Thus the shortest OS will be consumed
first while the longest will be gradually consumed (Boss-
cher et al., 2006). Inulin is extracted from chicory roots
(Cichorium intybus) where it is present in more than 70%
in dry matter. Other foods naturally rich in inuline or FOS
include onions, artichokes, asparagus, leeks and cabbage
(Rossi et al., 2005). The oligofructose or FOS, are formed
by partial hydrolysis of inulin by fructanases and sucrases
(Chichlowski et al., 2011). They can also be produced by
transfructosylation from fructose. Inulin and FOS arrive
intact in the colon as they are neither absorbed nor
degraded due to their β bonds (1-2). The fermentation of
carbohydrates takes place in the proximal part of the
colon, which is highly saccharolytic comparing to the dis-
tal portion, which is more proteolytic. Fermentation of
inulin and FOS by lactobacilli and bifidobacteria pro-
duces organic acids such as lactate and succinate that can
exert antimicrobial effect against pathogenic bacteria by
reducing their growth, spread and passage into the blood-
stream, while promoting the growth of beneficial bacteria
and thus the defenses of host. In addition, thanks to its
high degree of polymerization, inulin is able to reach the
distal parts of the colon where it is preferentially proteol-
ysis, and is able to reduce the latter in favour of a more
beneficial saccharolytic activity (Bosscher et al., 2006).
Some strains of bifidobacteria are able to consume oli-
gofructose and inulin through a β-fructofuranosidase acti-
vity. Some strains are able to degrade small oligosaccha-
rides by intracellular degradation (Fig. 1(a)). This confers
a competitive advantage to those strains against inulin-
type fructan degraders such as lactobacilli, bacteroides
and roseburia. Some other strains are able to metabolize
long chain oligofructose and inulin. A recent study (Sti-
verson et al., 2014) demonstrated that a commercial for-
mulation of long chain inulin (Beneo® Synergy 1) exer-
ted a bifidogenic effect by increasing total bifidobacteria
and more specifically B. longum in infant microbiota. A
study performed with pig fecal microbiota showed that
long chain inulin increased total bifidobacteria (Han et
al., 2014). In this study, it was suggested that animal bifi-
dobacterial strains were better able to metabolize inulin
than human strains, especially long chain inulin (Average
DP of 25).
Fermentation of inulin and FOS produces short chain
fatty acid (SCFA), lactic acid and gas (carbon dioxide and
hydrogen). The produced SCFA such as acetate, propi-
onate and butyrate are either used by the intestinal micro-
biota, or used as an energy source by the host. Inulin and
FOS are able to provide 1.0 or 1.5 kcal/g, respectively
(Bossher et al, 2006). Inulin fermentation provide mainly
butyrate, while FOS provide preferentially acetate and
lactate. SCFA, especially butyrate, have an important role
in preventing colon cancer (Rossi et al., 2005). However,
as mentioned earlier, the production of butyrate is not due
to direct metabolism of inulin by bifidobacteria but rather
by cross-feeding interaction with butyrate-producing
colon bacteria, such as clostridia (De Vuyst et al., 2013).
Two types of cross-feeding have been identified, the first
concerns mono or oligosaccharides formed by bifidobac-
teria during degradation, while the second is the organic
acids such as lactate and acetate (De Vuyst and Leroy,
2011).
Galacto-oligosaccharides (GOS)
Galacto-oligosaccharides (GOS) are synthetized from
lactose and β-galactosidase. The main component of GOS
is 4’-galactosyl-lactose, which consists of one galactose
bonded to lactose through galactose β1-3/4/6 linkages.
The polymerization degree ranges from 3 to 15 and there
is a terminal glucose (Garrido et al., 2013). GOS are
widely used for their bifidogenic properties. However,
other species such as Bacteroides sp. and Clostridium sp.
are likely to metabolism GOS too.
In commercial formulations for infants, GOS are often
mixed with FOS. In previous described studies, the mix-
ture was composed of 90% GOS short chain and 10%
long chain FOS (inulin having DP> 23). With this ratio,
an increase in the number of bifidobacteria was observed
in infant feces. In parallel, a decrease in the incidence of
pathogens such as E. coli, Enterococcus and an improve-
ment of transit time and stool consistency was observed
(Chichlowski et al., 2011; Scholtens et al., 2014). A re-
cent study showed that GOS alone or in combination with
inulin were able to support the growth of B. longum and
to induce a strong antimicrobial effect against E. coli,
mainly due to the production of acetic acid (Stiverson et
al., 2014). A study performed with a gastrointestinal
model for pig demonstrated that B. thermophilum RBL67
was able to metabolize GOS and produce antimicrobial
effect against Salmonella Typhimurium through the pro-
duction of acetate (Tanner et al., 2014). Finally, another
study showed the potential of B. breve 46 to metabolize
GOS in a gastrointestinal model comparing to B.
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Fig. 1. A schematic representation of the degradations patterns of complex oligosaccharides by bifidobacteria.  Inspired from
Smilowitz et al., 2014, Garrido et al., 2012, Cardelle-Cobas et al., 2011, Zivkovic and Barile, 2011, Sela and Mills, 2010,
Boscher et al., 2006. (a) Degradation of FOS or inulin by bifidobacteria using a β-fructofuranosidase activity. Degrada-
tion of GOS by bifidobacteria using specific carriers and β-galactosidase activity. (b) Degradation of HMO by Bifidobac-
terium longum subsp. infantis using transport systems, intracellular glycosyl hydrolase and α-fucosidase, α-sialidase, β-
galactosidase and β-N-hexosaminidase. Degradation of HMO by Bifidobacterium bifidum using lacto-N-biosidase, α-
fucosidase, α-sialidase and LNB phosphorilase. Use of extracellular metabolized HMOs by B. breve and B. longum subsp.
longum. (c) Hypothetic degradation of BMO by bifidobacteria using mainly sialidase activity. Both potential pathways
involving either intracellular or extracellular degradation are represented. FOS, fructooligosaccharides; GOS, glucooligosaccha-
rides; HMO, human milk oligosaccharides; BMO, bovine milk oligosaccharides; LNB, lacto-N-biose; LNT: lacto-N-tetraose;
LNnT: lacto-N-neotetraose.
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pseudocatenulatum JCM1200 or B. animalis subsp. lactis
8:8 (Adamberg et al., 2014).
To degrade GOS, bifidobacteria should be able to syn-
thetize specific carriers and β-galactosidases (Fig. 1(a)).
For example, B. longum subsp. infantis has 5 genes en-
coding β-galactosidases, 3 of them being involved in me-
tabolism of GOS. It preferentially consumes GOS with a
polymerisation degree of 4, but all subspecies, due to
phenotypic differences, will not consume the same way
(Garrido et al., 2013). In addition, the degree of polymer-
ization and the connection types influence its degradation
and the speed of degradation too (Cardelle-Cobas et al.,
2011).
Human milk oligosaccharides (HMO) and bovine
milk oligosaccharides (BMO)
Human milk oligosaccharides (HMO)
The formation of HMO occurs in the mammary gland
with β-galactotransferase in the presence of α-lactalbu-
min. Glucose and galactose, linked by a β1-4 linkage form
the so-called lactose heart. HMOs are formed from 5
monosaccharides: glucose, galactose, N-acetylglucosa-
mine, fucose and sialic acid. They may be linear or
branched and include from 3 to 14 monosaccharides. The
terminal lactose can be linked to a fucose (through α-1,2,
α-1,3 or α-1,4 liaisons) or sialic acid (through α-2,3 or α-
2,6 liaisons). This terminal lactose can be elongated by a
lacto-N- biose type 1 or N- acetyllactosamine. In human
milk, a recent estimate fixed fucosylated HMO to 35 to
50%, sialylated to 12 to 14% HMO and 42 to 55% as
neutral nonfucosylated HMO. In the presence of nega-
tively charged sialic acid, HMO is qualified as acid. Oth-
erwise it is called neutral (Smilowitz et al., 2014).
HMO concentration reaches 25 g/L in colostrum and 10
to 15 g/L in mature milk. More than 200 different struc-
tures have been identified so far (Mehra et al., 2014).
Because of their bifidogenic properties, HMOs play an
active role in the development of a beneficial microbiota
in infant by allowing the growth of specific bacteria. In
addition, it is described that HMOs increase the immune
defenses of the host. One of the mechanism is that fuco-
sylated HMOs present similarity with surface receptors of
the mucous layer in the intestinal tract and therefore bind
to pathogens, allowing them to be washed out naturally
(Smilowitz et al., 2014). The sialylated HMOs are also
involved in brain and cognitive development of the child
(Wu et al., 2011). HMOs are protected from human dige-
stion through their terminal sialylated and fucosylated
chains. Therefore, bifidobacteria must have clusters of
genes encoding specific enzymes and carriers to be able
to digest these HMOs. It has been described that those
gene clusters are located on mobile parts (Sela, 2011). In
addition, there is a co-evolution between HMO present in
the microbiota and bifidobacteria able to use them (Ger-
man et al., 2008). More recently, it has been described that
some bifidobacteria clusters are more particularly adapted
for HMO catabolism (Milani et al., 2014). Indeed, that
cluster seems to have lost genes encoding glycosyl hydro-
lases involved in the degradation of plant polysaccha-
rides.
B. longum subsp. infantis preferentially metabolize
small HMO (degree of polymerization of less than 8 and
molecular weight of less than 1400 Da), which represent
64 % of the available HMO (Sela and Mills, 2010). It is
able to grow in a medium containing HMO as a sole car-
bon source. With its gene cluster of 43 kb which encodes
transport systems and intracellular glycosyl hydrolases,
B. infantis possesses genes coding for 4 enzymes neces-
sary for digestion of HMO: α-fucosidase , α-sialidase , β-
galactosidase and β-N-hexosaminidase. This bacterium
possesses as well genes of ABC transporters and their
associated specific binding proteins (SBP). B. infantis
internalizes the HMO and only then exposes the degraded
lactose heart deprived of its fucose or sialic acid (Sela et
al., 2008; Sela, 2011; Smilowitz et al., 2014).
On the opposite, the digestion of HMO by B. bifidum is
an extracellular process. The cluster of genes present in
B. infantis is absent from the genome of B. bifidum and
different enzymes are synthetized: lacto-N-biosidase in
addition to sialidase and fucosidases. These separate LNB
(lacto-N-biose) from HMO. It passes through the mem-
brane, with an ABC transporter associated with a specific
SBP, and is then degraded intracellularly (Sela, 2011;
Smilowitz et al., 2014). Interestingly, B. bifidum and B.
infantis grow relatively well in HMOs, but have distinct
clusters of genes involved in their metabolism (Barile and
Rastall, 2013). A schematic representation of the degra-
dations patterns is presented in Fig. 1(b).
Interestingly, unlike B. longum subsp. infantis that has
all the necessary genes to digest HMO and is conse-
quently highly represented in the microbiota of a breast-
fed child, B. longum subsp. longum (part of the majority
bifidobacteria microbiota in adult) is unable to metabolize
HMO (De Vuyst et al., 2013). However, there is a close
cooperation in the metabolism of HMO between different
bifidobacteria. B. longum subsp. longum, B. bifidum and
B. breve are able to metabolize lacto-N-biose obtained
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after HMO metabolism by B. infantis. LNB can be meta-
bolized through the action of fucosidases and lacto-N-
biosidases in an extracellular process. Monosaccharides
obtained from successive HMO degradations are mainly
used by B. breve (Barile and Rastall, 2013; Sela and
Mills, 2010).
Bovine milk oligosaccahrides (BMO)
The concentration of BMO in bovine colostrum range
from 0.7 to 1.2 g/L while the concentration of HMO in
human milk range from 20 to 23 g/L. More than 60 kinds
of BMO have already been identified (Pacheco et al.,
2014). The composition of sialylated BMO compounds
reaches 70%, whereas it is 20% for HMOs (Kelly et al.,
2013). They are constructed from a lactose heart, but can
also be constructed from a lactosamine heart that human
milk does not contain. Sialic acids are two in number: N-
acetylneuraminic  acid (NeuAc) and N-glycolylneuraminic
acid (NeuGc). Out of the 70% of sialylated BMO, 5%
contain NeuGc. Monomers of BMO are: glucose, galac-
tose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc),
NeuAc and NeuGc. The NeuGc is not found in human
milk, HMOs being highly fucosylated (70%), while in
bovine milk, fucosilation is potentially possible but in
very small quantities. The amount of fucose is estimated
to be less than 0.01% (Tao et al., 2008).
BMO could represent an inexpensive and effective
source of prebiotic. Indeed, the cheese industry produce
whey in large quantities and whey is naturally rich in
BMO. The structure of BMO, because of its ramifica-
tions, is much closer to HMO than FOS or linear struc-
ture. As a result, profits on the host health may be imp-
roved (Mehra et al., 2014; Zivkovic et Barile, 2011). In
addition they enhance the growth of bifidobacteria, inhi-
bit the attachment of pathogens to the intestinal mucosa
and modulate immunity (Urashima et al., 2013).
The polymerization degree of BMOs is lower than that
of the HMOs, but the β-glycosidic bonds of galactose and
N- acetylglucosamine to lactose are similar. Those bonds,
like those of HMOs, protect BMO from human digestive
enzymes. Indeed, the host has only the ability to digest the
glycosidic bond of lactose. The fact that there are more
sialylated BMO (N-acetylneuraminic acid and N-lylneu-
raminic acid) probably affects the bioavailability of BMO
(Chichlowski et al., 2011). A hypothesis about the possi-
ble mechanisms comparing to HMO is presented in Fig.
1(c).
An interesting study from Meli and coll (2014) assessed
the use of a commercial infant formula supplemented with
BMOs instead of lactose. This is the first study reporting
the use of BMOs in infant formula. Two formulas were
tested: one containing BMOs (Formula 1) and another
one containing BMOs and the probiotics B. longum Bl999
and Lactobacillus rhamnosus LPR (Formula 2). Both for-
mulas were able to induce changes in infant microbiota
by increasing total number of bifidobacteria. No signifi-
cant difference were observed between Formula 1 or 2
suggesting that with the bifidobacteria concentrations used
in this study, the BMOs exerted a more influent effect on
total bifidobacteria counts. However, total lactobacilli
were not influenced by those formulas.
Conclusion
Recent progress in molecular biology allowed consider-
able evolution of the knowledge about bifidobacteria. The
study of phylogeny within a specific microbial taxon
using only one molecular marker is limited today consid-
ering the tremendous progress in molecular biology. Sev-
eral alternatives approaches were described using 16S
rRNA gene associated with several housekeeping genes.
Those approaches allowed a significant increase of dis-
crimination. Recent studies about bifidobacteria allowed
to obtain an Average Nucleotide Identity (ANI) using
whole genome sequencing of 48 taxa of bifidobacteria.
Using that method, the taxonomy of bifidobacteria could
be refined with the recognition of only 34 species of bifi-
dobacteria instead of 39. Indeed, some pairs presented a
ANI of 97% such as B. stercoris, B. coryneforme, B. ka-
shiwanohense and B. saeculare comparing to respectively
B. adolescentis, B. indicum, B. catenulatum and B. galli-
narum/B. pullorum). On the other hand, the B. pseudolon-
gum subsp. pseudolongum and B. pseudolongum subsp.
globosum pair presented an ANI below 94% and should
therefore be reclassified into two different species.
In addition, a better knowledge of the genome of bifi-
dobacteria allows a better understanding of the mecha-
nisms involved in complex carbohydrate metabolism. For
example, a co-evolution between HMO present in the mi-
crobiota and bifidobacteria able to use them can be iden-
tified in the genome. Some bifidobacteria clusters are more
particularly adapted for HMO catabolism and that cluster
seems to have lost genes encoding glycosyl hydrolases
involved in the degradation of plant polysaccharides.
The metabolism of complex sugars such as inuline,
fructo-oligosaccharides, galacto-oligosaccharides, human
milk oligosaccharides and bovine milk oligosaccharides
is well known for several species such as B. longum subsp.
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infantis, B. bifidum and B. breve. The genome of other
species of bifidobacteria originated from human and ani-
mal demonstrates a remarkable enrichment in genes invol-
ved in the metabolism of a wide variety of complex poly-
saccharides. Those species should be further tested to con-
firm their potential to metabolize complex oligosaccha-
rides in vitro and in vivo.
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By shaping the microbiota, the complex oligosaccharides found in human milk (HMO) contribute to 
infant health by promoting the growth of bacteria beneficial to health, such as Bifidobacterium bifidum 
or Bifidobacterium longum subsp. infantis. The oligosaccharides found in bovine milk (BMO) are 
structurally similar to HMO and could share some common properties. In addition, 
Bifidobacterium mongoliense FR/49/f/2 and Bifidobacterium crudilactis FR/62/b/3, two 
Bifidobacterium strains of bovine origin, could possess the enzymatic arsenal to degrade them. 
Interestingly, the fermentation of oligosaccharides by bifidobacteria could lead to antivirulent 
metabolites, which might be able to modulate the virulence gene expression of intestinal pathogens 
without interfering with their growth. 
 
The primary objective of this work was to evaluate the synbiotic effect of these two Bifidobacterium 
strains of bovine origin, B. crudilactis FR/62/b/3 (also deposited as reference strain under the name 
LMG 23609) and B. mongoliense FR/49/f/2, and the BMO, especially the 3’-sialyllactose (3’SL), 
against intestinal pathogenic bacteria and on the modulation of young child gut microbiota. 
Specific objectives 
 
The three principal topics of the present research with their main objectives are presented below: 
 
-First part: ability of B. crudilactis FR/62/b/3 and B. mongoliense FR/49/f/2 to 
metabolize BMO  
Objective 1: highlight the presence of the enzymes and transport systems involved in HMO/BMO 
metabolism in B. crudilactis LMG 23609 and B. mongoliense DSM 21395 genomes (study 2). 
Objective 2: determine if B. crudilactis FR/62/b/3 and B. mongoliense FR/49/f/2 are able to grow in 
the presence of whey (rich in BMO) and 3’SL, as the main source of carbohydrates (studies 1 and 2). 
 
-Second part: virulence gene expression analysis of intestinal pathogens after contact 
with cell-free spent media (CFSM; containing antivirulent metabolites) obtained from 
BMO fermentation by B. crudilactis FR/62/b/3 and B. mongoliense FR/49/f/2. 
Objective 3: determine if the CFSM obtained from BMO fermentation by B. crudilactis FR/62/b/3 
and B. mongoliense FR/49/f/2 contains metabolites able to modulate the virulence gene expression of 
Escherichia coli O157:H7 and Salmonella enterica serotype Typhimurium (studies 1 and 2). 
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-Third part: challenges in a toddler simulator of the human intestinal microbial 
ecosystem (SHIME®) model inoculated with prebiotic (3’SL), probiotic (B. crudilactis 
FR/62/b/3), synbiotic (3’SL+B. crudilactis FR/62/b/3) and CFSM (metabolites): impact 
on the microbiota. 
Objective 4: inoculate feces from young children in the ascending, transverse and descending colons 
of the SHIME® model, in order to reproduce the digestion process and a colonic environment 
(study 3). 
Objective 5: evaluate the prebiotic (3’SL), probiotic (B. crudilactis FR/62/b/3), synbiotic 
(3’SL+B. crudilactis FR/62/b/3) and CFSM (metabolites) effects on the microbiota of young children 
implemented in the SHIME® model (study 3). 
Investigate in each colon: the short chain fatty acids (SCFA) and branched chain fatty acids (BCFA) 
concentrations, the quantity of bifidobacteria, the main Bifidobacterium species present, the evolution 
of microbial populations, and the modulation of virulence gene expression of E. coli O157:H7 after 
contact with the filtered supernatants harvested from each colon. 
 
This work will contribute to a better understanding of the complexity of microorganism interactions 
inside the microbiota and highlight the potential impact of prebiotics, probiotics and synbiotics by 
using a toddler in vitro gastrointestinal model. In addition, this study will allow better understanding 
of the advantages and limitations of digestive models. 
 
Because studies exposed in this work do not follow chronology of objectives, the table below 
summarizes the different correspondences: 
 










Fermentation of BMO by B. crudilactis 










According to the literature, Bifidobacterium crudilactis FR/62/b/3, a strain of bovine origin deposited 
as reference strain under the name LMG 23609, might contain in its genome some genes encoding the 
enzymatic machinery necessary to digest bovine milk oligosaccharides (BMO). Interestingly, whey, a 
by-product of the dairy industry, is rich in BMO, especially in 3’-sialyllactose (3’SL). In addition, 
recent studies have shown that fermentation of carbohydrates by bifidobacteria results in the 
production of metabolites with an anti-virulent effect against intestinal pathogens. 
 
Therefore, the aims of this study were to: 
- Confirm if B. crudilactis FR/62/b/3 and Bifidobacterium bifidum BBA1, a strain isolated from 
the feces of breastfed infants, are able to grow in the presence of whey or 3’SL as the main 
source of carbohydrate.  
- Confirm if the cell-free spent medium (CFSM) obtained from these cultures and supposed to 
contain anti-virulent metabolites is able to exert any effect on virulence gene expression of 
Escherichia coli O157:H7 ATCC 43890 and Salmonella enterica serotype Typhimurium 
ATCC 14028. 
 
This first study entitled “Cell-free spent media obtained from Bifidobacterium bifidum and 
Bifidobacterium crudilactis grown in media supplemented with 3'-sialyllactose modulate virulence 
gene expression in Escherichia coli O157:H7 and Salmonella Typhimurium” was published in 
Frontiers in Microbiology in 2016 (https://doi.org/10.3389/fmicb.2016.01460). 
 84 
The strain used in the first study was probably not the Escherichia coli O157:H7 ATCC 43890 strain, 
but rather the Escherichia coli O157:H7 ATCC 35150 strain. A corrigendum has been submitted to 
Frontiers in Microbiology. 
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Complex oligosaccharides from human milk (HMO) possess an antimicrobial activity
and can promote the growth of bifidobacteria such as Bifidobacterium bifidum and
Bifidobacterium longum subsp. infantis. In addition, fermentation of carbohydrates by
bifidobacteria can result in the production of metabolites presenting an antivirulence
effect on several pathogenic bacteria. Whey is rich in complex bovine milk
oligosaccharides (BMO) structurally similar to HMO and B. crudilactis, a species of bovine
origin, is able to metabolize some of those complex carbohydrates. This study focused
on the ability of B. bifidum and B. crudilactis to grow in a culture medium supplemented
in 3′-sialyllactose (3′SL) as the main source of carbon, a major BMO encountered in
cow milk. Next, the effects of cell-free spent media (CFSM) were tested against virulence
expression of Escherichia coli O157:H7 and Salmonella enterica serovar Typhimurium.
Both strains were able to grow in presence of 3′SL, but B. crudilactis showed the best
growth (7.92 ± 0.3 log cfu/ml) compared to B. bifidum (6.84 ± 0.9 log cfu/ml). Then,
CFSM were tested for their effects on virulence gene expression by ler and hilA promoter
activity of luminescent mutants of E. coli and S. Typhimurium, respectively, and on wild
type strains of E. coli O157:H7 and S. Typhimurium using RT-qPCR. All CFSM resulted
in significant under expression of the ler and hilA genes for the luminescent mutants
and ler (ratios of −15.4 and −8.1 respectively) and qseA (ratios of −2.1 and −3.1) for
the wild type strain of E. coli O157:H7. The 3′SL, a major BMO, combined with some
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bifidobacteria strains of bovine or human origin could therefore be an interesting synbiotic
to maintain or restore the intestinal health of young children. These effects observed
in vitro will be further investigated regarding the overall phenotype of pathogenic agents
and the exact nature of the active molecules.
Keywords: Bifidobacterium bifidum, Bifidobacterium crudilactis, bovine milk oligosaccharide, Escherichia coli
enterohemorragic O157:H7, Salmonella enterica serovar Typhimurium, virulence expression, 3′-sialyllactose,
whey
INTRODUCTION
Due to the influence on the microbiota of carbohydrate
source present in food, breast-fed children are generally in
better health than children fed with formula (Arrieta et al.,
2014; Smilowitz et al., 2014; Scott et al., 2015). Human
milk oligosaccharides (HMO) are complex oligosaccharides
found in human milk. Their concentration can reach 15 g/l
and more than 500 structures have been identified (Pacheco
et al., 2015). These HMO, produced in mammary glands,
cannot be metabolized either by the host or most bacteria,
while bifidobacteria species have enzymatic activity able to
degrade specific α- and β-bonds (Garrido et al., 2013). These
bacteria such as Bifidobacterium bifidum subsp. infantis or
Bifidobacterium bifidum are mainly found in the feces of
breast-fed children. Indeed, the fecal microbiota of breast-
fed child contain more than 75% bifidobacteria (Di Gioia
et al., 2014). In addition to facilitating the growth of beneficial
bacteria such as bifidobacteria, HMO can bind with pathogenic
virus or bacteria, limiting adhesion to intestinal epithelium
and therefore decreasing pathogens colonization by promoting
natural excretion (Smilowitz et al., 2014). Also, other metabolites
produced by lactic acid bacteria and bifidobacteria are able to
inhibit virulence gene expression of Escherichia coli O157:H7
(Medellin-Pena and Griﬃths, 2009; Zeinhom et al., 2012),
Salmonella enterica serovar Typhimurium SA 941256 (Medellin-
Pena et al., 2007; Bayoumi and Griﬃths, 2012; S. Typhimurium)
and Campylobacter jejuni (Mundi et al., 2013).
Five monosaccharides can be found in diﬀerent HMO
structures: glucose (Glc), galactose (Gal), N-acetylglucosamine
(GlcNAc), fucose (Fuc), and sialic acid, also called N-
acetylneuraminic (NeuAc). High quantities of lacto-N-biose type
I (LNB: Galβ1-3GlcNAc) and fucosylated HMO are an important
characteristic of human milk (Chichlowski et al., 2011; Garrido
et al., 2013; Dotz et al., 2014; Smilowitz et al., 2014). B. infantis is
able to fully degrade HMO intracellularly, contrary to B. longum,
B. breve, and B. bifidum (Sela and Mills, 2010; Underwood
et al., 2015). It possesses genes encoding specific transporters and
four enzymes necessary for HMO degradation (α-fucosidase, α-
sialidase, β-galactosidase, and β-N-hexosaminidase) (Sela et al.,
Abbreviations: 3′SL, 3′-sialyllactose; AE, attaching and eﬀacing; BHI, brain
heart infusion; BMO, bovine milk oligosaccharide; CFSM, cell-free spent
medium; EHEC, enterohaemorragic Escherichia coli; FOS, fructo-oligosaccharide;
Fuc, fucose; Gal, galactose; Glc, glucose; GlcNAc, N-acetylglucosamine;
GOS, galacto-oligosaccharide; HMO, human milk oligosaccharide; LacNac,
N-acetyllactosamine; LB, Luria Bertani; LNB, lacto-N-biose; LNnT, lacto-N-
neotetraose; LNT, lacto-N-tetraose; MRS, De Man, Rogosa and Sharpe medium;
NeuAc, N-acetylneuraminic acid or sialic acid; NeuGc, N-glycolylneuraminic
acid; OD, optical density; T3SS, type III secretion system.
2008; Sela, 2011; Smilowitz et al., 2014). HMO degradation
by B. bifidum occurs outside the cells. Indeed, B. bifidum
possesses a lacto-N-biosidase, which cleaves LNB from HMO.
LNB is internalized using a specific transport system and is then
degraded using LNB-phosphorylase (Sela, 2011; Smilowitz et al.,
2014). Therefore, B. infantis and B. bifidum, despite their diﬀerent
gene clusters, both grow very well in the presence of HMO as sole
source of carbon (Asakuma et al., 2011; Barile and Rastall, 2013).
Common oligosaccharides used in infant formula are galacto-
oligosaccharides (GOS) and fructo-oligosaccharides (FOS),
including inulin. GOS are composed of Glc and Gal, while
FOS are composed of fructose and Glc. Their structures are
very simple and linear. They are also bifidogenic, but because
of their simple structure, they can also be consumed by other
members of the intestinal microbiota such as Bacteroides spp.
or Clostridium spp. (Chichlowski et al., 2011; Scholtens, 2014).
This is probably why the fecal microbiota of formula-fed children
contains only 30% bifidobacteria (Di Gioia et al., 2014) and the
species that are present are diﬀerent from those observed in the
feces of breast-fed children. The predominant bifidobacteria in
formula-fed children are those encountered in adult feces, such
as Bifidobacterium longum subsp. longum and Bifidobacterium
adolescentis, which present a less diverse enzymatic arsenal (De
Vuyst et al., 2013).
Bovine milk oligosaccharides (BMO) can have similar
composition and branching as HMO, so they could share some
common properties. In addition, B. infantis or B. bifidum can
grow in the presence of these carbohydrates (Sela, 2011; Milani
et al., 2014). More than 60 BMO have been identified so far
(Pacheco et al., 2015) and whey, a by-product of the dairy
industry, is an important low cost source of BMO (Barile et al.,
2009; Zivkovic and Barile, 2011). Furthermore, Lactobacillus
acidophilus La-5 grown in medium supplemented with dairy
ingredients such as whey, presented a protective eﬀect in
EHEC-infected mice (Zeinhom et al., 2012). However, BMO
concentration in bovine milk is lower than HMO concentration
in human milk (Barile et al., 2009; Tao et al., 2009; Kelly et al.,
2013). Also, fucosylation occurs at very low frequency compared
to sialylation, which is contrary to human milk (Tao et al.,
2008). Even if the degree of polymerization in BMO is lower
than in HMO, they are also protected by α- and β-bonds which
are less accessible to other bacteria (Chichlowski et al., 2011).
One of the most important BMO found in cow milk is 3′-
sialyllactose (3′SL: NeuAcα2-3Galβ1-4Glc) and its concentration
in colostrum can reach 0.85 mg/ml (Nakamura et al., 2003;
Urashima et al., 2013). The majority of bifidobacteria grows
only in anaerobic conditions, an environment very diﬃcult to
reproduce on an industrial scale. In addition, they have to survive
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the acidity of the stomach, bile salts and pancreatic enzymatic
activity of the digestive tract in order to reach the colon where
they will consume oligosaccharides. Bifidobacterium crudilactis
FR/62/B/3, a species isolated from raw cow’s milk cheese, is
oxygen tolerant (Daube et al., 2006; Delcenserie et al., 2013). The
genome encodes enzymes degrading BMO (Delcenserie et al.,
2007;Milani et al., 2014). These strains from bovinemilk could be
an interesting source of probiotics for formula supplementation
(Delcenserie et al., 2013).
The type III secretion system (T3SS) has a major role in
virulence expression of S. Typhimurium and E. coli O157:H7
by injecting eﬀector proteins in intestinal cells and forming
attaching and eﬀacing (AE) lesions on host enterocytes (Bayoumi
and Griﬃths, 2012). The proteins produced by S. Typhimurium
are controlled and activated by hilA and sopD genes and the
ssrB2 gene is a major regulator of the T3SS (Guri et al., 2016).
Regarding E. coli O157:H7, AE lesions are controlled by a
pathogenicity island named locus of enterocyte eﬀacement (LEE)
through ler gene, which is regulated by qseA gene also implicated
in quorum sensing (Medellin-Pena et al., 2007). The gene luxS,
major regulator of quorum sensing and influencing the qseA and
ler genes, is also involved in expression of genes encoding flagella
and biofilm formation (fliC) or synthesis of shiga-toxin (stxB2)
(Kaper et al., 2004; Wood et al., 2006).
The aims of this work were therefore to study the growth
potential of B. crudilactis FR/62/B/3 compared to B. bifidum
BBA1 in culture media supplemented with whey or 3′SL and
to evaluate the eﬀects of CFSM on virulence expression of
Escherichia coliO157:H7 and Salmonella Typhimurium. Because
of its bovine origin, the hypothesis is that B. crudilactis FR/62/B/3
can metabolize components present in whey, especially BMO,
as explained previously. B. bifidum BBA1, a strain isolated from
breastfed children feces, was chosen to provide a comparison
with a strain of human origin as this strain should be able
to use BMO or 3′SL as a source of carbon, due to their
similarity with HMO (Zivkovic and Barile, 2011). Tanimomo
et al. (2016) developed a culture medium answering to the
specificities of B. crudilactis FR/62/B/3. This formula, more
suited to bifidobacteria from bovine origin, was used in this
study as an optimized medium in which diﬀerent sources of
carbohydrates have been tested. The eﬀects of CFSM obtained
from theses cultures on intestinal pathogens virulence were
firstly investigated using rapid-testing on a luminescent reporter
mutants. Next, virulence gene expression was more deeply
investigated on several virulence genes using RT-qPCR on wild
pathogenic strains. A special attention was given to the controls
(unfermented media). Indeed, some nutrients have previously
been shown to have a repressive eﬀect on virulence gene
expression of E. coli O157:H7 (Delcenserie et al., 2012) and
therefore, it was important to exclude that potential eﬀect from
the observed results with the fermented media.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
B. bifidum BBA1 was isolated from feces from a breast-fed
child (CHU - Hôpital des Bruyères, Liège, Belgium) and B.
crudilactis FR/62/B/3 from Saint-Marcellin, a raw cow milk
cheese from Vercors (France). Both strains were stored at
−80◦C and grown on De Man, Rogosa, and Sharpe (MRS)
medium (Oxoid, Hampshire, UK) supplemented with cysteine-
HCl (0.5 g/l) and mupirocin (0.08 g/l) at 37◦C for 48 h in an
anaerobic workstation (Led Techno, Heusden-Zolder, Belgium)
containing 10% H2, 10% CO2, and 80% N2. Several successive
cultures, in the same conditions as described previously, have
been carried out in MRS broth, prior to use. Pathogenic
enterohaemorrhagic E. coli (EHEC) strain O157:H7 ATCC 43890
(stx2+) and S. enterica serovar Typhimurium strain ATCC 14028
were stored at −80◦C and grown in Luria Bertani (LB) media
(Sigma-Aldrich, Diegem, Belgium). Two reporter mutants, E. coli
O157:H7 ATCC 43888 (stx−, LEE:lux) containing plasmid LEE1-
luxCDABE and resistant to ampicillin (Ampr) and kanamycin
(Kanr) and S. Typhimurium SA 941 256 containing plasmid
pSB377 (hilA::luxCDABE; Ampr) were designed by Medellin-
Pena et al. (2007) and Bayoumi and Griﬃths (2010), respectively.
Both strains were from the Canadian Research Institute for Food
Safety Collection and were grown under aerobic conditions at
37◦C in brain heart infusion (BHI) broth (Bio-Rad, Marnes-
la-coquette, France) supplemented with ampicillin (50 mg/l). A
medium optimized for B. crudilactis FR/62/B/3, called MRS2
(Tanimomo et al., 2016) was considered as the reference
medium for this study (Table 1) and was modified by removing
or replacing glucose: MRS2 without any glucose (MRS2 G)
(control), MRS2 with a mix of glucose and whey (MRS2-
Wh), and MRS2 with 3′SL (MRS2-3′SL) as the main source of
carbohydrate (Table 1). Whey was collected at the beginning
of a curdling process of a Belgian cheese factory (Liège area,
Belgium) and frozen at −20◦C before further use. The quantity
of lactose inMRS2-Whmediumwas estimated to 25 g/l, based on
lactose concentration of sweet whey (50 g/l of lactose; Food and
Agriculture Organization/Organisation Mondiale de la Santé,
1998). However, mature bovinemilk contains only traces of BMO
(Kelly et al., 2013). The 3′SL, added to MRS2-3′SL, was provided
by Carbosynth laboratory (Berkshire, UK). The concentration
of 0.85 g/l was chosen to be close to natural concentrations
TABLE 1 | Composition of modified MRS2 media.
MRS2 G MRS2 MRS2-Wh MRS2-3′SL
Yeast extract (g/l) 15.5 15.5 15.5 15.5
Peptone of casein (g/l) 15.5 15.5 15.5 15.5
K2HPO4 (g/l) 0.9 0.9 0.9 0.9
KH2PO4 (g/l) 0.9 0.9 0.9 0.9
NaCl (g/l) 0.009 0.009 0.009 0.009
MnSO4.H2O (g/l) 0.17 0.17 0.17 0.17
MgSO4.7H2O (g/l) 0.007 0.007 0.007 0.007
FeSO4.7H2O (g/) 0.009 0.009 0.009 0.009
Tween 80 (ml/l) 0.9 0.9 0.9 0.9
Cysteine (g/l) 0.4 0.4 0.4 0.4
Glucose (g/l) – 20 10 –
Whey (ml/l) – – 500 –
3′-sialyllactose (g/l) – – – 0.85
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found in colostrum (Nakamura et al., 2003). B. bifidum BBA1
and B. crudilactis FR/62/B/3 were grown in three independent
experiments under anaerobic conditions at 37◦C for 48 h to reach
7 log/ml. Next, the cultures were used to inoculate fresh media
to reach 5 log/ml of bifidobacteria (1% v/v). The concentration
of 5 log/ml was confirmed by plating several dilutions of
bifidobacteria at day 0 post inoculation. Bacterial growth was
determined by viable counts after 48 h incubation. Cell free spent
media (CFSM) were obtained after two centrifugation steps at
5000× (Eppendorf Centrifuge 5804, Hamburg, Germany) for 10
min. Supernatants were then sterilized by filtration (Minisart R⃝
0.45µmand 0.2µm, Sartorius, Vilvoorde, Belgium). Next, CFSM
were freeze-dried (Virtis Benchtop 3.3 EL, SP Scientific, Suﬀolk,
United-Kingdom) and rehydrated with sterile distilled water to
obtain a 10x concentration. The same treatment was applied to
non-fermented culture media (controls). The pH of rehydrated
CFSM was adjusted to 7 using 1M NaOH.
Measurement of LEE and hilA Promoter
Activity
Both E. coli reporter strains were grown overnight in BHI
broth supplemented with ampicillin (BHI-Amp). Each
overnight culture was diluted 1:100 with fresh BHI-Amp
broth supplemented (test samples) or not (control samples) with
10% concentrated CFSM obtained from fermented MRS2-3′SL.
Two hundred microliters of each sample were distributed into
triplicate wells of a sterile, opaque 96-well microliter plate
(Corning 3610, Fisher Scientific, Ottawa, Ontario, Canada) and
incubated at 30◦C. Luminescence was measured every hour for
24 h, with a Victor multilabel counter (Wallac, PerkinElmer Life
Sciences Canada, Woodbridge, Ontario, Canada). Luminescence
was expressed in counts per second. Optical density (OD) was
determined using a Genesys 20 spectrophotometer (Thermo
scientific, Erembodegen, Belgium) adjusted to 600 nm.
Contact between Concentrated CFSM
and Wild Type Pathogenic Strains
E. coli O157:H7 ATCC 43890 was grown in LB agar and a single
colony was taken from the plate and incubated overnight in LB
broth at 37◦C with aeration. The same procedure was applied for
S. Typhimurium ATCC 14028 using BHI medium. The cultures
were homogenized and 50 µl were diluted in 4.5ml of LB broth
for E. coli and BHI broth for S. Typhimurium. Then, 450 µl of
each concentrated CFSM was added to the bacterial suspensions.
Triplicate cultures were incubated at 37◦C for 4 h on a shaker at
150 rpm. Bacterial growth was determined by OD measurement
at 600 nm. E. coli O157:H7 and S. Typhimurium were grown in
LB and BHI broth alone, respectively, as controls.
Gene Expression Analysis by RT-qPCR
The method was adapted with some modifications from Tellez
et al. (2012), Mith et al. (2014) and Guri et al. (2016). After
4 h of incubation (Delcenserie et al., 2012), cells were collected
by centrifugation at 5000 × g for 10 min at room temperature
(Eppendorf Centrifuge 5804, Hamburg, Germany). The pellet
was suspended in 100 µl TE buﬀer (10 mM Tris and 1 mM
EDTA) containing 1% lysozyme (Roche, Mannheim, Germany).
Samples were stored at −20◦C overnight. On the next day,
RNA was extracted using the RNeasy R⃝ Mini Kit (Qiagen,
Antwerp, Belgium). DNA contamination was eliminated from
each sample using the DNase I Recombinant RNase-free Kit
(Roche Diagnostics GmbH, Mannheim, Germany). To inactivate
the DNase, samples were heated at 75◦C for 10 min. The
quantity of RNA was determined by measuring the absorbance
at 260 nm using a Nanodrop 2000 Spectrophotometer (Thermo
Scientific, USA). The purity and quality of RNA were verified
by measuring the ratio of absorbance (260 nm/280 nm) and by
using agarose gel electrophoresis (Eurogentec, Seraing, Belgium).
The concentration of RNA used for reverse transcription
was normalized to 100 ng/µl for E. coli and to 50 ng/µl for
S. Typhimurium. Next, the RNA was subjected to reverse
transcription polymerase chain reaction (RT-PCR) using a high-
capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Ghent, Belgium). Briefly, 1 µg of RNA was reverse transcribed
with 0.8 µl of desoxyribonucleoside triphosphate (dNTP;
100mM), 1 µl of Multiscribe R⃝ Reverse Transcriptase (50U/µl),
2 µl of 10X RT Random Primers and 2 µl of 10X RT Buﬀer in an
adjusted total volume of 20 µl. For each sample, a no-RT control
was included to confirm the absence of DNA contamination.
Synthesis of cDNA was performed in a Mastercycler Gradient
Thermocycler (Flexigene, Cambridge, UK) under the following
conditions: 25◦C for 10 min, 37◦C for 120 min, 85◦C for 5 min
and a cooling step at 4◦C. Then, cDNA was stored at−20◦C.
To study the eﬀects of bioactive molecules present in culture
supernatant on gene expression of E. coli O157:H7 ATCC
43890, the expression of genes ler (involved in attaching eﬀacing
lesions), fliC (involved in mobility), stxB2 (encoding subunit
B of Shiga-toxin 2), luxS (major regulator of quorum sensing
and producing AI-2), and qseA (involved in quorum sensing
and regulator of LEE expression) was determined using qPCR.
The same method was used to study eﬀects on S. Typhimurium
virulence gene expression of hilA (invasion protein regulator),
ssrB2 (Type III secretion system regulator), and sopD (secreted
eﬀector protein). Quantitative PCR amplification was conducted
using the GoTaq R⃝ qPCR Master Mix (Promega, Leiden,
Netherlands) and using the ABI 7300 Real Time PCR System
(Applied Biosystems, Singapore) for E. coli or the Light
Cycler 480 (Roche Diagnostics, Mannheim, Germany) for S.
Typhimurium. The primers were synthesized by Eurogentec
(Liège, Belgium) and have been used in previous studies
(Table 2). The RT-qPCR was performed in a total volume of 20
µl, containing 10µl of GoTaq R⃝Master Mix, 5.75µl of molecular
grade water, 1 µl of forward primer (10 µM), 1 µl of reverse
primer (10 µM), 0.25 µl of carboxy-X-rhodamine (30 µM), and
2 µl of diluted cDNA. The qPCR conditions for E. coli were:
initial denaturation at 95◦C for 3 min; denaturation, annealing
and elongation repeated 45 times: 95◦C for 15 s, 58◦C for 30 s and
72◦C for 45 s; melting curve program: 60–95◦C with a heating
rate of 0.1◦C/s. The qPCR conditions for S. Typhimurium were:
denaturation at 95◦C for 10 min; 40 cycles of amplification and
quantification: 95◦C for 30 s, 56◦C for 30 s and 72◦C for 30 s;
melting curve program: 60–95◦C with a heating rate of 0.1◦C s.
The annealing temperature, optimized at 56◦C, was determined
experimentally. Each specific amplicon was validated for the
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presence of a single melting temperature peak and a single
band of expected size on a 2% agarose gel after electrophoresis.
Cycle threshold (Ct) values were determined using the ABI 7300
System SDS Software for E. coli and the Light Cycler Software 480
version 1.5 for S. Typhimurium. Four housekeeping genes were
tested for E. coli: gnd (6-phosphogluconate deshydrogenase),
gst (glutathione S-transferase), 16S gene (ribosomal RNA) and
recA (recombinase A). Three housekeeping genes were tested
for S. Typhimurium: gmk (guanylate kinase), rpoD (sigma
factor) and 16S gene (ribosomal RNA gene). Because recA
and gmk were the most stable under diﬀerent treatments,
they were selected for normalizing transcript expression
levels. The experiments were replicated three independent
times. To determine relative changes in gene expression,
the formula described by Pfaﬄ (Pfaﬄ, 2001) was used: ratio =
(Etarget)!Ct target(control-sample)/(Ereference)!Ct reference(control-sample),
TABLE 2 | Primers of virulence genes used for qPCR (F: forward;
R: reverse).
Primer Sequence of PCR primers (5′-3′)a References
E. coli Housekeeping and Virulence Genes
gnd
F: 5′-GGTAATACCTTCTTCCAGGACACC-3′
















et al., 2007R: 5′-TGCGGAGATTATTTATTATGA-3′
fliC
F: 5′-TACCATCGCAAAAGCAACTCC-3′ Medellin-Pena
et al., 2007R: 5′-GTCGGCAACGTTAGTGATACC-3′
luxS
F: 5′-GATCATACCCGGATGGAAG-3′ Medellin-Pena
et al., 2007R: 5′-AGAATGCTACGCGCAATATC-3′
stxB2
F: 5′-AGATGTTTATGGCGGTTTTA-3′ Medellin-Pena
et al., 2007R: 5′-TTAAACTGCACTTCAGCAAA-3′
qseA
F: 5′-CGCGGATCCCGTTGGCACAGGTTTGTACA-3′ Medellin-Pena
et al., 2007R: 5′-CGCGGATCCCGTTGGCACAGGTTTGTACA-3′
S. Typhimurium Housekeeping and Virulence Genes
gmk
F: 5′-TTGGCAGGGAGGCGTTT-3′
Rashid et al., 2006
R: 5′-GCGCGAAGTGCCGTAGTAAT-3′
rpoD
















Guri et al., 2016
R: 5′-GGTCAATGTAACGCTTGTTT-3′
where E is the eﬃciency of the qPCR, calculated according to the
equation: E= 10(−1/slope).
Statistical Analysis
The data are means ± standard error of three replicates. A
Student’s t-test was used to assess the statistical significance of
the diﬀerences between test and control groups, where p ≤ 0.05
was considered as significant.
RESULTS
Growth of Bifidobacterium bifidum and
Bifidobacterium crudilactis
B. crudilactis FR/62/B/3 showed increase in viable counts in
MRS2, MRS2-Wh and MRS2-3′SL compared to MRS2 G, but the
highest counts were observed onMRS2-Wh (8.9± 0.6 log cfu/ml,
Table 3). The same trend was observed for B. bifidum BBA1
with slightly lower counts (Table 3) compared to B. crudilactis
FR/62/B/3. The highest counts were also observed for MRS2-Wh
(8.1± 0.3 log cfu/ml).
Activity of CFSM from MRS2-3′SL
Fermented by Bifidobacteria on
Bioluminescent Reporter Gene Expression
Luminescence expression of the plasmids LEE::luxCDABE and
hilA:luxCDABE reached its maximum at 4 h for the E. coli
mutant and at 13 h for the S. Typhimurium mutant, respectively.
In the presence of supernatants from fermented MRS2-3′SL
medium, bioluminescence induction decreased for both mutants
(Figures 1, 2) showing a decrease in promoter expression of
ler and hilA. These results, statistically significant for both
strains, were more pronounced for hilA gene expression of
S. Typhimurium (Figure 2).
Effect of CFSM on E. coli O157:H7
Virulence Gene Expression
After incubation of 4 h, the diﬀerent CFSM had no negative
impact on growth. The average OD of E. coli O157:H7 at
600 nm after 4 h exposure was around 1.286 ± 0.119. From
every tested housekeeping gene, recA was the most stable and
was chosen to normalize the results according to the eﬃciency
of each pair of primers (virulence genes ler, fliC, stxB2, luxS,
and qseA) monitored using qPCR (Pfaﬄ, 2001; Tellez et al.,
2012) (Table 4). The fermented MRS2 G, MRS2, and MRS2-
Wh media did not show significant impact on gene expression
TABLE 3 | Counts of B. bifidum and B. crudilactis after 48 h of incubation
in MRS2 G, MRS2, MRS2-Wh, and MRS2-3′SL media.
Final concentrations after 48h incubation (log cfu/ml)
B. bifidum B. crudilactis
MRS2 G 6.9 ± 0.3 5.5 ± 0.5
MRS2 7.3 ± 0.8 7.8 ± 1.4
MRS2-Wh 8.1 ± 0.3 8.9 ± 0.6
MRS2-3′SL 6.8 ± 0.9 7.9 ± 0.3
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FIGURE 1 | Effect of CFSM from MRS2-3′SL medium fermented with B. bifidum and B. crudilactis on E. coli O157:H7 (stx−, LEE1:lux) ATCC 43888
expression. The E. coli control is E. coli grown on BHI only. The MRS2-3′SL control is E. coli grown on BHI and CFSM from MRS2-3′SL medium unfermented. Data
are the means ± the standard deviations derived from triplicate and expressed as relative light units (RLU) defined as counts per seconds, adjusted to OD600
(RLU/OD600) and where OD is fixed at 0.806 and was taken after 4 h of incubation. LUM: luminescence; OD: optical density. ***P ≤ 0.005.
FIGURE 2 | Effect of CFSM from MRS2-3′SL medium fermented with B. bifidum and B. crudilactis on S. Typhimurium (hilA::lux) SA 941256 expression.
The Salmonella control is Salmonella grown on BHI only. The MRS2-3′SL control is S. Typhimurium grown on BHI and CFSM from MRS2-3′SL medium unfermented.
Data are the means ± the standard deviations derived from triplicate and expressed as relative light units (RLU) defined as counts per seconds, adjusted to OD600
(RLU/OD600) and where OD is fixed at 0.909 and was taken after 13 h of incubation. LUM: luminescence; OD: optical density. ***P ≤ 0.005.
(Figures 3A–C) compared to non-fermented control media,
meaning that CFSM had no eﬀects. However, significant down-
regulation of virulence genes of E. coli O157:H7 was observed
in the presence of fermented MRS2-3′SL medium (Figure 3D).
The medium fermented by B. bifidum BBA1 and B. crudilactis
FR/62/B/3 induced a down-regulation of the E. coli ler gene
(ratios of −15.4; P ≤ 0.01 and −8.1; P ≤ 0.05, respectively).
A down-regulation of the qseA gene was also observed (ratios
of −2.1; P ≤ 0.01 and −3.1; P ≤ 0.05, respectively). A non-
significant trend for up-regulation of the fliC gene (ratios
of 25.8 and +20.8, respectively) was noted while a non-
significant trend for down-regulation of the stxB2 gene (ratios
of −4.6 and −4.2, respectively) was observed. In the case of
fermentation by B. crudilactis FR/62/B/3, a slight non-significant
trend for down-regulation of the luxS gene was observed
(ratio of−2.1).
Effect of CFSM on S. Typhimurium
Virulence Gene Expression
After incubation of 4 h, the OD measurements showed no
negative impact on growth. The average OD of S. Typhimurium
at 600 nm and after 4 h of exposure was 0.862 ± 0.078. From
every tested housekeeping gene, gmk was the most stable and
was chosen to normalize and adjust the results according to the
eﬃciency of each pair of primers (virulence genes hilA, ssrB2, and
sopD) monitored using qPCR (Guri et al., 2016, Table 5). The
CFSM of MRS2-3′SL medium fermented by B. bifidum induced
a slight down-regulation of the ssrB2 gene (−2.1; P ≤ 0.05). The
same trend was observed for the genes hilA and sopD (−2.5 and
−1.9, respectively). MRS2-3′SL CFSM fermented by B. crudilactis
FR/62/B/3 did not show any significant eﬀect on virulence gene
expression (Figure 4B). A significant increase of sopD expression
is observed but too light to be biologically meaningful (1.1; P ≤
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0.05), and the same but non-significant trend is observed with
hilA gene (1.6). Interestingly, a down-regulation of virulence
genes was observed with CFSM obtained from MRS2 without
glucose. In the case of fermentation by B. crudilactis FR/62/B/3,
the genes hilA, ssrB2 and sopDwere down regulated (−8.3,−10.9,
and −6.2, respectively; P ≤ 0.05). The same but non-significant
trend was observed for B. bifidum BBA1 (−8.5, −8.0, and −2.6,
respectively, Figure 4A).
DISCUSSION
B. crudilactis FR/62/B/3 presented the best growth potential
compared to B. bifidum BBA1, particularly with whey or 3′SL
instead of glucose. This could be explained by the fact that
B. crudilactis FR/62/B/3 was originally isolated from raw cow
milk and raw milk cheese. This species possesses the genetic
machinery suggesting some ability to synthetize specific enzymes
for BMO degradation, as highlighted by the presence of genes
coding for β-galactosidase and α- or β-glucosidase, genes also
present in other bacteria such as B. bifidum, B. longum subsp.
infantis, B. mongoliense, B. biavatii, B. kashiwanohense, and B.
stellenboschense (Delcenserie et al., 2007; Milani et al., 2014,
2015; Bondue and Delcenserie, 2015). B. bifidum BBA1 grew
as well on medium containing 3′SL as the main carbohydrate
source. This species possesses genes encoding some of the
enzymes cleaving BMO bonds, so their expression would lead
to growth. However, the growth results of bifidobacteria on
this media were similar to those observed with MRS2 G
(control). This could mean that those genes may not be
expressed eﬃciently under the conditions tested, or another
function is necessary. A next step would be to measure the
expression of genes involved in carbohydrate metabolism such
as genes coding for β-galactosidase and α- or β-glucosidase
to validate the expression of those genes in the presence of
BMO. Another hypothesis could be attributed to the presence
of residual glucose from MRS culture allowing bifidobacteria to
grow in medium exempt of carbohydrate. Indeed, the glucose
present in initial MRS medium was in excess (Tanimomo
et al., 2016), but a negligible part of it (maximum 1mg) has
been transferred with the inoculum. Another source of glucose
could be the presence of residual carbohydrate in the yeast
extracts or peptone extracts used in MRS media. The positive
eﬀects of media supplemented with milk products on growth
of probiotics has been demonstrated previously (Champagne
et al., 2014). This is confirmed in the present study as the best
levels of growth were reached on MRS2-Wh media for both
strains studied. In addition to BMO, whey is rich in lactose
(Food and Agriculture Organization/Organisation Mondiale de
la Santé, 1998), a carbohydrate source that is easily consumed by
bifidobacteria (Delcenserie et al., 2007).
As demonstrated previously, the CFSM obtained from some
lactic acid bacteria or bifidobacteria can induce a decrease
in virulence gene expression of pathogenic bacteria such as
C. jejuni (Mundi et al., 2013). Likewise, B. bifidum ATCC
29521, and L. acidophilus La-5 CFSM were able to produce
metabolites inhibiting virulence gene expression of E. coli
O157:H7 (Medellin-Pena et al., 2007) and S. Typhimurium
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FIGURE 3 | Effect of CFSM from MRS2 G medium (A), MRS2 medium (B), MRS2-Wh medium (C), and MRS2-3′ SL medium (D) fermented by B. bifidum
(light gray) and B. crudilactis (dark gray) on virulence gene expression of enterohaemorrhagic E. coli O157:H7 (EHEC) after 4 h of incubation. Gene
expression ratios of E. coli O157:H7 were normalized to the expression of the housekeeping gene recA and compared with those of the unfermented media. Negative
values represent down-regulation of genes and positive values represent up-regulation of genes. *P ≤ 0.05; **P ≤ 0.01.
(Bayoumi and Griﬃths, 2012). In our study, CFSM collected
from MRS2-3′SL medium fermented by B. bifidum BBA1 and
B. crudilactis FR/62/B/3 down-regulated most of the virulence
genes tested in E. coli O157:H7, except the fliC gene, which
tended to be up-regulated. This is not surprising according
to the fact that fliC gene is not coded by the LEE operon
and therefore not necessarily regulated as other virulence genes
involved in T3SS and situated within the LEE operon (Falcao
et al., 2004). No significant eﬀect has been observed with CFSM
fromMRS2 andMRS2-Whmedium. In addition, CFSMobtained
from bifidobacteria grown in media enriched in 3′SL were able
to aﬀect virulence gene expression of E. coli O157:H7 without
having any impact on its growth, at least during the first 4 h of
incubation.
In those media, higher in carbohydrates, more fermentation
products such as lactate or acetate are synthetized and could
have an inhibiting eﬀect on pathogenic bacteria, as well as
acidifying the media. However, all CFSM were neutralized
before testing them against E. coli or Salmonella, meaning that
the pH did not exert any eﬀect on E. coli O157:H7 growth.
Furthermore, under neutral pH, the organic acids were under
dissociated form and should not present any bactericidal or
bacteriostatic action, contrary to un-dissociated forms (Momose
and Hirayama, 2008).
The genes involved in virulence expression such as ler but
also fliC genes are regulated by luxS, involved in quorum
sensing. However, nutrients can interfere with quorum sensing
mechanisms (Henke and Bassler, 2004; Kaper et al., 2004;
Nakanishi et al., 2006; Mellies et al., 2007) and induce a
decrease in virulence gene expression through a decrease in luxS
expression. Delcenserie et al. (2012) previously demonstrated the
eﬀects of glucose in down-regulating virulence gene expression
of E. coli O157:H7. The present study brought out similar
observations with lactose instead of glucose (data not shown).
The ler gene was the most aﬀected by the presence of those
carbohydrates and the eﬀect was dose-dependent. Media used as
controls and containing glucose or lactose (MRS2 and MRS2-
Wh) down-regulated this gene but no eﬀect was observed with
medium containing mainly 3′SL as a source of carbohydrate
(MRS2-3′SL).
To be able to metabolize 3′SL, B. bifidum and B. crudilactis
have to secrete sialidases through which NeuAc (sialic acid) can
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TABLE 5 | Effect of CFSM on expression (cycle threshold values ± standard error) of virulence gene expression of S. Typhimurium after 4 h incubation.
Gene PCR efficiencya (%) BHI controlb Test supernatants from CFSM from fermented media CFSM from fermented media
unfermented mediac by B. bifidumd by B. crudilactise
MRS2 G MRS2-3′SL MRS2 G MRS2-3′SL MRS2 G MRS2-3′SL
gmk 100 23 23.3 ± 0.3 24.4 ± 1.2 23.4 ± 0.4 24.4 ± 1.6 21.8 ± 0.2 25.0 ± 1.6
hilA 91 31.5 28.6 ± 0.2 31.2 ± 0.7 31.4 ± 2.8 32.5 ± 1.2 30.2 ± 0.4 31.3 ± 2.0
ssrB2 115 31.2 28.7 ± 1.1 30.8 ± 0.1 30.9 ± 1.6 31.6 ± 1.6 30.2 ± 0.6 32 ± 2.0
sopD 91 30.1 27.7 ± 0.5 30.2 ± 1.0 29.3 ± 1.6 31.2 ± 1.5 28.9 ± 0.6 30.9 ± 2.1
aPCR efficiency: E = [(10(-1/slope))/2] x 100%.
bS. Typhimurium grown in BHI broth for 4 h.
cS. Typhimurium grown in BHI broth supplemented with concentrated supernatants from culture media unfermented for 4 h.
dS. Typhimurium grown in BHI broth supplemented with concentrated supernatants from culture media fermented B. bifidum for 4 h.
eS. Typhimurium grown in BHI broth supplemented with concentrated supernatants from culture media fermented B. crudilactis for 4 h.
FIGURE 4 | Effect of CFSM from MRS2 G medium (A) and MRS2-3′ SL medium (B) fermented by B. bifidum (light gray) and B. crudilactis (dark gray) on
virulence gene expression of S. Typhimurium after 4 h of incubation. Gene expression ratios of S. Typhimurium were normalized to the expression of the
housekeeping gene gmk and compared with those of the unfermented media. Negative values represent down-regulation of genes and positive values represent
up-regulation of genes. *P ≤ 0.05.
be produced. B. bifidum does not use this sialic acid, which is
available for other bacteria such as B. breve (Milani et al., 2015).
Therefore, if 3′SL is metabolized by B. bifidum, free sialic acid
was probably present in fermented CFSM from 3′SL medium.
Usually, pathogenic bacteria are able to bind this free sialic acid to
their cell surface and use it to improve their resistance to the host’s
innate immune response, or can consume it as a nutrient (Vimr
et al., 2004; Severi et al., 2007). NeuAc also exerts a major role
in Salmonella enterica subsp. enterica serovar Typhi adhesion
to intestinal epithelium (Sakarya et al., 2010). This means that
in theory, sialic acid could have an impact on S. Typhimurium
and E. coli growth, but no eﬀect on growth as measured by OD
has been observed. In addition, NeuAc had probably no impact
on virulence gene expression in our study, when supplied in the
medium.
The non-significant trend for up-regulation of fliC observed
in our study should be clarified. Indeed, this trend seems higher
when E. coli O157:H7 was exposed to CFSM from fermented
3′SL. A hypothesis could be that the presence of residual complex
carbohydrates aﬀects gene expression of fliC. The presence or
absence of some nutrients, or stress, could play a role in virulence
expression, including fliC (Mei et al., 2015). Several studies
investigated the eﬀects of some stress (oxidative stress, heat
shock, long storage) on down-regulation of fliC gene while other
virulence genes were upregulated (Carey et al., 2009; Mei et al.,
2015; Singh and Jiang, 2015). The experimental protocol of this
study submitted E. coli O157:H7 to some stress, which may
influence virulence gene expression. Genes involved in general
stress (uspA and rpoS), in starvation (phoA and dpS), in cold
shock (cspA, cspC, and cspE) and in acid resistance (gadW)
have been investigated and the results have shown that the
diﬀerent treatments did not aﬀect expression of stress-related
genes (data not shown). This leads us to suppose that virulence
factor expression has not been influenced by the experimental
conditions.
The results observed using RT-qPCR with CFSM from
fermented MRS2-3′SL on S. Typhimurium virulence gene
expression did not confirm the results observed with luminescent
reporter strains. However, CFSM obtained after fermentation
of MRS2 without any glucose fermented by B. crudilactis
FR/62/B/3 down-regulated several virulence genes. Regarding
B. bifidum BBA1 CFSM, a trend to down-regulation was
observed as well. These down-regulations could be caused by
other non-carbohydrate metabolites produced by bifidobacteria
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and these bioactive molecules could originate from the
degradation of proteins. Most known bioactive molecules, such
as subpeptin JM4-A and subpeptin JM4-B are antimicrobial
peptides synthetized by Bacillus subtilis and active against
Salmonella, Staphylococcus aureus, and Bacillus cereus (Sumi
et al., 2015). Nisin, a bacteriocin well known, is produced by
Lactococcus lactis and has a negative impact on Listeria or
Clostridium (Ebbensgaard et al., 2015). The results of our study
suggest that the CFSM activity is not due to an antimicrobial
eﬀect but due to an antivirulent eﬀect.
In conclusion, this study provides the information that
CFSM obtained from MRS2-3′SL medium fermented by B.
bifidum BBA1 and B. crudilactis FR/62/B/3 down-regulated
LEE1 expression of the luminescent E. coli reporter strain
and hilA expression of luminescent S. Typhimurium reporter
strain. These results agree with the decreasing virulence gene
expression of ler and qseA for E. coli, but not for S.
Typhimurium. The contact between S. Typhimurium and CFSM
from fermented MRS without glucose showed down-regulation
of genes hilA, ssrB2, and sopD. According to this in vitro
study, the antivirulent metabolites issuing from fermentation by
bifidobacteria could have a negative impact on T3SS of both
pathogens, decreasing expression of genes mainly implicated
in this virulence mechanism (ler and qseA genes for E. coli
O157:H7; hilA, ssrB2, and sopD genes for S. Typhimurium). The
potential upregulation of fliC in E. coli O157:H7 could increase
the motility as well as biofilm formation. A phenotypic analysis
of the pathogens under the experimental conditions could bring
more insights about its virulence pattern. Information is lacking
about the nature of the active molecules, but the activity of
those CFSM might be due to small peptides or proteins with low
molecular weight and resistant to pH modification and heat, or
products obtained from carbohydrate metabolism. Size exclusion
chromatography could contribute to separating and isolating
these bioactive molecules in order to identify them. In the future,
the eﬀects of these metabolites will be investigated in a human
gastrointestinal model to study the impact on microbiota to
mimic in vivo conditions.
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Study 2: 
Fermentation of BMO by B. mongoliense 
FR/49/f/2 and production of 
antivirulent metabolites 
 
 Analysis of B. crudilactis LMG 23609 and 





The results of the previous study suggested that the combination of 3’-sialyllactose (3’SL), a major 
bovine milk oligosaccharides (BMO), with bifidobacteria of bovine (Bifidobacterium crudilactis 
FR/62/b/3) or human (Bifidobacterium bifidum BBA1) origin could lead to an interesting synbiotic 
effect, even if the exact nature of these antivirulent metabolites is not yet known. The same 
experiments were tested with Bifidobacterium mongoliense FR/49/f/2, another Bifidobacterium from 
bovine origin. As in the previous study, the aim of this second study was to determine if 
B. mongoliense FR/49/f/2 is able to grow in the presence of whey or 3’SL as the main source of 
carbohydrate, and if their corresponding cell-free spent media (CFSM) are able to modulate the 
virulence gene expression of intestinal pathogens.  
 
In addition, in collaboration with the University of Parma, we performed a thorough exploration of the 
B. crudilactis LMG 23609 and B. mongoliense DSM 21395 genomes, highlighting the encoded 
putative enzymes and transport systems involved in human milk oligosaccharides (HMO) and BMO 
metabolism. 
 
This second study entitled “Cell-free spent media obtained from whey or 3’-sialyllactose fermentation 
by Bifidobacterium mongoliense modulate the virulence expression of intestinal pathogens” is 







Bifidobacterium mongoliense genome is particularly 
adapted to milk oligosaccharide digestion leading to 
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Background: Human milk oligosaccharides (HMO) could promote the growth of bifidobacteria, 
improving young children’s health. In addition, fermentation of carbohydrates by bifidobacteria can 
result in the production of metabolites presenting an antivirulent activity against intestinal pathogens. 
Bovine milk oligosaccharides (BMO), structurally similar to HMO, are found at high concentration in 
cow whey. This is particularly observed for 3’-sialyllactose (3’SL). This study focused on enzymes 
and transport systems involved in HMO/BMO metabolism contained in B. crudilactis LMG 23609 
and B. mongoliense DSM 21395 genomes, two strains from bovine milk origin. The ability of 
B. mongoliense FR/49/f/2 to grow in media supplemented with whey or 3’SL was assessed. Next, the 
effects of cell-free spent media (CFSM) were tested against the virulence expression of Escherichia 
coli O157:H7 and Salmonella enterica serotype Typhimurium. 
Results: Due to the presence of genes encoding β-galactosidases, β-hexosaminidases, α-sialidases and 
α-fucosidases, B. mongoliense DSM 21395 presents a genome more sophisticated and more adapted to 
the digestion of BMO/HMO than B. crudilactis LMG 23609 (which contains only β-galactosidases). 
In addition, HMO/BMO digestion involves genes encoding oligosaccharide transport systems found in 
B. mongoliense DSM 21395 but not in B. crudilactis LMG 23609.   B. mongoliense FR/49/f/2 seemed 
able to grow on media supplemented with whey or 3’SL as main source of carbon (8.3±1.0 and 
6.7±0.3 log CFU//L, respectively).  CFSM obtained from whey resulted in a significant under-
expression of ler, fliC, luxS, stx1 and qseA genes  (–2.2, –5.3, –2.4, –2.5 and –4.8, respectively) 
of E. coli O157:H7. CFSM from 3’SL resulted in a significant up-regulation of luxS (2.0) gene and 
down-regulation of fliC (–5.0) gene. CFSM obtained from whey resulted in significant up-regulations 
of sopD and hil genes (2.9 and 3.5, respectively) of S. Typhimurium, while CFSM obtained from 3’SL 
fermentation down-regulated hil and sopD genes (—2.7 and –4.2, respectively).  
Conclusion: From enzymes and transporters highlighted in the genome of B. mongoliense DSM 21395 
and its potential ability to metabolise 3’SL and whey, B. mongoliense seems well able to digest 
HMO/BMO. The exact nature of the metabolites contained in CFSM has to be identified still. These 
results suggest that BMO associated with B. mongoliense could be an interesting synbiotic formulation 
to maintain or restore intestinal health of young children. 
 
Keywords: Bifidobacterium mongoliense, Bifidobacterium crudilactis, whey, bovine milk 
oligosaccharide, 3’-sialyllactose, antivirulent effect, Escherichia coli O157:H7, Salmonella enterica 
serotype Typhimurium  




The carbohydrate sources present in food influence microbiota composition and have an impact on 
young children’s health (Arrieta et al., 2014; Smilowitz et al., 2014; Scott et al., 2015). Simple and 
linear oligosaccharides, such as galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS), 
are added to infant milk formula. They are bifidogenic but can be metabolized as well by other 
bacteria such as Bacteroides spp. or Clostridium spp., other bacteria found in the microbiota 
(Chichlowski et al., 2011; Scholtens et al., 2014). In comparison, human milk is rich in complex 
sugars called human milk oligosaccharides (HMO). More than 500 structures have been identified and 
their concentration can reach up to 50 g/L or more in the colostrum (Lane et al., 2013) and 15 g/L in 
the mature milk (Pacheco et al., 2015).  The presence of α- and β-bonds protects them against 
digestion by the host and by most bacteria. A little quantity of HMO is absorbed across the epithelial 
barrier to reach the systemic circulation and then be excreted in the urine (Triantis et al., 2018). In 
addition, free milk oligosaccharides are able to decrease pathogen colonization of intestinal cells by 
altering cell surface glycosylation and to increase bifidobacteria adherence (Ross et al., 2016). 
In children’s feces, the microbiota is dominated by Bifidobacterium longum (56.2%) and 
Bifidobacterium bifidum (10.7%) (Turroni et al., 2012). These two species, especially Bifidobacterium 
longum subsp. infantis, possess the enzymatic activity able to degrade these specific α- and β-bonds 
(Garrido et al., 2013; Di Gioia et al., 2014). In addition, the bifidobacteria proportion in breastfed 
children’s faeces can reach more than 90% (Hidalgo-Cantabrana et al., 2017). In addition, 
bifidobacteria and lactic acid bacteria produce several metabolites inhibiting virulence gene expression 
of different pathogenic bacteria such as Escherichia coli O157:H7 (Medellin-Pena et al., 2007; 
Medellin-Pena et al., 2009; Zeinhom et al., 2012), Salmonella enterica serotype Typhimurium SA 
941256 (Bayoumi and Griffiths, 2012) and Campylobacter jejuni (Mundi et al., 2013).  
Because they have a similar structure, bovine milk oligosaccharides (BMO) share common properties 
with HMO. More than 60 BMO have been identified (Pacheco et al., 2015) and a significant overlap 
between BMO and HMO has been demonstrated (Barile et al., 2009). The BMO concentration in 
bovine milk is 20-fold lower than the HMO concentration in human milk (Barile et al., 2009). In 
addition, the BMO degree of polymerisation is lower and fucosylated oligosaccharides are very poorly 
represented (Tao et al., 2008, 2009; Kelly et al., 2013). Like HMO, BMO present α- and β-bonds and 
are therefore protected against degradation by other bacteria (Chichlowski et al., 2011). With a 
concentration of 0.85 g/L in colostrum, the 3′-sialyllactose (3′SL: NeuAcα2-3Galβ1-4Glc) is one of 
the most important BMO found in cow milk (Nakamura et al., 2003; Urashima et al., 2013).  
The whey, a by-product issued from the dairy industry, is obtained after the casein precipitation 
(Dallas et al., 2014). Its composition, depending on the method of cheese manufacture, is rich in 
protein such as b-lactoglobulin and a-lactalbumin, in lactose and in minerals (Walzem et al., 2002). 
The whey permeate (whey stripped of its large proteins after membrane filtration) contains the BMO 
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found in the milk and may be considered as a potential source of prebiotics able to improve human 
health (Dallas et al., 2014). In addition, the high quantities of whey produced by the dairy industry 
could easily contribute to an oligosaccharides production at very large-scale, increasing its economic 
value (Lee et al., 2015). The 3’SL is the most abundant oligosaccharide found in the whey permeate 
and its concentration in a whey issued from colostrum reached 94 g/L (Lee et al., 2016). The 
consumption of BMO issued from whey is safe and well-tolerated (Smilowitz et al., 2017) and its 
supplementation with an appropriate probiotic had a bifidogenic effect (Meli et al., 2014). 
The epithelial adhesion of B. longum subsp. infantis ATCC 15697 was improved up to 9.8-fold to 
HT-29 cells in presence of 3’SL and 6’sialyllactose (6’SL) (Kavanaugh et al., 2013) and up to 3.3-fold 
in the presence of immunoglobulin G enriched from bovine whey oligosaccharides (Cooper et al., 
2016). Zeinhom et al. (2012) highlighted the protective effect of Lactobacillus acidophilus La-5 
grown in medium supplemented with whey against enterohaemorrhagic E. coli (EHEC) infection in 
mice. Recently, Cooper et al. (2016) demonstrated that a synbiotic combination of B. animalis subsp. 
lactis CNCM I-3446 and whey permeate containing 3’SL had a strong bifidogenic effect on 
microbiota of children who were born to an HIV+ mother. 
Before reaching the colon to digest oligosaccharides, bifidobacteria must survive to the stomach 
acidity, bile salts and pancreatic enzymatic activity. Most bifidobacteria do not support the presence of 
oxygen, making their production at industrial scale more challenging.  One strain of 
Bifidobacterium mongoliense (FR/49/f/2), has been isolated from raw cow milk cheese (Daube et al., 
2006; Watanabe et al., 2009; Delcenserie et al., 2013). With Bifidobacterium crudilactis FR/62/b/3 
(also deposited as reference strain under the name LMG 23609), another strain isolated from raw cow 
milk cheese, B. mongoliense FR/49/f/2 is oxygen tolerant (Daube et al., 2006; Watanabe et al., 2009; 
Delcenserie et al., 2013) and its genome encodes enzymes degrading BMO (Milani et al., 2014). 
Therefore, these two strains could be an interesting source of probiotics for formula supplementation 
(Delcenserie et al., 2013). 
A recent study demonstrated that cell-free spent medium (CFSM) obtained from culture of B. bifidum 
or B. crudilactis FR/62/b/3 in presence of 3’SL was able to modulate virulence gene expression of 
intestinal pathogens such as E. coli O157:H7 and S. Typhimurium. Genes involved in the type III 
secretion system (T3SS) have been evaluated: hilA, sopD and ssrB2 genes for S. Typhimurium and ler 
and qseA genes for E. coli O157:H7, as well as the fliC gene (flagella and biofilm formation) and the 
stx1 gene (synthesis of shigatoxin) (Bondue et al., 2016). 
The first aim of this study was to determine the enzyme and transport systems involved in BMO 
degradation using the complete genome of B. crudilactis LMG 23609 and B. mongoliense DSM 
21395. The second aim of this work was to evaluate the potential growth of B. mongoliense FR/49/f/2 
in culture media supplemented with whey or 3′SL and to assess the effects of filtered supernatants on 
virulence expression of E. coli O157:H7 and S. Typhimurium.  
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Materials and methods 
 
Genome analysis 
The genomes of the two reference strains, B. crudilactis LMG 23609 and B. mongoliense DSM 21395 
are available on GenBank using accession number JHAL00000000 and JGZE00000000, respectively 
(Delcenserie et al., 2013; Milani et al., 2014; Lugli et al., 2014). The encoded genomes were 
submitted to homology search against the CAZy database (PMID: 24270786) using the 
MEGAnnotator software (REF PMID: 26936607).  Transporters’ specificity was predicted by means 
of the Transporter Classification DataBase (TCDB) (REF PMID: 26546518). Cellular localization of 
putative HMO/BMO degradation genes was defined based on the PSORTb v3.0 web server (REF 
PMID: 20472543). 
 
Bacterial Strains and Growth Conditions 
B. mongoliense FR/49/f/2 and B. crudilactis FR/62/b/3 have been isolated from Saint-Marcellin, a raw 
cow milk cheese from the Vercors area (France).  These strains as well as EHEC strain O157:H7 
ATCC 43890 and S. enterica serotype Typhimurium strain ATCC 14028 were stored and grown 
following the experimental protocol described previously by Bondue et al. (2016).  
Four media with different carbohydrate sources were used: a medium without any glucose (MRS2 G) 
(control), a reference medium with glucose (MRS2-G) (Tanimomo et al., 2016), a medium with a mix 
of glucose and whey as a source of BMO (MRS2-Wh), and a medium with 3′SL (MRS2-3′SL) as the 





















 MRS2 G MRS2-G  MRS2-Wh MRS2-3’SL 
Yeast extract (g/L) 15.5 15.5 15.5 15.5 
Peptone of casein (g/L) 15.5 15.5 15.5 15.5 
K2HPO4 (g/L) 0.9 0.9 0.9 0.9 
KH2PO4 (g/L) 0.9 0.9 0.9 0.9 
NaCl (g/L) 0.009 0.009 0.009 0.009 
MnSO4.H2O (g/L) 0.17 0.17 0.17 0.17 
MgSO4.7H2O (g/L) 0.007 0.007 0.007 0.007 
FeSO4.7H2O (g/L) 0.009 0.009 0.009 0.009 
Tween 80 (mL/L) 0.9 0.9 0.9 0.9 
Cysteine (g/L) 0.4 0.4 0.4 0.4 
Glucose (g/L) - 20 10 - 
Whey (mL/L) - - 500 - 
3’-sialyllactose (g/L) - - - 0.85 
     
Table 6 Composition of the modified MRS2 media adapted from Tanimomo et al. (2016). 
 
The yeast extract, peptone of casein and glucose were provided by the Oxoid firm (Temse, Belgium). 
The tween 80 was provided by Sigma-Aldrich Laboratory (Diegem, Belgium) and the K2HPO4, 
KH2PO4, NaCl, MnSO4.H2O, MgSO4.7H2O, FeSO4.7H2O and cysteine by Merck Laboratory 
(Overijse, Belgium). Sweet whey (12°D) was collected at the beginning of a curdling process in a 
Belgian cheese factory (Liège area, Belgium) and frozen at −20℃ before further use.  Whey was then 
sterilised using double filtration (Minisart® 0.45 μm and 0.2 μm, Sartorius, Vilvoorde, Belgium). The 
quantities of lactose and protein in MRS2-Wh medium were estimated to be around 25 g/L and 4 g/L, 
respectively (FAO, 1998). The 3’SL, added to MRS2-3’SL, was provided by Carbosynth Laboratory 
(Berkshire, UK). The purity of the 3’SL was of minimum 98%. The concentration of 0.85 g/L was 
chosen to be close to natural concentrations found in colostrum (Nakamura et al., 2003). The 
experiments to obtain the concentrated CFSM containing bioactive molecules issued from 
B. crudilactis FR/62/b/3 metabolism, were elaborated by Bondue et al. (2016). B. mongoliense 
FR/49/f/2 was grown in three independent experiments on De Man, Rogosa, and Sharpe (MRS) 
medium (Oxoid, Hampshire, UK) supplemented with cysteine-HCl (0.5 g/L) and mupirocin (0.08 g/L) 
under anaerobic conditions at 37℃ for 48 h. A maximum of two successive cultures have been carried 
out in MRS broth to reach 8 log/mL, prior to use. Next, the cultures were used to inoculate the four 
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previously described media to reach 6 log/mL of bifidobacteria (1% v/v) (concentration was 
confirmed by plating several dilutions of bifidobacteria at day 0 post inoculation). Bacterial growth 
was determined using viable plate counts after 48 h incubation. CFSM were obtained after two 
centrifugation steps at 5000 rpm (Eppendorf Centrifuge 5804, Hamburg, Germany) for 10 min. 
Supernatants were then sterilised by double filtration (Minisart® 0.45 μm and 0.2 μm, Sartorius, 
Vilvoorde, Belgium). Next, CFSM were freeze-dried (Virtis Benchtop 3.3EL, SPS Scientific, Suffolk, 
United Kingdom) and rehydrated with sterile distilled water to obtain a 10-fold concentration. The 
same treatment was applied to non-fermented culture media (controls). To prevent an inhibition of 
pathogenic bacteria growth due to media acidification, the pH of rehydrated CFSM was adjusted to 7 
using 1 M NaOH. 
 
Exposure of pathogenic strains to CFSM, gene expression analysis by RT-qPCR and statistical 
analysis 
The applied method was fully described in the previous study of Bondue et al. (2016). E. coli 
O157:H7 ATCC 43890 and S. Typhimurium ATCC 14028 were incubated overnight at 37℃ under 
agitation in LB and BHI broth, respectively. Volumes of 50 μL of homogenized cultures and 450 μL 
of each concentrated CFSM (fermented and unfermented) were then added to 4.5 mL of LB broth for 
E. coli and BHI broth for S. Typhimurium. Triplicate cultures were incubated at 37℃ for 4 h 
(Delcenserie et al., 2012) on a shaker at 150 rpm. E. coli O157:H7 and S. Typhimurium were grown in 
LB and BHI broth alone, respectively, as controls. Bacterial growth was determined by OD 
measurement at 600 nm. 
Cells were then collected by centrifugation at 5000 x g for 10 min at room temperature (Eppendorf 
Centrifuge 5804, Hamburg, Germany) and pellets were suspended in Tris-EDTA buffer containing 1% 
lysozyme (Roche, Mannheim, Germany). RNA was extracted using the RNeasy® Mini Kit (Qiagen, 
Antwerp, Belgium) and DNA contamination was eliminated using the DNase I Recombinant RNase-
free Kit (Roche Diagnostics GmbH, Mannheim, Germany). Samples were heated at 75℃ for 10 min 
in order to inactivate the DNase. The concentration of RNA was normalised to 100 ng/μL for E. coli 
and to 50 ng/μL for S. Typhimurium. The RNA was then subjected to reverse transcription polymerase 
chain reaction (RT-PCR) using a high-capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Ghent, Belgium). Synthesis of cDNA was performed in a Mastercycler Gradient 
Thermocycler (Flexigene, Cambridge, United Kingdom) under the following conditions: 25℃ for 10 
min, 37℃ for 120 min, 85℃ for 5 min and a cooling step at 4℃. A no-RT control was made to 
confirm the absence of DNA contamination in each sample. 
To highlight the effects of filtered supernatants on virulence gene expressions of E. coli O157:H7 
ATCC 43890, the expression of ler, fliC, stx1, luxS, and qseA genes was determined using qPCR with 
gnd as a reference housekeeping gene (Tellez et al., 2012; Mith et al., 2014). For S. Typhimurium 
ATCC 14028, the virulence expressions of hilA, ssrB2 and sopD genes were assessed using gmk as a 
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reference housekeeping gene (Guri et al., 2016). Quantitative PCR amplification was performed using 
the GoTaq® qPCR Master Mix (Promega, Leiden, Netherlands) and using the Light Cycler 480 (Roche 
Diagnostics, Mannheim, Germany). The primers were synthesised by Eurogentec (Liège, Belgium) 
and had been designed and validated in previous studies (Bondue et al., 2016). The qPCR conditions 
for E. coli were: initial denaturation at 95℃ for 3 min; denaturation, annealing and elongation 
repeated 45 times: 95℃ for 15 s, 58℃ for 30 s and 72℃ for 45 s; melting curve program of 60–95℃ 
with a heating rate of 0.1℃/s. The qPCR conditions for S. Typhimurium were: denaturation at 95℃ 
for 10 min; 40 cycles of amplification and quantification at 95℃ for 30 s, 56℃ for 30 s and 72℃ for 
30 s; melting curve program of 60–95℃ with a heating rate of 0.1℃/s. The experiments were 
replicated three independent times and special attention was given to the controls to exclude any 
potential effect observed from the non-fermented media as described previously (Delcenserie et al., 
2012; Bondue et al., 2016). The relative changes in gene expression were calculated using the Pfaffl 
formula (Pfaffl, 2001): ratio = (virulence gene Efficiency)Ct unfermented – Ct fermented / (reference gene 
Efficiency)Ct unfermented – Ct fermented, with Efficiency = 10(−1/slope). To determine a statistical significance, a 
Wilcoxon test for paired samples was performed where p<0.05 was considered as significant. 
  




Genome analysis: genes coding for enzymes and transporters involved in milk oligosaccharides 
metabolism 
From genome analysis of B. mongoliense DSM 21395, 57 genes encoding for glycoside hydrolases 
(GH) were identified (Figure 14a), among which 10 encode for GH family GH3, 12 for GH13 and 2 
for GH33. Seventy and 19 genes encoding for glycoside transferases (GT) and carbohydrate-binding 
modules (CBM) were found, respectively (Figure 14b and 14c). Six genes encoding for enzymes 
involved in HMO or BMO degradation were highlighted: one cytoplasmic β-hexosaminidase (GH20), 
one cytoplasmic α-L-fucosidase (GH95), two cytoplasmic β-galactosidases (GH2 and GH42) and two 
extracellular α-sialidases (GH33) (Figure 15). In addition, 36 genes were predicted to be involved in 
sugars transport, among which 12 encode for HMO or BMO monosaccharides and oligosaccharides 
(Figure 16b).   Putative transporters belonging to the TCDB family 3.A.1.24, 3.A.1.25 and 3.A.1.2.20 
provided glucose transport.  Putative transporters 3.A.1.1.18, 3.A.1.2.22 and 3.A.1.1.48 assured 
transport of GlcNAc, oligosaccharides and lacto-N-biose or galacto-N-biose, respectively.  
 
Figure 14 Enzymatic profiles involved in sugar degradation by B. crudilactis LMG 23609 and 
B. mongoliense DSM 21395. 
Heat maps showing the number of genes identified for each glycoside hydrolases (GH) family (a), glycoside transferases (GT) family (b) and 
each carbohydrate-binding modules (CBM) family (c) in B. crudilactis LMG 23609 and B. mongoliense DSM 21395 genomes. 
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Figure 15 Digestion of milk oligosaccharides by B. crudilactis LMG 23609 and B. mongoliense DSM 
21395.  
The figure reports the presence/absence and CAZy classification of genes involved in metabolism of milk oligosaccharides metabolism 
found in B. crudilactis LMG 23609 and B. mongoliense DSM 21395 genomes. Genes predicted to be intracellular are written in black while 
genes predicted to be extracellular are written in orange. ORF: open reading frame; GH: glycoside hydrolase. 
 
 
From genome analysis of B. crudilactis LMG 23609, 48 genes encoding for GH were identified 
(Figure 14a), among which 3 encode for GH family GH3 and 12 for GH13. Sixty-eight and 19 genes 
encoding for GT and CBM were found, respectively (Figure 14b and 14c). Two genes encoding for 
cytoplasmic β-galactosidases (GH2 and GH42) were highlighted (Figure 15). From the 
B. mongoliense DSM 21395 genome, 28 genes were predicted to be involved in sugars transport, 
among which eight encode for HMO or BMO monosaccharides and oligosaccharides (Figure 16a). 
Putative transporters belonging to the TCDB family 2.A.1.68.1 and 2.A.7.5.5 provided glucose 
transport. Putative transporters 2.A.2.2.3 and 3.A.1.1.48 assured transport of galactose and 







ORF GH ORF GH 
Fucosidase     BMON_1216 GH95 
β-galactosidase BCRU_0262 / BCRU_1422 GH42 / GH2 BMON_1218 / BMON_1624 GH2 / GH42 
LNB-phosphorylase         
β-hexosaminidase     BMON_0456 GH20 




Number of predicted genes: Localisation: extracellular/cytoplasmic 
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Figure 16 Sugar transporters identified in B. crudilactis LMG 23609 (a) and B. mongoliense DSM 
21395 (b) genomes.  
Genes involved in milk sugars transport are indicated in red while the others are indicated in black. An E-value close to zero is indicated in 
dark yellow while an E-value far from zero is indicated in pale yellow. ORF: open reading frame; TCDB: Transporter classification 
database; E: E-value. 
 
Growth of B. mongoliense FR/49/f/2 
The highest counts were observed on MRS2-G and MRS2-Wh media (8.6 ± 0.8 log CFU/mL and 
8.3 ± 1.0 log CFU/mL, respectively) and the lowest count on MRS2-3’SL medium (6.7 ± 0.3 log 





ORFs TCDB family TCDB Description Sugar Transported 
BCRU_0171 3.A.1.1.45 ABC transporter Maltose 
BCRU_0172 3.A.1.1.45 ABC transporter Maltose 
BCRU_0200 2.A.8.1.1        H+ symporter D-Gluconate 
BCRU_0218 2.A.86.1.6  Probable aldose transporter Aldose 
BCRU_0260 3.A.1.1.48 ABC transporter Lacto-N-biose/galacto-N-biose 
BCRU_0261 3.A.1.1.48 ABC transporter Lacto-N-biose/galacto-N-biose 
BCRU_0264 3.A.1.1.48 ABC transporter Lacto-N-biose/galacto-N-biose 
BCRU_0970 2.A.1.7.17 Putative fructose porter Fructose 
BCRU_1142 2.A.1.68.1 Glucose transporter Glucose 
BCRU_1319 2.A.1.68.1 Glucose transporter Glucose 
BCRU_1423 2.A.2.2.3 Galactose permease Galactose 
BCRU_1459 2.A.1.68.1 Glucose transporter Glucose 
BCRU_1489 3.A.1.1.23 ABC transporter Cellobiose/cellotriose 
BCRU_1490 3.A.1.1.23 ABC transporter Cellobiose/cellotriose 
BCRU_1491 3.A.1.1.23 ABC transporter Cellobiose/cellotriose 
BCRU_1504 3.A.1.1.45 ABC transporter Maltose 
BCRU_1507 3.A.1.1.45 ABC transporter Maltose 
BCRU_1508 3.A.1.1.45 ABC transporter Maltose 
BCRU_1509 3.A.1.1.45 ABC transporter Maltose 
BCRU_1526 3.A.1.1.28 ABC transporter Raffinose/stachyose 
BCRU_1527 3.A.1.1.28 ABC transporter Raffinose/stachyose 
BCRU_1528 3.A.1.1.28 ABC transporter Raffinose/stachyose 
BCRU_1538 2.A.7.5.5 Glucose uptake porter Glucose 
BCRU_1543 3.A.1.1.23 ABC transporter Cellobiose/cellotriose 
BCRU_1600 3.A.1.5.6 ABC transporter  β-glucoside/maltose  
BCRU_1601 3.A.1.5.6 ABC transporter  β-glucoside/maltose  
BCRU_1602 3.A.1.5.6 ABC transporter  β-glucoside/maltose  
BCRU_1603 3.A.1.5.8 ABC transporter  β-glucoside/maltose  
ORFs TCDB family TCDB Description Sugar Transported 
BMON_0262 3.A.1.1.27 ABC transporter Maltose/maltotriose/maltodextrin 
BMON_0263 3.A.1.1.27 ABC transporter Maltose/maltotriose/maltodextrin 
BMON_0264 3.A.1.1.27 ABC transporter Maltose/maltotriose/maltodextrin 
BMON_0403 3.A.1.1.24 ABC transporter Glucose/mannose 
BMON_0404 3.A.1.1.25 ABC transporter Glucose/mannose 
BMON_0429 3.A.1.2.20 ABC transporter Glucose /xylose 
BMON_0430 3.A.1.2.20 ABC transporter Glucose /xylose 
BMON_0441 3.A.1.1.23 ABC transporter Cellobiose/cellotriose 
BMON_0442 3.A.1.1.23 ABC transporter Cellobiose/cellotriose 
BMON_0479 3.A.1.1.26 ABC transporter Maltose 
BMON_0480 3.A.1.1.22 ABC transporter Maltose 
BMON_0481 3.A.1.1.22 ABC transporter Maltose 
BMON_0688 3.A.1.2.22 ABC transporter Sugar 
BMON_0771 3.A.1.2.22 ABC transporter Sugar 
BMON_0772 3.A.1.2.22 ABC transporter Sugar 
BMON_0773 3.A.1.2.22 ABC transporter Sugar 
BMON_0776 3.A.1.2.23 ABC transporter Sugar (fructose) 
BMON_1054 2.A.1.7.5 2-Deoxy-D-ribose porter 2-Deoxy-D-ribose 
BMON_1236 3.A.1.1.26 ABC transporter Maltose 
BMON_1237 3.A.1.1.52 ABC transporter Sugar (sucrose, maltose, glucose, fructose, esculin) 
BMON_1238 3.A.1.1.45 ABC transporter Maltose 
BMON_1409 3.A.1.1.45 ABC transporter Maltose 
BMON_1421 3.A.1.1.28 ABC transporter Raffinose/stachyose 
BMON_1422 3.A.1.1.29 ABC transporter Aldouronate 
BMON_1423 3.A.1.1.30 ABC transporter Glucose 
BMON_1433 3.A.1.1.45 ABC transporter Maltose 
BMON_1446 3.A.1.1.45 ABC transporter Maltose 
BMON_1447 3.A.1.1.46 ABC transporter Glucoside 
BMON_1448 9.B.142.5.1 Putative glycosyl transferase Maltose 
BMON_1623 3.A.1.1.48 ABC transporter Lacto-N-biose/galacto-N-biose 
BMON_1649 3.A.1.1.48 ABC transporter Lacto-N-biose/galacto-N-biose 
BMON_1650 3.A.1.1.48 ABC transporter Lacto-N-biose/galacto-N-biose 
BMON_1651 3.A.1.1.48 ABC transporter Lacto-N-biose/galacto-N-biose 
BMON_1652 3.A.1.2.1 ABC transporter Ribose 
BMON_1757 3.A.1.1.22 ABC transporter Maltose, maltotriose, mannotetraose 




a) b) B. crudilactis B. mongoliense 
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Table 7 Counts of B. mongoliense FR/49/f/2 after incubation in MRS2 G, MRS2-G, MRS2-Wh and 
MRS2-3’SL media. 
 
Effect of CFSM on E. coli O157:H7 virulence gene expression 
After an incubation of 4 h, the CFSM had no negative impact on growth. The average OD of E. coli 
O157:H7 at 600 nm after 4 h exposure was around 0.91 ± 0.14, while it was initially at 0.05 ± 0.03. 
The CFSM obtained from MRS2-Wh medium induced statistically significant down-regulation of ler, 
fliC, luxS, stx1 and qseA genes (–2.2, –5.3, –2.4, –2.5 and –4.8, respectively; P<0.05) (Figure 17c). 
The CFSM from MRS2 G medium induced a significant down-regulation of fliC, luxS and stx1 genes 
(–15.8, –9.5 and –2.3, respectively; P<0.05) (Figure 17a). A significant increase of ler gene 
expression was observed with this same medium, but too low to be biologically meaningful (1.7; 
P<0.05).  CFSM from MRS2-G medium tended to over-express the luxS gene (2.2) and two 
significant up-regulations of ler and stx1 genes (5.3 and 2.5, respectively; P<0.05) were observed 
(Figure 17b). A significant down-regulation of the fliC gene was noted with the CFSM from MRS2-
3’SL medium (–5.2; P<0.05) (Figure 17d). A significant up-regulation was also observed with the 
luxS gene (2.0; P<0.05), while the significant increase of the stx1 gene expression was considered too 
low to be biologically meaningful (1.6; P<0.05). The details of the cycle threshold values 
corresponding to the effects of CFSM on E. coli O157:H7 gene expression are available in the 





Final concentrations after 48 h incubation  
(log cfu/ml) 
MRS2 G 6.0 ± 0.1 
MRS2-G 8.6 ± 0.8 
MRS2-Wh 8.3 ± 0.8 
MRS2-3’SL 6.7 ± 0.3 
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Figure 17 Effects of CFSM on E. coli O157:H7 virulence gene expression. 
Virulence modulations observed with CFSM obtained from MRS2 G (a), MRS2-G (b), MRS2-Wh (c) and MRS2-3’SL (d) media fermented 
by B. mongoliense FR/49/f/2 after 4 h of incubation. Gene expression ratios of E. coli O157:H7 were normalized to the housekeeping gene 
gnd and compared with those of the unfermented media. Values are expressed as the average of at least 3 independent replicates, bars 
representing standard errors. Negative values (lower than –2) represent down-regulation of genes and positive values (upper than 2) represent 
up-regulation of genes. *P<0.05. 
 
Effect of CFSM on S. Typhimurium virulence gene expression 
After the 4 h incubation, the OD measurements showed no negative impact on growth. The average 
OD of S. Typhimurium at 600 nm and after 4 h of exposure was 0.90 ± 0.04, while it was initially at 
0.05 ± 0.02. CFSM obtained from MRS2 G medium induced a significant up-regulation of the sopD 
gene (2.8; P<0.05) (Figure 18a) while the MRS2-Wh CFSM led to significant up-regulation of sopD 
and hil genes (2.9 and 3.4, respectively; P<0.05) (Figure 18c). 
Three significant up-regulations of hil, ssrB2 and sopD genes (11.6, 37.2, 47.5, respectively; P<0.05) 
were noted for the CFSM from MRS2-G medium (Figure 18b). A trend for down-regulation of hil 
and sopD genes (–2.7 and –4.2, respectively) was observed with CFSM obtained from MRS-3’SL 
medium (Figure 18d). The details of the cycle threshold values corresponding to the effects of CFSM 
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Figure 18 Effects of CFSM on S. Typhimurium virulence gene expression. 
Virulence modulations observed with CFSM obtained from MRS2 G (a), MRS2-G (b), MRS2-Wh (c) and MRS2-3’SL (d) media fermented 
by B. mongoliense FR/49/f/2 after 4h of incubation. Gene expression ratios of S. Typhimurium were normalized to the housekeeping gene 
gmk and compared with those of the unfermented media. Values are expressed as the average of at least 3 independent replicates, bars 
representing standard errors. Negative values (lower than –2) represent down-regulation of genes and positive values (upper than 2) represent 











































































































As explained previously, B. mongoliense FR/49/f/2 and B. crudilactis FR/62/b/3 are both from bovine 
origin (Delcenserie et al., 2013) but B. mongoliense DSM 21395 seems to have a more sophisticated 
enzymatic arsenal to digest BMO compared to B. crudilactis LMG 23609. In the B. mongoliense DSM 
21395 genome, many genes encoded enzymes belonging to the GH families involved in complex 
carbohydrates degradation, such as GH2 (β-galactosidase), GH3 (glucosidases), GH13 (amylases), 
GH20 (β-hexosaminidases), GH33 (α-sialidases), GH42 (β-galactosidases) and GH95 (α-L-
fucosidases). Those genes were found in the B. crudilactis LMG 23609 genome too, with exception of 
those encoding for GH20 and GH95 (involved in HMO or BMO digestion) and GH33, which could be 
considered an advanced genetic adaptation to the intestinal environment due to its involvement in 
degradation of both HMO/BMO and intestinal glycoconjugates such as mucin (Milani et al., 2016). In 
addition, with its 14 potential genes involved in milk sugars transport, half of them being related to 
transfer of oligosaccharides, the transport system of B. mongoliense DSM21395 seems more 
diversified compared to B. crudilactis LMG 23609. Regarding B. crudilactis LMG 23609, eight 
potential genes are involved in milk sugar transport and most of them are involved in the transport of 
monosaccharides such as glucose and galactose. From the analysis of the TCDB families, 
B. mongoliense DSM21395 and B. crudilactis LMG 23609 could be able to transport LNB. However, 
LNB is a disaccharide associated with HMO rather than BMO (Tao et al., 2008). Indeed, for most of 
the HMO, Gal and GlcNAc are linked to β1-3 liaison (corresponding to LNB in HMO), contrarily to 
BMO, for which Gal and GlcNAc are linked to β1-4 linkage (related to LacNac in BMO). In addition, 
the very high E-values observed with transporters belonging to the TCDB family 3.A.1.1.48 indicate a 
very low confidence index and could suggest that another disaccharide close to LNB, such as LacNac, 
could be internalised by B. mongoliense DSM21395 or B. crudilactis LMG 23609. 
According to the schematic representation of the BMO metabolism available in the additional file 3: 
Figure S3, B. mongoliense DSM 21395 could be able to digest most of the oligosaccharides found in 
BMO, except the sialic acid, which should stay in the external environment. In the same way, 
B. mongoliense DSM 21395 could be able to metabolize 3’SL (NeuGcα2-3Galβ1-4Glc) using an 
extracellular α-sialidase. Then, the lactose (Galβ1-4Glc) could be internalized using an ABC 
transporter and metabolized using a cytoplasmic β-galactosidase. According to this representation, the 
BMO or 3’SL degradation by B. crudilactis FR/62/b/3 seems impossible without a previous cross-
feeding step involving other bifidobacteria. 
B. mongoliense FR/49/f/2 showed good growth on media supplemented with either whey or glucose, 
whey contribution making no significant difference compared to glucose. In addition, whey is rich in 
lactose (FAO, 1998), a carbohydrate source easily consumed by bifidobacteria, and in several BMO 
(encompassing 3’SL) (Delcenserie et al., 2007). Finally, the important growth observed with the 
medium supplemented with whey is mainly due to the high concentration in lactose, glucose and 
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potentially BMO. Interestingly, the strain B. mongoliense FR/49/f/2 grew on medium containing 3’SL 
as the main carbohydrate source, in comparison to the absence of growth observed on medium without 
any carbohydrate source. According to B. mongoliense DSM21395 genome analysis, this growth 
could result from the expression of the enzymes cleaving BMO or 3’SL bonds, such as α-sialidases, 
β-galactosidases and β-hexosaminidases. Genes involved in BMO degradation are also present in other 
bifidobacteria such as B. bifidum subsp. infantis and B. bifidum (Delcenserie et al., 2007; Milani et al., 
2014; Bondue et al., 2015). In a recent study, Bondue et al. (2016) demonstrated the ability of 
B. bifidum BBA1, a species isolated from breast-fed children’s faeces, and B. crudilactis FR/62/b/3, 
another species of bovine origin, to grow on media containing BMO, and more particularly, the 3’SL 
as the main carbohydrate source. The B. crudilactis LMG 23609 genome does not seem to possess any 
genetic abilities to metabolise BMO unless in the presence of cross-feeding. This present study does 
not explain the ability of B. crudilactis FR/62/b/3 to grow on medium with 3’SL as the main 
carbohydrate source, as observed by Bondue et al. (2016). Some residual glucose or carbohydrates 
present in yeast or peptone extracts of culture media associated with a genome adapted to simple 
sugars digestion could be responsible for B. crudilactis growth in MRS2-3’SL (Bondue et al., 2016). 
CFSM issued from lactic acid bacteria or bifidobacteria contained metabolites decreasing virulence 
gene expression of C. jejuni (Mundi et al., 2013), E. coli O157:H7 (Medellin-Pena et al., 2007, 2009) 
and S. Typhimurium (Bayoumi et al., 2012). In our study, CFSM obtained from medium 
supplemented with whey and fermented by B. mongoliense FR/49/f/2 was able to decrease E. coli 
O157:H7 ATCC 43890 virulence gene expression. All the 5 tested virulence genes were significantly 
under-expressed (ler, fliC, luxS, stx1 and qseA). Furthermore, with CFSM obtained from medium 
fermented without any glucose, three genes were significantly down-regulated (fliC, luxS and stx1). In 
the study of Bondue et al. (2016), CFSM obtained from medium supplemented with 3’SL and 
fermented by B. bifidum BBA1 and B. crudilactis FR/62/b/3 presented a significant effect against 
E. coli O157:H7 ATCC 43890 virulence gene expression. Indeed, most of the virulence gene 
expressions were down-regulated (ler, luxS, stxB2 and qseA), except the fliC gene, which tended to be 
up-regulated. These results are different from what is observed in this study with B. mongoliense 
FR/49/f/2 (significant down-regulation of fliC gene and significant up-regulation of luxS and stx1 
genes). According to the genome of B. mongoliense DSM 21395, including many genes encoding 
enzymes from the GH family, metabolites produced in medium supplemented with 3’SL and 
fermented by B. mongoliense FR/49/f/2 could be different than those produced by B. crudilactis 
FR/62/b/3 and B. bifidum BBA1. Also, the down-regulation of the fliC gene while other virulence 
genes were up-regulated has already been demonstrated in other studies (Carey et al., 2009; Mei et al., 
2015; Singh et al., 2015). Quorum sensing, which is regulated by the luxS gene, influences expression 
of virulence genes such as ler and fliC. However, nutrients can interfere with quorum sensing 
mechanisms (Henke et al., 2004; Kaper et al., 2004, Nakanishi et al., 2006; Mellies et al., 2007) and 
induce an increase in virulence gene expression through an increase in luxS expression. Also, stress 
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could play a role in virulence expression causing up- or down-regulation (Carey et al., 2009; Mei et 
al., 2015; Singh et al., 2015). However, our previous experimental conditions did not influence 
virulence factor expression (Bondue et al., 2016). The media MRS2-G and MRS2-Wh are rich in 
carbohydrates, and fermentation products such as lactate and acetate are synthesized. To prevent an 
inhibition of pathogenic bacteria growth due to media acidification, all CFSM were neutralized before 
testing them with E. coli or S. Typhimurium as described previously (Medellin-Pena et al., 2016; 
Bondue et al., 2016). 
After contact with the CFSM, S. Typhimurium ATCC 14028 virulence gene expression was 
modulated, but not always in the same way as E. coli O157:H7 ATCC 43890. The CFSM from 
medium supplemented with glucose gave the same kind of regulation for both pathogens, and all the 
tested genes were over-expressed with S. Typhimurium (hil, ssrB2 and sopD). CFSM from media 
without any glucose or supplemented with whey under-expressed E. coli virulence genes, while these 
CFSM induced mainly up-regulations of Salmonella virulence genes (hil and sopD). The only trend 
for down-regulation of Salmonella virulence genes was observed with CFSM supplemented with 3’SL 
(hil and sopD genes). The metabolites obtained from the fermentation of 3’SL by B. mongoliense 
FR/49/f/2 could decrease pathogenicity of S. Typhimurium. This effect had already been observed 
with CFSM fermented by B. bifidum BBA1, where all the tested genes were under-expressed (Bondue 
et al., 2016).  
Little is known about the exact nature of these metabolites. These bioactive molecules could originate 
from the degradation of proteins such as nisin or subpeptins similar to JM4-A and JM4-B, produced 
by lactic bacteria and having an antimicrobial effect (Ebbensgaard et al., 2015; Sumi et al., 2015). The 
3’SL or whey digestion by B. crudilactis FR/62/b/3 or B. mongoliense FR/49/f/2 has an antivirulent 
effect on E. coli O157:H7 and S. Typhimurium (Bondue et al., 2016) and these bioactive molecules 
could be related to some carbohydrate residues, if they are obtained from carbohydrate metabolism. 
β-galactosidase genes, necessary for 3’SL degradation, have been identified in the B. crudilactis LMG 
23609 genome but do not seem sufficient to easily metabolise the BMO. The enzymatic machinery 
proposed for BMO degradation identified in the B. mongoliense DSM21395 genome is more 
sophisticated with the putative presence of β-galactosidases, but also with α-sialidases and 
β-hexosaminidases. This highlights the putative capacity of B. mongoliense to metabolise the 3’SL and 
other complex BMO. The carbohydrate residues issuing from this degradation, such as sialic acid, Glc, 
Gal or GlcNac, could be involved in this antivirulent effect (Figure S3). The potential metabolites 
from 3’SL or whey degradation are probably different from those mentioned above and could explain 
why the 3’SL and whey fermentation by B. mongoliense FR/49/f/2 CFSM did not have the same 
antivirulence effect on E. coli O157:H7 compared to B. crudilactis FR/62/b/3 CFSM. Information is 
lacking about the exact nature of these molecules (peptides or glucidic residues), and a size-exclusion 
chromatography in association with a mass spectrometry could contribute to further identifying them. 
  




In conclusion, according to the genome analysis of B. mongoliense DSM21395 associated to the 
growth of B. mongoliense FR/49/f/2 on media supplemented with whey or 3’SL, B. mongoliense 
presents a genotype and a phenotype more adapted to the digestion of BMO compared to 
B. crudilactis. These two different kinds of metabolism observed for these two bifidobacteria species 
from bovine origin could have an impact on the nature of produced residual metabolites, which could 
differ in their influence on the virulence expression of pathogens. CFSM obtained from medium 
supplemented with whey and fermented by B. mongoliense FR/49/f/2 presented the most interesting 
effect by decreasing the virulence expression of the five tested genes of E. coli O157:H7 (ler, fliC, 
luxS, stx1 and qseA). For S. Typhimurium, the CFSM obtained after 3’SL fermentation presented the 
most interesting effect by decreasing 2 of the 3 tested genes (hil and sopD). According to this study, 
B. mongoliense FR/49/f/2 could be a potential probiotic, which associated to BMO, could maintain the 
young child’s gastrointestinal health through a synbiotic effect.  




The author wishes to acknowledge François Brose for his valuable help on this project.  
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aPCR efficiency: E =  [(10(-1/slope))/2] x 100 % 
bE. coli O157:H7 grown in LB broth for 4 h. 
cE. coli O157:H7 grown in LB broth supplemented with unfermented culture media CFSM for 4 h. 
















Table S1 Cycle threshold values corresponding to the effects of tested CFSM on E. coli O157:H7 genes expression. 
aPCR efficiency: E =  [(10(-1/slope))/2] x 100 % 
bE. coli O157:H7 grown in LB broth for 4 h. 
cE. coli O157:H7 grown in LB broth supplemented with unfermented culture media CFSM for 4 h. 
dE. coli O157:H7 grown in LB broth supplemented with fermented concentrated culture media CFSM from B. mongoliense for 4 h. 
 
Gene PCR efficiencya (%) LB controlb 
Test supernatants from unfermented mediac CFSM from fermented media byB. mongoliensed 
  
MRS2 G MRS2 MRS2-Wh MRS2-3’SL MRS2 G MRS2 MRS2-Wh MRS2-3’SL 
gnd 98.5 16.5 ± 0.9 21.3 21.2 25.8 24.3 21.8 ± 0.4 20.9 ± 0.7 25.3 ± 0.7 22.2 ± 1.1 
ler 99 17.9 ± 0.8 24.9 27.2 28.9 27.8 24.6 ± 0.3 24.6 ± 0.7 29.2 ± 0.9 25.1 ± 1.3 
fliC 98 20.4 ± 2.3 17.8 21.9 29.2 22.6 21.7 ± 1.2 22.3 ± 1.0 31.2 ± 0.9 22.3 ± 1.7 
luxS 100 23.7 ± 2.2 26.7 28.8 33.8 32.2 30.0 ± 0.9 27.4 ± 1.2 34.5 ± 0.9 29.3 ± 1.2 
stx1  98 28.9 ± 1.7 26.1 28.2 31.5 30.1 27.7 ± 0.5 26.9 ± 0.9 32.3 ± 0.9 27.3 ± 0.9 
qseA 99 20.1 ± 1.3 24.5 25.0 28.9 27.5 25.8 ± 0.3 24.7 ± 1.0 30.6 ± 0.9 25.7 ± 0.3 
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Table S2 Cycle threshold values corresponding to the effects of tested CFSM on S. Typhimurium 
gene expression. 
 
 aPCR efficiency: E =  [(10(-1/slope))/2] x 100 % 
bS. Typhimurium grown in BHI broth for 4 h. 
cS. Typhimurium grown in BHI broth supplemented with concentrated supernatants from culture media unfermented for 4 h. 
dS. Typhimurium grown in BHI broth supplemented with concentrated supernatants from culture media fermented B. mongoliense FR/49/f/2 
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Figure S3 Schematic representation of BMO and 3’SL metabolism by B. mongoliense DSM 21395 
and B. crudilactis LMG 23609. 
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Following the findings from the previous studies, the next step was to test the effects of 
3’-sialyllactose (3’SL) associated with Bifidobacterium crudilactis FR/62/b/3 on the young child 
microbiota. Simulator of the human intestinal microbial ecosystem (SHIME®) model seems 
particularly adapted to highlight interactions between pre/probiotics and the microbiota and was used 
to partially reproduce the digestive physiology and microbiota of young children. 
 
This third study entitled “Effect of synbiotic combination of Bifidobacterium crudilactis and 
3’-sialyllactose on a toddler microbiota implemented in the SHIME® model” tested the prebiotic effect 
of 3’SL, probiotic effect of B. crudilactis FR/62/b/3 and synbiotic effect of their association on a 
toddler microbiota implemented in SHIME® model. The effect of metabolites presents in cell-free 
spent media (CFSM) obtained from their culture was also investigated.  
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The objective of this study was to investigate the prebiotic effect of a bovine milk oligosaccharide, the 
3’sialylactose (3’SL), and the probiotic effect of a bifidobacteria strain from bovine origin, 
Bifidobacterium crudilactis FR/62/b/3, by using a simulator of the human intestinal microbial 
ecosystem, the SHIME® model. The synbiotic effect of 3’SL combined with B. crudilactis FR/62/b/3 
was evaluated, in addition to the filtered supernatant obtained from their culture, which could contain 
antivirulent metabolites. The ascending, transverse and descending colons of the simulator of the 
human intestinal microbial ecosystem (SHIME®) model were inoculated with feces from 3 donors 
aged between 1 and 2 years old, in separate vessels. After two weeks of stabilization of the microbiota, 
four treatments of one week (prebiotic, probiotic, synbiotic and filtered supernatants) were 
administered. In all colons, short chain fatty acid and branched chain fatty acid concentrations were 
determined using HPLC. A quantitative PCR targeting the hsp60 gene was applied to quantify the 
bifidobacteria population. The main bifidobacteria species present in each colon were identified using 
a PCR targeting the 16S rRNA gene. The bacterial diversity and the microbial composition in each 
colon were evaluated using 16S rDNA sequencing. In addition, supernatants from the three colons 
were filtered and placed in contact with Escherichia coli O157:H7. The RNA was extracted, 
normalized and reverse transcribed in cDNA to evaluate the modulation of virulence gene expression. 
The short chain fatty acid concentrations, the microbial diversity and the bacterial populations 
observed in the three colons confirmed that microbiota implemented in the SHIME® model shared 
characteristics found both in adults and infants. Bifidobacteria were able to survive in this toddler 
model, especially B. crudilactis FR/62/b/3, and the synbiotic treatment tended to a bifidogenic effect. 
Interestingly, the filtered supernatants from the donor feces significantly up-regulated the luxS gene of 
E. coli O157:H7. In conclusion, the SHIME® model developed in this study seemed well adapted to 
study the specific microbiota of toddlers. On the other hand, this study is the first to highlight some 
biofilm development in in vitro systems. Globally, although additional investigation should be 
performed, the combination of 3’SL and B. crudilactis FR/62/b/3 could have beneficial effect on 
infant microbiota by favoring increased bifidobacteria. 
 
Key words: Bifidobacterium crudilactis, 3’-sialyllactose, synbiotic, toddler, in vitro model 
  




The adult digestive microbiota harbors 1014 bacteria and contains 1000 to 2000 species, with at least 
160 widely shared (Qin et al., 2010; Nova et al., 2016). It is mainly composed of four phyla: 
Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria (Baothman et al., 2016). Conversely, 
the infant microbiota is less complex and less diversified (Belizário et al., 2015). In the first years of 
life, also called “window of opportunity”, the important changes in dietary (introduction of solid 
food), in environmental exposure and in maturation of the immune system strongly modulate its 
composition (Nuriel-Ohayon et al., 2016; Laursen et al., 2017). After birth and during lactation, the 
gut microbiota is dominated by the genus Bifidobacterium (Tanaka and Nakayama, 2017). The 
weaning period increases prevalence of species found in adults and belonging to the phyla 
Bacteroidetes and Firmicutes (Clostridium, Ruminococcus, Faecalibacterium, Roseburia and 
Anaerostipes) (Nuriel-Ohayon et al., 2016). Around the age of three, its diversity and composition are 
closer to the adults (Tanaka and Nakayama, 2017), although no consensus about the age has been 
found (Laursen et al., 2017).  
The microbiota is highly influenced by food intake (Guinane and Cotter, 2013), and breast-milk, rich 
in complex human milk oligosaccharides (HMO) improves growth of bifidobacteria mainly 
represented by Bifidobacterium longum subsp. infantis or Bifidobacterium bifidum (Di Gioia et al., 
2014). Simple oligosaccharides (fructo-oligosaccharides, galacto-oligosaccharides or inulin) added to 
formula are less bifidogenic (Di Gioia et al., 2014) and formula-fed children microbiota is more 
diversified and dominated by Bacteroides, Clostridium and Enterobacteriaceae (Younes et al., 2018).  
Bovine milk oligosaccharides (BMO) are structurally similar to the HMO and bifidobacteria such as 
B. infantis and B. bifidum can grow in presence of these carbohydrates (Sela, 2011; Milani et al., 
2015). Because of their enzymatic arsenal, two strains from bovine origin and isolated from raw milk 
cheese, Bifidobacterium crudilactis FR/62/b/3 and more particularly Bifidobacterium mongoliense 
FR/49/f/2, are supposed to degrade 3’-sialylactose (3’SL), one of the most representative BMO 
(Bondue and Delcenserie, 2015; Bondue et al., 2016, unpublished data). Cell free spent media 
(CFSM) obtained from co-cultures of these bifidobacteria with BMO modulated virulence gene 
expression of Escherichia coli O157:H7 ATCC 43890 and Salmonella enterica serotype Typhimurium 
ATCC 14028 (Bondue et al., 2016, unpublished data). Therefore, BMO associated with B. crudilactis 
FR/62/b/3 or B. mongoliense FR/49/f/2 could result in an interesting synbiotic effect to maintain or 
restore intestinal health in young children.  
In addition to ethical difficulties, the intestinal environment in a mouse model will never represent the 
complexity of microbial ecosystems found in the human intestine (Sannasiddappa et al., 2011). Also, 
the analyses performed on feces, as it is usually the case in many studies, are not an exact reflection of 
what is going on in the intestine (Cani and Delzenne, 2011). These last years, experimental models 
mimicking the human gastrointestinal tract have been developed (Williams et al., 2015; Dupont et al., 
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2018) and the simulator of the human intestinal microbial ecosystem (SHIME®) model is particularly 
adapted to study the interactions between probiotics and microbiota at several stages of digestion 
(Molly et al., 1993; Van den Abbeele et al., 2010; Dupont et al., 2018).   
The aim of this study was to investigate the prebiotic effect of 3’SL, the probiotic effect of 
B. crudilactis FR/62/b/3 and the synbiotic effect of 3’SL combined to B. crudilactis FR/62/b/3 in a 
SHIME® model inoculated with feces from young children. The metabolites contained in CFSM 
obtained from cultures with B. crudilactis FR/62/b/3 associated to 3’SL were also evaluated in this in 
vitro system. 
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Materials and methods 
 
Bacterial strains and growth conditions 
B. crudilactis FR/62/b/3 was isolated from Saint-Marcellin, a raw cow milk cheese from Vercors 
(France). This strain and E. coli O157:H7 ATCC 43890 were stored and grown following the 
experimental protocol from Bondue et al. (2016). The CFSM containing bioactive molecules and 
issued from fermentation between B. crudilactis FR/62/b/3 and 3’SL, was obtained following the 
protocol of Bondue et al. (2016) as well.  
 
Feces collection 
Fresh feces from three healthy formula-fed children aged between one and two years-old (donor 1: 
boy, 23 months-old; donor 2: boy, 12 months-old; donor 3: girl, 24 months-old) and taking solid foods 
were collected. The three donors were delivered at full term (gestation time of 37–42 weeks) and had a 
normal birth weight (female: 2.7–5.0 kg; male: 2.9–5.2 kg) (Rocha Martin et al., 2019). They were 
vaginally delivered and did not suffer any gastro-enterical disorders or sickness. Only the first donor 
received an antibiotic treatment at one-month-old. The first child was breastfed 5 months, the second 
10 months and the third 12 months. The fecal samples were immediately stored in anaerobic jars using 
Anaerogen 3.5 bag (Oxoid, Aalst, Belgium) at 4 °C before being transferred to the laboratory in a 
cooler (4°C). A delay of 12 hours was tolerated between the sampling and the inoculation. 
 
Description of the toddler SHIME® model 
The SHIME® system consists of five double-wall vessels simulating the stomach, the small intestine 
and the three colons as fed-batch cultures (Molly et al., 1993). The model of this study (Figure 13) 
was adapted from the validated adult model developed by Ghent University and ProDigest (Van den 
Abbeele et al., 2010, 2012). The fed-batch cultures were maintained at 37 °C, under agitation, closed 
and kept in anaerobic conditions using nitrogen flushing. The ascending (AC), transverse (TC) and 
descending (DC) colons were inoculated with fecal samples before starting each run. A 20% (w/v) 
solution made from fecal samples and phosphate buffer was homogenized in a stomacher and 
filteredwith stomacher bag with a mesh screen liner (80 microm pore size) (Biomérieux, Basingstoke, 
England). The filtered inoculum was mixed with a nutritional medium (5% v/v) and added in AC, TC 
and DC to obtain a volume of 100 mL, 160 mL and 120 mL, respectively. The medium was provided 
by the ProDigest firm (Ghent, Belgium) and was composed of pectin (1 g/L), glucose (1 g/L), starch 
(1 g/L), cellobiose (1 g/L), proteose peptone (2 g/L), mucin (6 g/L), lactose (2.1 g/L), casein (0.2 g/L), 
whey proteins-lactalbumin (2.7 g/L), L-cystein-HCl (0.2 g/L) (reference: PD-NM005). In all the 
colons, the pH was adjusted and continuously controlled to be in a range of 5.4–5.6, 6.0–6.3, and 6.3–
6.5, respectively. Three times a day, 28 mL of nutritional medium (adjusted to pH 3.8–4.0) and 12 mL 
of pancreatic juice were added to the stomach (pH=3.8–4.0) and the small intestine (pH=5.9–6.1), 
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respectively. The pancreatic juice was made of NaHCO3 (2.5 g/L), Oxgall (4 g/L) and pancreatin (0.9 
g/L). The components were also provided by the ProDigest company (Ghent, Belgium). After fecal 
inoculation, an initial stabilization of two weeks was necessary to allow a specific microbiota 
adaptation to each colon.  
 
Treatments  
After stabilization, four treatments of one week were applied to the system through the stomach 
compartment, three times a day (Figure 19). The first treatment was the prebiotic treatment. Fifty mg 
of 3’SL (Carbosynth, Berkshire, UK) were inoculated three times per day in order to obtain a daily 
intake of 150 mg corresponding to a human breastfeeding contribution (ten Bruggencate et al., 2014). 
The second treatment was a supernatant of B. crudilactis FR/62/b/3 co-culture with 3’SL and 4 mL of 
this filtered supernatant were administrated three times a day (CFSM treatment) (Bondue et al., 2016). 
To avoid a potential bacterial implantation in the model, the two last treatments involving alive 
B. crudilactis FR/62/b/3 (probiotic and synbiotic treatments) were tested at the end of the run on the 
SHIME® system. Regarding the probiotic treatment, 4 mL of a Maximum Recovery Diluant solution 
(Oxoid, Temse, Belgium) containing 9 log CFU/mL of B. crudilactis FR/62/b/3 was added three times 
per day. The synbiotic treatment consisted of the prebiotic and probiotic treatments administered 
simultaneously, as explained previously. Regarding the runs 1 and 2, the first treatment was started 
after two weeks of stabilization. Then, the treatments were administrated, one after the other, with a 
pause of one week between each (short stabilizations). Regarding run 3, the two first treatments were 
started at the same time but separately and inoculated with the same feces (feces 3a). One month later, 
the two last treatments were also started together but separately and inoculated with the same feces 
sampled from the same donor (feces 3b). For the third run, the four treatments were tested separately, 
and the two corresponding stabilization weeks were respected. 
 
 
Figure 19 Chronology of the different treatments applied during experimentation with the toddler 
SHIME® model. 
3SL: prebiotic treatment with 3’-sialylactose; CFSM: metabolic treatment with cell-free spent media obtained from culture between 
3’-sialyllactose and B. crudilactis FR/62/b/3; Bc: probiotic treatment with B. crudilactis FR/62/b/3; Bc+3SL: synbiotic treatment with 
3’-sialyllactose and B. crudilactis FR/62/b/3. 
 
 




Samples from AC, TC and DC were collected at the end of treatments periods and during the 
stabilization periods preceding them. These samples were stored at —20 °C before analysis. 
 
Short-chain fatty acid (SCFA) and branched-chain fatty acid (BCFA) determination 
Samples obtained from the different compartments of the SHIME® system were filter-sterilized, 
acidified and subsequently injected automatically into the Alliance HPLC System e2695 
(Waters, Milford, USA), for the determination of short chain fatty acids. Isocratic HPLC was 
performed using an Aminex HPX-87H column (Bio-Rad, Hercules, CA, USA) combined with a UV 
detector (210 nm) with sulfuric acid (5 mM) as mobile phase at a flow rate of 0.6 mL/min with a 
temperature of 60 °C. Each peak was integrated by the Empower 3 software (Waters, Milford, USA) 
after the encoding of the standard curve and manual verification. The results are shown in mM. 
 
DNA extraction, sequencing and bifidobacterium identification 
Total DNA was extracted from each colon sample using the DNeasy Blood and Tissue kit (Qiagen, 
Hilden, Germany) following the manufacturer’s recommendations. The final concentrations were 
estimated using a Nanodrop 2000 spectrophotometer (Thermo Scientific, USA). The purity and 
quality of DNA was assessed by measuring the ratio of absorbance (260/280 nm). The genus 
Bifidobacterium was targeted by PCR amplification of the hsp60 gene (F: 5’-TCM-GAC-GCC-ATC-
GTC-AA-3’ and R: 5’-GCG-ATC-TGM-TCC-TTG-GT-3’) (Delcenserie et al., 2005). The primers 
were synthetized by Eurogentec (Liège, Belgium). Quantitative PCR was conducted using the GoTaqâ 
qPCR Master Mix (promega, Leiden, Netherlands) and using the ABI 7300 Real Time PCR system 
(Applied Biosystems, Singapore). The qPCR was performed in a total volume of 20 µL containing 10 
µL of GoTaqâ Master Mix, 5.75 µL of molecular grade water, 1 µL of forward primer (10 µM) and 1 
µL of reverse primer (10µM), 0.25 µL of carboxy-X-rhodamine (30 µM) and 2 µL of DNA.  The 
samples were subjected to a preheat at 50 °C for 2 minutes followed by an initial denaturation at 95 °C 
for 10 minutes. Then, a denaturation at 95 °C for 15 seconds and a step of annealing and elongation at 
54 °C for one minute were repeated 45 times. For all fecal samples, the cycle thresholds were 
converted into CFU using a calibration curve.  
Then, a specific bifidobacteria 16S rDNA gene was amplified to identify the main species in each 
colon before and after the different treatments (F: 5’-AAT-AGC-TCC-TGG-AAA-CGG-GT-3’ and R: 
5’-CGT-AAG-GGG-CAT-GAT-GAT-CT-3’) (Delcenserie et al., 2004). The primers were synthetized 
by Eurogentec (Liège, Belgium). The PCR mix was carried out with the TaKaRa TaqTM kit (TaKaRa, 
Saint-Germain-en-Laye, France) in a total volume of 50 µL containing 0.25 µL of TaKaRa Taq (5 
U/µl), 5µL of buffer, 4 µl of DNTP mixture (2.5 mM each), 2 µL of the forward primer (final 
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concentration at (10 µM), 2 µL of the reverse primer (10 µM), 4 µL of the template ( < 500 ng) and 
sterilized distilled water up to 50 µL. The amplification was performed in a Mastercycler Gradient 
Thermocycler (Flexigene, Cambridge, UK). The samples were submitted to an initial denaturation at 
95 °C for 5 minutes. Then, a denaturation at 95 °C for 30 seconds, an annealing step at 58 °C for 30 
seconds and an elongation step at 72 °C for 1.5 minutes were repeated 50 times. Amplified PCR 
products were then analyzed using gel electrophoresis (agarose 1%) to confirm the presence and the 
length of the amplicons. Sanger sequencing was performed using the ABI 7300 (Applied 
Carbosystem, Carlsbad, CA) by the GIGA institute (Liège, Belgium) and the sequences were analyzed 
using the BLAST tool on the NCBI site (www.ncbi.nlm.nih.gov/BLAST).  The species presenting the 
highest identity with the analyzed sequence were considered as the bifidobacteria species present in 
majority.  
 
16S rDNA sequencing and data analysis 
PCR-amplification of the V1–V3 region of the 16S rDNA and library preparation were performed 
with the following primers (with Illumina overhand adapters): forward (5’-
GAGAGTTTGATYMTGGCTCAG-3’) and reverse (5’-ACCGCGGCTGCTGGCAC-3’). Each PCR 
product was purified using the Agencourt AMPure XP beads kit (Beckman Coulter; Pasadena, CA, 
USA) and submitted to a second PCR round for indexing, using the Nextera XT index primers 1 and 
2. After purification, PCR products were quantified using the Quant-IT PicoGreen (ThermoFisher 
Scientific; Waltham, MA, USA) and diluted to 10 ng/µL. A final quantification, by quantitative qPCR, 
of each sample in the library was performed using the KAPA SYBR FAST qPCR Kit 
(KapaBiosystems; Wilmington, MA, USA) before normalization, pooling and sequencing on a MiSeq 
sequencer using V3 reagents (Illumina; San Diego, CA, USA). Sequence reads processing was, as 
described previously, using MOTHUR software package v1.39 (https://www.mothur.org) for 
alignment and clustering, and UCHIME algorithm (https://www.drive5.com/uchime/) for chimera 
detection (Schloss et al., 2009; Edgar et al., 2011; Rodriguez et al., 2016). A clustering distance of 
0.03 was used for OTU generation. 16S rDNA reference alignment and taxonomical assignment were 
based upon the SILVA database (v1.32) (https://www.arb-silva.de) of full-length 16S rDNA 
sequences (Quast et al., 2011). Subsample datasets with 10,000 reads were obtained and used to 
evaluate alpha-diversity (richness estimation–Chao1 estimator, microbial biodiversity–reciprocal 
Simpson index and the population evenness–derived from Simpson index) using MOTHUR. Beta-
diversity (bacterial community composition) was assessed with MOTHUR using distance matrix 
based on Bray-Curtis dissimilarity index. Phylogenetic distance matrix has been evaluated with 
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DNA extraction and virulence gene expression analysis of E. coli O157:H7 
The samples from the three colons, before and after the treatments, were centrifuged twice at 5000 X g 
for 10 minutes and the supernatant was then filter-sterilized (Minisartâ 0.2 µm, Sartorius, Vilvoorde, 
Belgium). Following the experimental protocol from the validated study of Bondue et al. (2016), the 
CFSM were exposed to E. coli O157:H7 ATCC 43890 for 4 hours. Briefly, the RNA was extracted, 
normalized at 100 ng/µl and reverse transcribed in cDNA. Next, the expression of genes ler (involved 
in attaching effacing (A/E) lesions, fliC (involved in mobility), stx1 (encoding shiga-toxin), luxS 
(major regulator of quorum sensing and producing autoinducer-2) and qseA (involved in quorum 
sensing and locus of effacement enterocyte expression regulator) were determined using qPCR (with 
gnd as reference housekeeping gene). A special attention was given to the controls to exclude any 
potential effect observed from the control media. The relative changes in gene expression were 
calculated using the Pfaffl formula (Pfaffl, 2001): ratio  =  (virulence gene Efficiency) Ct control – Ct sample / 
(reference gene Efficiency) Ct control – Ct sample, with Efficiency = 10(−1/slope). A positive ratio was 
considered as an over-expression, and a negative as an under-expression.  
 
Statistical analysis 
All the experiments on the SHIME® system were 3 independent replicates from three different donors. 
The Ct obtained after hsp60 gene amplification and the SCFA analysis were made in triplicate, for all 
the samples from the three runs. Linear regression was used to consider treatments, colons, runs and 
time impact on the observed results. Statistical significance was set at P < 0.05 and calculations were 
performed with R software (version 3.4.0; https://www.R-project.org/). The normality of the data and 
the equality of the variance were evaluated (Levenne test) and a paired t-test comparing results before 
and after treatments were made, where P < 0.05 was considered as significant. Also, Virulence gene 
expression was evaluated with a multinomial or logistic analysis with R software. The ratio obtained 
from the virulence analysis was not normally distributed; therefore, a non-parametric Wilcoxon test 
was performed to compare the results before and after treatments. In the same way, differences were 
considered significant at P values < 0.05. Regarding the metagenetic analysis, differences between 
population variances were evaluated with AMOVA (with 10,000 iterations) and beta-dispersions with 
HOMOVA (with 10,000 iterations), before and after treatments, in MOTHUR. Differences were 
considered significant when P < 0.05.   




SCFA and BCFA analysis 
The SCFA were quantified using HPLC in AC, TC and DC, after each of the 4 treatments and 
stabilizations. In all the colons, expected profiles of SCFA were detected and the SCFA productions 
observed for the 3 runs were mostly similar (Figure 20). According to the linear regression analysis, 
all the treatments had a highly significant impact on SCFA concentrations (P = 0.0005), especially the 
CFSM treatment, which were statistically different from the prebiotic (P = 0.0002) and synbiotic (P = 
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Figure 20 Effects of prebiotic, metabolic, probiotic and synbiotic treatments on short chain fatty acid 
(SCFA) and branched chain fatty acid (BCFA) concentrations measured in ascending (a), transverse 
(b) and descending (c) colons all along the three runs by using HPLC.  
Stab.: stabilization period before starting the experiments and between each treatment; 3SL: prebiotic treatment with 3’-sialylactose; CFSM: 
metabolic treatment with cell free spent media obtained from culture of 3’-sialyllactose and B. crudilactis FR/62/b/3; Bc: probiotic treatment 
with B. crudilactis FR/62/b/3; Bc+3SL: synbiotic treatment with 3’-sialyllactose and B. crudilactis FR/62/b/3. *P<0.05. 
 
The CFSM treatment led to significant increases of total SCFA and butyrate concentrations in AC 
(from 59.4±0.4 mM to 134.2±2.0 mM and from 9.4±3.7 mM to 21.2±9.7mM, respectively; P = 0.002 
and P = 0.004, respectively), TC (from 83.0±2.8 mM to 151.3±10.0 mM and from 10.8±2.9 mM to 
33.2±6.9 mM, respectively; P = 0.005 and P = 0.029, respectively) and DC (from 80.8±3.1 mM to 
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respectively). A high significant increase of propionate concentration was observed in AC (from 
8.8±1.7 mM to 84.2±6.4 mM; P = 0.005) and two slight significant increases in TC (from 11.7±1.1 
mM to 21.5±4.1 mM; P = 0.048) and in DC (from 10.5±0.9 mM to 18.9±2.8 mM; P = 0.040). 
Significative increases of valerate and iso-forms concentrations were notified in AC (from 9.8±0.4 
mM to 19.8±2.7 mM and from 3.3±1.2 mM to 16.6±0.9 mM, respectively; P = 0.045 and P = 0.018, 
respectively), TC (from 11.7±1.1 mM to 21.4±2.5 mM and from 20.0±3.1 mM to 2.4±0.7 mM; P = 
0.030 and P = 0.022, respectively) and DC (from 11.5±1.3 mM to 22.6±2.3 mM and 20.0±4.2 mM, 
respectively; P = 0.015 and P = 0.019, respectively) (Figure 20). The prebiotic treatment significantly 
increased the acetate concentration in DC (from 48.9±2.6 mM to 54.3±2.4 mM; P = 0.001) and the 
synbiotic treatment decreased valerate concentration in AC (from 10.7±0.8 mM to 9.8±0.9 mM; P = 
0.027) and butyrate concentrations in TC and DC (from 9.1±3.6 mM to 8.6±3.2 mM and from 9.1±3.4 
mM to 6.1±3.3 mM, respectively; P = 0.048 and P = 0.020, respectively) (Figure 20). The probiotic 
treatment increased total SCFA concentration in TC (from 60.4±11.6 mM to 64.6±8.6 mM; P = 0.043) 
(Figure 20). 
 
Quantification and identification of bifidobacteria 
According to the linear regression analysis, the feces inoculated in the SHIME® model contained 
quantities of bifidobacteria significantly different from each other (P < 0.0001). In addition, a 
significative impact on bifidobacteria quantities was observed by comparing the samplings before and 
after treatments (P = 0.0025) (Figure 21). 
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Figure 21 Effects of prebiotic, metabolic, probiotic and synbiotic treatments on bifidobacteria counts 
in ascending (a), transverse (b) and descending (c) colons all along the three runs by using a 
quantitative qPCR targeting the hsp60 gene. 
J0: day of feces inoculation; stab.: stabilization period before starting the experiments and between each treatment; 3SL: prebiotic treatment 
with 3’- sialyllactose; CFSM: metabolic treatment with cell free spent media obtained from culture of 3’-sialyllactose and B. crudilactis 
FR/62/b/3; Bc: probiotic treatment with B. crudilactis FR/62/b/3; Bc+3SL: synbiotic treatment with 3’-sialyllactose and B. crudilactis 
FR/62/b/3. **P<0.05; *P<0.1. 
 
 
After 2 weeks of stabilization into the SHIME® system, a significant increase of bifidobacteria was 
observed in AC (from 4.4 ± 0.2 log CFU/mL in the initial feces to 5.0 ± 0.5 log CFU/mL; P = 0.032) 
followed by a significant decrease after the prebiotic treatment (3.9 ± 0.5 log CFU/mL; P = 0.032) 
(Figure 21). The synbiotic treatment tended to increase the bifidobacteria quantities in AC and TC 
(from 4.9 ± 0.3 log CFU/mL to 5.7 ± 0.5 log CFU/mL and from 4.4 ± 0.2 log CFU/mL to 5.7 ± 0.1 log 
CFU/mL, respectively; P = 0.096 and P = 0.093, respectively) (Figure 21). Only one repetition was 
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Amplicon sequencing allowed the identification of 3 bifidobacteria species potentially dominant for 
run 1 (B. longum, B. bifidum and B. pseudocatenulatum), 7 for run 2 (B. longum, B. bifidum, 
B. pseudocatenulatum, B. adolescentis, B. breve, B. crudilactis, B. kashiwanohense) and 3 for run 3 
(B. pseudocatenulatum, B. kashiwanohense and B. catenulatum) (Table 8). B. kashiwanohense was 
characterized as the dominant bifidobacteria in the third inoculated feces. During this run, this species 
was identified in each colon after the synbiotic treatment, in AC and DC after the CFSM treatment and 
in DC after the prebiotic treatment. During run 2, B. kashiwanohense was identified in each colon after 
the prebiotic treatment and in TC and DC after the probiotic treatment. After the prebiotic and 
probiotic treatments, B. pseudocatenulatum was identified in each colon for run 1 and in the AC for 
run 3. B. pseudocatenulatum was also identified after the CFSM treatment in TC of runs 2 and 3. 
B. catenulatum seemed to be predominant after the probiotic treatment in the TC and DC of the run 3. 
B. bifidum was identified in the feces inoculated in the run 2, also observed after the CFSM treatment 
in the TC and DC of the run 1 and in the AC of the run 2. B. longum were only identified in the feces 
inoculated at the beginning of the run 1 and then only appeared once in the AC of run 2 after the first 
pause. B. adolescentis was only present in the DC of run 2 after the first post treatment stabilization 
period and B. breve was identified in the same colon after the CFSM treatment. B. crudilactis was 
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 Run 1 Run 2 Run 3 
Feces B. longum B. bifidum B. kashiwanohense 
ASCENDING COLON 
Stabilization B. pseudocatenulatum B. kashiwanohense B. kashiwanohense 
3SL B. pseudocatenulatum B. kashiwanohense B. pseudocatenulatum 
Stabilization B. pseudocatenulatum B. longum B. kashiwanohense 
CFSM B. pseudocatenulatum B. bifidum B. kashiwanohense 
Stabilization B. pseudocatenulatum B. kashiwanohense B. pseudocatenulatum 
Bc B. pseudocatenulatum B. crudilactis B. pseudocatenulatum 
Stabilization B. bifidum ND B. kashiwanohense 
Bc+3SL B. pseudocatenulatum ND B. kashiwanohense 
TRANSVERSE COLON 
Stabilization B. bifidum B. kashiwanohense B. kashiwanohense 
3SL B. pseudocatenulatum B. kashiwanohense B. pseudocatenulatum 
Stabilization B. bifidum B. kashiwanohense B. kashiwanohense 
CFSM B. bifidum B. pseudocatenulatum B. pseudocatenulatum 
Stabilization B. bifidum B. kashiwanohense B. pseudocatenulatum 
Bc B. pseudocatenulatum B. kashiwanohense B. catenulatum 
Stabilization B. bifidum ND B. kashiwanohense 
Bc+3SL B. pseudocatenulatum ND B. kashiwanohense 
DESCENDING COLON 
Stabilization B. bifidum B. kashiwanohense B. kashiwanohense 
3SL B. pseudocatenulatum B. kashiwanohense B. kashiwanohense 
Stabilization B. pseudocatenulatum B. adolenscentis B. kashiwanohense 
CFSM B. bifidum B. breve B. kashiwanohense 
Stabilization B. bifidum B. kashiwanohense B. catenulatum 
Bc B. pseudocatenulatum B. kashiwanohense B. catenulatum 
Stabilization ND ND B. kashiwanohense 
Bc+3SL ND ND B. kashiwanohense 
 
Table 8 Bifidobacteria species detected in majority in the initial feces and in ascending, transverse and 
descending colons all along the three runs by using a PCR targeting 16S rDNA, before and after the 
prebiotic, metabolic, probiotic and synbiotic treatments. 
Stabilization: period before starting the experiments and between each treatment; 3SL: prebiotic treatment with 3’-sialylactose; CFSM: 
metabolic treatment with cell free spent media obtained from culture of 3’-sialyllactose and B. crudilactis FR/62/b/3; Bc: probiotic treatment 
with B. crudilactis FR/62/b/3; Bc+3SL: synbiotic treatment with 3’-sialyllactose and B. crudilactis FR/62/b/3; ND: not determined. 
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Virulence gene expression  
The CFSM obtained from the previously described samples were incubated with E. coli O157:H7 
ATCC 43890 for 4 hours. According to a logistic regression analysis, the filtered supernatants from 
the inoculated feces were able to significantly modulate the virulence gene expression (P = 0.0087) of 
E. coli O157:H7 (Figure 22a; Table S1a). A significative up-regulation of the luxS gene 
(systematically observed with all the feces) was confirmed by a Wilcoxon test (P = 0.013) 
(Figure 22a; Table S1a). The effects of the microbiota on virulence gene expression were also 
assessed. According to a multinomial regression analysis, the gene expression was significantly 
modulated by the microbiota implanted into the SHIME® model (P = 0.0035) (Figure 22b; Table 
S1b). In addition, the virulence gene expression could be significantly up- or down-regulated 
according to the administered treatment (P = 0.0194) and according to the run (P = 0.0065) 




Figure 22 Impacts of filtered supernatants obtained from feces (a), microbiota implemented in the 
SHIME® model without treatment (b) and microbiota implemented in the SHIME® model after 
prebiotic, metabolic, probiotic and synbiotic treatments (c) on virulence gene expression of E. coli 
O157:H7.  
The down- or up-regulation were determined from gene expression ratios of E. coli O157:H7 obtained after the normalization to the 
housekeeping gene gnd and compared with those of the corresponding control. A negative value was considerate as a down-regulation and a 
positive value as an up-regulation.  
AC: ascending colon; TC: transverse colon; DC: descending colon; 3SL: prebiotic treatment with 3’-sialyllactose; CFSM: metabolic 
treatment with cell free spent media obtained from culture of 3’-sialyllactose and B. crudilactis FR/62/b/3; Bc: probiotic treatment with 
B. crudilactis FR/62/b/3; Bc+3SL: synbiotic treatment with 3’-sialyllactose and B. crudilactis FR/62/b/3. *P<0.05. 
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16S rDNA sequencing analyses 
In the initial feces, the Chao1 richness index (which considers the richness of the microbial 
community) was on average of 527±251 and the reciprocal Simpson biodiversity index (which 
measures the microbial diversity, taking into account both evenness and richness) was on average of 
9±3 (Figures 23a et 23b). After the first two weeks of stabilization and taking into account all the 
colons together, these same indexes decreased to an average of 223±115 and 4±2, respectively 
(Figures 23a et 23b). Also, index dispersions (Chao1, reciprocal Simpson and Simpson evenness) 
were less important once the microbiota was inoculated in the SHIME® model (Figures 23a, 23b et 
23c). The Simpson evenness index evaluates how the OTU were evenly distributed between the 
groups. Compared to the control, the CFSM treatment seemed to decrease the alpha-dispersion 
indexes: the Chao1 index decreased from 239±128 to 215±79, the reciprocal Simpson index from 6±5 
to 2±0.6 and the evenness index from 0.036±0.018 to 0.022±0.007. In contrast, the synbiotic treatment 
seemed to increase them: the Chao1 index decreased from 237±51 to 291±112, the reciprocal Simpson 
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Figure 23 Effects of prebiotic, metabolic, probiotic and synbiotic treatments on Chao1 index (a), 
Simpson inverse (b) and evenness (c) all along the three runs. 
Stab.: stabilization period before starting the experiments and between each treatment; 3SL: prebiotic treatment with 3’-sialyllactose; CFSM: 
metabolic treatment with cell free spent media obtained from culture of 3’-sialyllactose and B. crudilactis FR/62/b/3; Bc: probiotic treatment 
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The AMOVA analyses did not reveal statistical differences in population variances constituting the 
microbiota before and after the different treatments. The microbiota beta-dispersion evaluation with 
HOMOVA analyses, using a Bray-Curtis matrix, presented the same conclusions. After the treatments, 
no changes in bacterial population proportions were statistically significant and the results mentioned 
below are based on descriptive observations. However, HOMOVA analyses highlighted statistically 
significant differences of intestinal microbiota between AC and TC and between AC and DC (P = 
0.0166 and P = 0.0082, respectively). No statistically differences were found between TC and DC.  
A total of 211 OTU was identified from the feces of the first donor. After the inoculation in the model, 
the richness observed in TC and DC were quite similar with an average of 182±34 OTU and 171±50 
OTU, respectively. An average of only 40±11 OTU was identified in AC. The feces were mainly 
composed of Prevotella (26%), Bacteroides (20%), Faecalibacterium (17%), Lachnospiraceae (8%), 
Ruminococcaeae (4%) and Sutturella (4%) (Figure 24a; Table S2). Two weeks after the inoculation, 
the genus Veillonella was mainly present in AC (91%) and much less in TC and DC (2% and 6% 
respectively). After the prebiotic treatment, Veillonella proportions increased in TC and DC becoming 
the dominant genus (45% and 47%, respectively) (Figure 24a; Table S2). After the CFSM treatment, 
Stenotrophomonas was predominant in each colon (75% in AC, 56% in TC and 49% in DC), while it 
represented only 1% of the population at the end of the corresponding stabilization. Not found before, 
the genus Paenibacillus represented 19% of the AC population at the end of CFSM treatment 
(Figure 24a; Table S2). The prebiotic treatment did not strongly modify the microbial population in 
the SHIME® model. The most represented genus were Stenotrophomonas, Veillonella and less 
abundantly Bacteroidetes (Figure 24a; Table S2). In the AC, the proportions of genus Pantoea 
increased from 0% to 14% after the synbiotic treatment and the proportions of the genus 
Stenotrophomanas decreased from 22% to 1 %. The dominant populations were Lactobacillus, 
Veillonella and Erysipelotrichaceae (Figure 24a; Table S2). 
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Figure 24 Effects of prebiotic, metabolic, probiotic and synbiotic treatments on composition of 
microbiota implemented in the toddler SHIME® model during the first (a), second (b) and third (c) 
runs. 
AC: ascending colon; TC: transverse colon: DC: descending colon; stabilization: period before starting the experiments and between each 
treatment; 3SL: prebiotic treatment with 3’-sialylactose; CFSM: metabolic treatment with cell free spent media obtained from culture of 
3’-sialyllactose and B. crudilactis FR/62/b/3; Bc: probiotic treatment with B. crudilactis FR/62/b/3; Bc+3SL: synbiotic treatment with 
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A total of 160 OTU was identified from the feces of the second donor. After the inoculation in the 
model, the richness observed in TC and DC were quite similar with an average of 87±34 and 110±15 
OTU, respectively. An average of 58±18 OTU was identified in AC. The feces were mainly composed 
of genus from Ruminococcaceae and Lachnospiraceae families (23% and 19%, respectively) 
(Figure 24b; Table S3). The genus Bacteroides, Ruminococcus and Lactobacillus were also very 
represented (14%, 11% and 10%, respectively). After two weeks of stabilization, the Megasphera 
genus was dominant in each colon (until 77% in AC), followed by the Bacteroides and 
Lachnoclostridium genus. The same profile was observed at the end of the prebiotic treatment 
(Figure 24b; Table S3). From the second stabilization and until the end of the run, the Enterobacter 
genus was highly dominant in each colon, with proportions varying from 67% to 95%. Although the 
Bacteroides and Lachnoclostridium genera were still present, the presence of Enterobacter made the 
results analysis difficult (Figure 24b; Table S3). 
A total of 422 and 336 OTU were observed from the two feces of the third donor (harvested at one-
month intervals). After the inoculation in the model, the richness observed in TC and DC were quite 
similar with an average of 149±56 OTU and 190±34 OTU, respectively. An average of 75±49 OTU 
was identified in AC. The two analyzed feces are mainly composed of Faecalibacterium (26% and 
58%, respectively), Bacteroides (31% and 18%, respectively) and one unknown genus from the 
Lachnospiraceae family (25% and 11%, respectively) (Figure 24c; Table S4). Two weeks after the 
inoculation of the first feces, the genus Megasphera was dominant in each colon and more particularly 
in AC where it reached 100%. The microbial composition did not seem to be influenced by the 
prebiotic treatment (Figure 24c; Table S4). The proportions in Acidaminococcus strongly increased 
from 4% to 75% in the AC, 11% to 84% in the TC and 14% to 78% in the DC after the CFSM 
treatment (Figure 24c; Table S4). In contrast, the populations in Lachnoclostridium decreased from 
39% to 6% in AC and from 25% to 7% in DC. The same trend was observed for the genus 
Megasphera, with proportions decreased from 90% to 6% in AC, 22% to 0% in TC and 42% to 3% in 
DC. The proportions of Bacteroides increased from 10% to 22% in TC and from 5% to 28% in DC 
after the probiotic treatment (Figure 24c; Table S4). The genus Acidaminococcus decreased from 
28% to 12% in AC, 31% to 11% in TC and 31% to 17% in DC after the synbiotic treatment. In 
contrast, the genus Lachnoclostridium increased from 3% to 31% in AC, 3% to 26% in TC and 3% to 
24% in DC (Figure 24c; Table S4). 
  




In vitro models 
In vitro models provide a quick and easy way to study microbiota in particular because ethical 
restrictions are limited to obtaining consent (Williams et al., 2015). Static models in batch cultures are 
limited by absence of food flow and by constant pH, digestive enzymes and bile concentrations 
(Dupont et al., 2018). Dynamic models, such as the SHIME® model, are closer to physicochemical 
conditions and parameters entered in the system allow reproductible experimentations. Nutrients 
intakes, retention times, pH, temperature and atmospheric environment are precisely controlled 
(Williams et al., 2015). TNO (the Netherlands organization) intestinal model (TIM) mimics the upper 
gastrointestinal tract with peristaltic movements and is particularly adapted to study microorganism 
survival (Dupont et al., 2018). TIM may be associated with ARCOL (artificial colon) model, which 
highlights effects on gut microbiota composition and metabolic activity (Cordonnier et al., 2015). The 
PolyfermS model is a continuous fermentation system mimicking the colon conditions. The main 
bacterial populations found in feces are immobilized in gel beads and are then released in culture 
medium (Cinquin et al., 2004; Rocha Martin et al., 2019). With five reactors corresponding to the 
stomach, small intestine, ascending, transverse and descendant colons, the SHIME® model is one of 
the most complete system to study interactions between probiotics and microbiota (Molly et al., 1993; 
Dupont et al., 2018). Experimentation over a long time period, reactor volumes close to the animal or 
human anatomy and the possibility of adding mucin beads to simulate a mucosal microbiome (M-
SHIME®) make this model very comprehensive (Van den Abbeele et al., 2012, 2013). The absence of 
enterocytes or immune cells could be corrected by adding Caco-2 cells or a macrophage cell line U937 
(Venema et al., 2013). A Host-Microbiota Interaction (HMI) module to study interactions with host 
cells during a long-term incubation may also be incorporated (Marzorati et al., 2014). Dialysis 
membranes could be added to mimic passive absorption. In addition, clinical studies about prebiotic 
metabolism have already validated the predictive power and the scientific reliability of the SHIME® 
model (Dupont et al., 2018). 
The proportion of SCFA (especially acetate, propionate and butyrate) is used as an indicator of 
bacterial colonization and high levels of SCFA are usually observed in in vitro systems, especially in 
DC, due to the lack of absorptive capacities (Williams et al., 2015). The metabolites analysed in this 
study confirmed the microbiota stabilization and colonization inside the three colon sectors. The 
observed total SCFA concentrations in each colon were in accordance with SCFA concentrations 
usually observed in feces. However, due to the variations of parameters between the different systems, 
comparison with other in vitro models is very difficult (Minekus et al., 2014). In addition, age of the 
feces donors was different from one study to another and no donors belonging to our pediatric 
population (young children) have been tested in other models.  
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The microbial composition of gastrointestinal models can be identified by classical microbiology 
methods on plate (Cinquin et al., 2004), by genetic analysis targeting specific populations, such as 
DGGE, FISH or qPCR (Cinquin et al., 2006, 2010; Van den Abbeele et al., 2010; Thevenot et al., 
2013) or by high throughput sequencing (Rocha Martin et al., 2019). The use of different methods 
complicates the comparison of microbial composition among studies. High throughput sequencing, as 
performed in this study, has been applied in the Lacroix model mimicking the infant proximal colon 
and prepared with a fecal sample from a 39-day-old donor and immobilized on gel beads (Rocha 
Martin et al., 2019). At the end of the stabilization, Bacteroides and Prevotella genera were 
predominant, followed by Veillonella and Parabacteroides genera. In our system, Bacteroides and 
Veillonella genera were well represented, contrary to Prevotella and Parabacteroides genera. After 
two weeks of feces stabilization, the microbial environments developed in our model were well 
distinct in function of the colon regions. As previously observed with the SHIME® model developed 
by Van den Abbeele et al. (2010), the ecological analysis of microbial communities (HOMOVA) 
highlighted important differences between AC and TC or AC and DC, while TC and DC remained 
similar to each other. Compared to the initial feces, the richness observed in each colon is lower, and 
more particularly in AC. This normal phenomenon is due to the environmental conditions 
programmed for the AC, which are strongly different from fecal conditions (pH, bile salts, nutrients) 
and contribute to an immediate loss of species richness. Also, some genera such as Bacteroides, 
Lachnoclostridium or Acidaminococcus seemed very well implanted in the system, while some genera 
present in initial feces, such as Coprobacillus seemed to disappear. Some bacteria, such as 
Lactobacillus or Veillonella genera, were found in minority in the initial feces. These genera, more 
abundant in the upper intestinal tract (Rajilić-Stojanović and de Vos., 2014), grew easily in this 
gastrointestinal model and more particularly in AC, in accordance with the literature.  
 
Metabolites: SCFA and BCFA 
According to the literature, total SCFA concentrations in feces are expected to be between 50 and 150 
mM (Rivière et al., 2016). In this study, the concentrations found in the reactors mimicking young 
children colons are in the same range of these data. This toddler gastrointestinal model was adapted 
from a dynamic adult model validated by Van den Abbeele et al. (2010). In both models, the highest 
concentrations were observed in DC (61.3±2.6 mM in adult model and 87.4±5.1 mM in infant model) 
and the lowest in AC (46.7±3.0 mM in adult model and 68.9±4.3 mM in infant model). The lower 
concentrations observed in AC could be explained by a more acidic pH less favorable to bacterial 
growth and therefore to SCFA production (Van den Abbele et al., 2010). Also, the high concentrations 
observed in DC could be due to the absence of absorption in this in vitro model and therefore to an 
accumulation of SCFA, increasing from reactor to reactor (Cinquin et al., 2004; Van den Abbeele et 
al., 2010). 
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Because of the age of the donors (between one and two years-old), the inoculated microbiota is 
different from that of neonates or young babies. The incorporation of solid foods in the diet strongly 
modulated the microbiota composition, sharing common properties with infants and adults. The SCFA 
proportions observed in infant feces followed a ratio close to 75:19:6 (Cinquin et al., 2006) and the 
SCFA proportions observed in adult feces followed a ratio of 60:20:20 (Hosseini et al., 2011). In AC, 
TC and DC of the model used in this study, SCFA proportions were dominated by acetate (62%, 67% 
and 70%, respectively) and followed by propionate (32%, 18% and 16%, respectively) or butyrate 
(12%, 15% and 14%, respectively). According to these SCFA proportions comprised between infant 
and adult normal values, the toddler model developed in this study could be an interesting in vitro 
system sharing both infant and adult characteristics. 
In humans, SCFA synthesis from the fermentation of carbohydrates or oligosaccharides takes place in 
the proximal colon. Because of its beneficial effects on health, especially against colorectal cancer and 
inflammation, butyrate is the most studied SCFA (Thippeswamy et al., 2011). Propionate is also 
considered beneficial for health with anti-lipogenic, cholesterol-lowering, anti-inflammatory and anti-
carcinogenic effects (Reichardt et al., 2014). The SCFA profiles are used to confirm the stability and 
the quality of the microbiota in presence but can be very difficult to interpret (Li et al., 2018). Indeed, 
ninety-five percent of SCFA are absorbed in human intestinal tract (Macfarlane and Macfarlane, 
2011). However, as the model used in this study did not mimic this absorption, analysis of the 
accumulation of SCFA was possible. The presence of butyrate, a SCFA produced by anaerobic 
bacteria (Rivière et al., 2016), confirmed the maintenance of anaerobic conditions of the model all 
along the experimentation. The BSFA (valerate, iso-butyrate and iso-valerate) are used as an indicator 
of proteins and amino acid catabolism and are considered harmful to epithelial intestinal cell 
metabolism (Fernandes et al., 2013; Zhou et al., 2014). The low quantities of BSFA detected all along 
the three runs could be a favorable indication that the implemented microbiota was well balanced. 
Interestingly, after the CFSM treatment, a significant increase in total SCFA concentrations was 
observed in all the colons and the propionate concentration was very high, especially in AC. In 
addition, the butyrate, valerate and iso-forms concentrations were important in AC, TC and DC. 
Additional analyses showed that high levels in SCFA, especially in propionate, came from the 
unfermented medium itself. The CFSM administered to this SHIME® model was a supernatant from 
culture of B. crudilactis FR/62/b/3 and 3’SL concentrated 10-fold with therefore high quantities of 
SCFA (1049 mM), composed mostly of propionate (714 mM).  
 
Bifidobacteria quantification and identification 
After two weeks of stabilization, bifidobacteria quantities increased in SHIME® system, meaning that 
culture media and choice of parameters of the system did not inhibit bifidobacteria growth. On the 
other hand, the synbiotic treatment could be responsible for an interesting bifidogenic effect, probably 
due to a cross-feeding mechanism.  
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Some bifidobacteria were identified in the initial feces. B. longum (identity 87%) was the predominant 
bifidobacteria in the first feces, B. bifidum (identity 92%) in the second feces and B. kashiwanohense 
(95% identity) in the third feces. The presence of B. longum and B. bifidum was expected as those 
bifidobacteria species are mainly represented in feces from breast-fed children (Di Gioia et al., 2014). 
Their presence in feces from formula-fed infants suggested they were able to maintain in long term, 
several months after breast-feeding stopped. This persistence has already been demonstrated in the 
study of Peiroten et al. (2018). B. kashiwanohense, a recently characterized species (Morita et al., 
2011), was isolated only in Japanese and Kenyan infant feces (Bunesova et al., 2016). 
B. kashiwanohense belongs to a small group of bifidobacteria encompassing B. longum subsp. infantis, 
B. bifidum, B. mongoliense and B. crudilactis, able to digest host glycans, including mucins but also 
HMO (Milani et al., 2015). During the third run, this bifidobacteria was identified many times as the 
dominant species. B. kashiwanohense was also identified during the second run, suggesting this 
species was initially present in the feces from the second donor. B. pseudocatenulatum was very 
represented in all runs. Considered as an adult-type bifidobacteria, B. pseudocatenulatum is also 
present in feces from breast-fed children. It was able to grow in different carbon sources and shared 
CAZY families with B. breve, B. dentium and B. longum (Benitez-Paez et al., 2016). B. catenulatum, 
only identified in the third run, is a species found in breast-fed children feces and its prevalence 
increased with age (Nagpal et al., 2017). B. crudilactis was only identified in the AC of the second run 
after the probiotic treatment. This bovine strain was able to resist stomach acidity (3.8-4.0) 
(Tanimomo et al., 2016), suggesting its survival in the SHIME® model. However, because of the low 
concentration of B. crudilactis FR/62/b/3 added to the system and the absence of a probe able to track 
this strain of interest more specifically, only the other dominant bifidobacteria species were detected. 
 
Modulation of virulence gene expression 
The feces inoculated in the SHIME® system and the implanted microbiota were able to modulate the 
virulence gene expression of E. coli O157:H7. However, probably due to different bacterial 
composition confirmed by the metagenomic analysis, the up-regulation of the luxS gene after a contact 
with feces was the sole statistically significant change. According to the linear regression analysis, the 
treatments had a significative effect on gene expression modulation, but no significant impact was 
attributed to a particular treatment.  
The concentration and the composition in SCFA are able to modulate the virulence gene expression of 
EHEC (Lackraj et al., 2016). In the small intestine, total SCFA concentrations are lower (20–40 mM) 
and contribute to overexpress EHEC genes involved in locus effacement of enterocyte (LEE) and in 
motility. In contrast, in the colons, total SCFA concentrations are higher (70–700 mM) and led to 
under-expression of these same genes (Lackraj et al., 2016). During the three runs, the total SCFA 
concentrations issued from the SHIME® model were closer to the concentrations found in human 
colons. However, the tested genes were not significantly down-regulated. In the small intestine, high 
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levels of acetate (10–30 mM) up-regulated the expression of ler and fliA genes in enteropathogenic 
(EPEC) E. coli and increased the motility and adherence of E. coli O127:H6 to Caco-2 cells. These 
effects were not observed with propionate and butyrate (Yang et al., 2018). The high acetate 
concentrations (above 10 mM) in this study did not significantly up-regulate the gene expression, as 
the propionate and butyrate concentrations.  
If prebiotics and probiotics might cause unexpected positive effect on virulence of pathogens, then 
they would have to be used with caution. A high concentration in butyrate decreased EHEC growth, 
while a low concentration (1.25 mM) increase virulence expression of genes involved in cell 
adherence and in attaching and effacing (A/E) lesions (Nakanashi et al., 2009). In addition, the 
interpretation of gene virulence analyses is very complex. Virulence gene expression analysis mimics 
in vitro conditions and a high acetate concentration that is supposed to be harmful (Yang et al., 2018) 
could also protect the host against E. coli O157:H7 by improving intestinal epithelium cell integrity 
and by inhibiting the passage of toxins to the systemic circulation (Rooks et al., 2017).  
 
16S rDNA sequencing analyses 
A high-throughput sequencing allows highlighting microorganisms present in high proportions in an 
environment, and some bacteria involved in biofilm formation have been detected. Biofilm formation 
was a major problem encountered during this experimentation. During the first run, the 
Stenotrophomonas genus became highly dominant in the three colons from the CFSM to the probiotic 
treatment. Stenotrophomonas rhizophila, the species attributed to the corresponding OTU, is close to 
Stenotrophomonas maltophila, bacteria involved in biofilm formation on abiotic surfaces (medical 
implants, catheters) (de Oliveira-Garcia et al., 2002). During the second run, Megasphera followed by 
Enterobacter were predominant in the SHIME® system. Megasphera_HQ748580, related to 
Megasphera massiliensis (by using the NCBI tool; identity 99%) could share some characteristics with 
Megasphera strain DISK 18 also involved in dental biofilms (Nallabelli et al., 2016). Finally, 
Enterobacter cloacae is known to have a high potential in biofilm formation (Asati et al., 2017; Sabir 
et al., 2017). At the end of the second run, Enterobacter cloacae proportions overran until 95% of the 
space, making the interpretation of metagenetic results difficult and probably not reliable. 
Megasphera_DQ905678, also related to Megasphera massiliensis (using NCBI tool; identity 99%), 
was involved in biofilm in the third run. 
Because of the abundance of nutrients and large surfaces, biofilm formation is often observed in the 
food industry or on plastic surfaces of medical devices (Costerton et al., 1995). The capacity of 
bacteria to adhere to surfaces, with for example, the presence of flagella, is an important parameter, 
but the hygienic status of the material is decisive (roughness, cleanability and vulnerability) (Van 
Houdt and Michiels, 2010). Although materials used in in vitro model conception is the same as 
materials used in the food industry, biofilm development in gastrointestinal models has never been 
described in the literature yet. This study is the first to mention their presence, which could have been 
Chapter 3  Study 3 
152 
unnoticed without a high-throughput sequencing analysis. A solution to avoid or delay biofilm 
formation in the SHIME® model would be to incorporate a “cleaning in place system” (Van Houdt et 
Michiels, 2010). Also, a more frequent change of tubing could be an alternative to the absence of a 
cleaning procedure. Initially, the bacteria involved in biofilm formation probably came from the donor 
feces.  The use of a standardized inoculum without biofilm-forming bacteria could improve of course 
the repeatability of the results and limit biofilm formation. However, steps should be taken to 
incorporate as many phylotypes as possible to mimic the diversity of actual feces. 
According to Koenig et al. (2011), the Firmicutes phylum is predominant at birth and progressively 
decreases during the two first years of life, while the Bacteroidetes phyla increases. The same trends 
were observed in the feces harvested from three donors in this study. The feces from the second donor, 
at the age of one year, contained a majority of Firmicutes (82%) and the second dominant phylum was 
the Bacteroidetes (18%). The feces from the first and third donor, aged two years, were less rich in 
Firmicutes (48% and 71.5 ± 7%, respectively) and richer in Bacteroidetes (48% and 27.5 ± 6%, 
respectively). After breast-feeding, the abundance of Bifidobacteriaceae, Enterobacteriaceae, 
Lactobacillaceae, Veillonellaceae, Clostridiaceae and Enterococcaceae families decreased, and, at 
two years-old, Bacteroidaceae, Lachnospiraceae and Ruminococcaceae families became dominant 
(Laursen et al., 2017). A microbial core present in feces from the majority of children was made of 
Bacteroides and Alistipes genera (phylum Bacteroidetes) and Ruminococcaceae and Lachnospiraceae 
families (phylum Firmicutes) (De Meij et al., 2015). In this study, the feces from the second donor 
were rich in Bacteroides and Ruminococcus genera and in Ruminococcaceae and 
Lachnoclostridiaceae families. The feces from the first and the third donors contained mainly 
Bacteroides and Faecalibacterium genera and a genus belonging to the Lachnospiraceae family. 
Prevotella was the dominant genus found in the feces from the first donor. The adult microbiota is 
distributed in three distinct enterotypes (Arumugan et al., 2012). By extrapolating the adult enterotype 
microbiota classification to young children, the donor 1 could belong to enterotype II, donor 2 to 
enterotype III and donor 3 to enterotype I. This is not surprising, and diet has an impact on young 
children gut microbial composition (Mancabelli et al., 2017; Shankar et al., 2017). The feces 
dominated by Prevotella (enterotye II) are observed with a diet rich in fibers, while the feces 
dominated by Bacteroides (enterotype I) are observed with a diet rich in proteins and fats (Graf et al., 
2015). Finally, feces dominated by Ruminococcus (enterotype III) are specialized in mucin 
degradation and are the most common one. However, those similitudes must be taken with caution 
because, as mentioned by Koenig et al. (2011), the non-stabilized microbiota of infants could still 
change over time. 
Although additional investigations have to be performed, a classification of infant microbiota in six 
main phylogenetic groups was proposed in the literature (Vallès et al., 2014; Milani et al., 2017). The 
group 1 is mainly composed of Enterobacteriales (Escherichia-Shigella spp.), the group 2 of 
Bacteroidales (Bacteroides spp. and Prevotella) and Verrucomicrobiales, the group 3 of 
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Selenomonadales (Veillonella spp.) and Clostridiales (genera Pseudoflavinofractor and 
Subdoligranum and Deltaproteobacteria Desulfovibrio), the group 4 of Pasteurellales, the group 5 of 
Clostridiales (Clostridium and Eubacterium) and the group 6 of Clostridiales (genera Anaerostipes, 
Faecalibacterium and Ruminococcus) and Lactobacillales (Enterococcus, Lactobacillus, 
Streptococcus) and Bifidobacteriales (Bifidobacterium). According to this classification, the first 
donor seems belong to the group 2, the second donor to the group 5 or 6, and the third donor to the 
group 2 or 6. 
Most known probiotics belong to the genera Lactobacillus and Bifidobacterium, but new promising 
strains have been proposed (Patel and DuPont, 2015). Akkermansia muciniphila and Faecalibacterium 
prauznitzii belong to this new generation of probiotic. A. muciniphila could be able to prevent or treat 
obesity and its associated metabolic disorders (inflammation, diabetes type 2) (Everard et al., 2013). 
These bacteria, frequently associated with a microbiota dominated by the Ruminococcus genus 
(enterotype III) (Guinane and Cotter, 2013; Derrien et al., 2016) was surprisingly identified in the 
feces from the first donor (enterotype II by extrapolation), and not in the feces from the second donor 
(enterotype III by extrapolation). Interestingly, A. muciniphila presence seemed to be maintained in 
the SHIME® model, especially after the probiotic and synbiotic treatments. F. prausnitzii possess anti-
inflammatory activities and its proportions are lower in patients suffering from Crohn disease and 
colorectal cancer (Rajilić-Stojanović and de Vos., 2014). With an average proportion of 37%, 
Faecalibacterium GQ897504 was very represented in the feces from the third donor and can be related 
to F. prausnitzii by using the NCBI tool. Interestingly, F. prausnitzii seemed to be maintained in the 
SHIME® model, especially after the synbiotic treatment. The potential growth or even maintenance of 
these two potential probiotics in the SHIME® system could highlight cross-feeding processes 
involving the carbohydrates and metabolites obtained from B. crudilactis FR/62/b/3 fermentation with 
or without the 3’SL. However, as this was observed only one time during the first run, future work 
should investigate other factors that may impact this process. This potential cross-feeding associated 
with the synbiotic treatment was also suggested by the increase of alpha-dispersion indexes such as 
Chao1, reciprocal Simpson biodiversity and evenness indexes. 
  




In conclusion, the SHIME® model is a comprehensive tool to study the interaction of probiotics, such 
as B. crudilactis FR/62/b/3, with the microbiota. The qPCR analyses highlighted the bifidobacterial 
survival all along the experimentation. The SCFA analyses showed the adaptation of the implemented 
microbiota in an anaerobic environment and the metagenetic analyses outlined the development of 
specific bacterial populations proper to each colon. In addition, due to the age of the donors (between 
one and two-years-old), this in vitro gastrointestinal tract seemed well adapted to study the toddler 
microbiota, with both infant and adult properties. Despite the presence of biofilms, the SHIME® model 
can be improved with incorporations of mucin, dialysis membranes or HMI modules, in order to be 
closer to the in vivo conditions. 
The combination of B. crudilactis FR/62/b/3 and 3’SL tended to a bifidogenic effect, probably due to 
some cross-feeding interactions. Interestingly, feces alone and the microbiota implanted in the model 
statistically influenced the virulence gene expression of E. coli O157:H7. In addition, the filtered 
supernatant obtained from the toddler’s feces was able to significantly up-regulate the luxS gene of 
this pathogen. Therefore, although additional experimentations need to be performed, the combination 
of B. crudilactis FR/62/b/3 and 3’SL seems encouraging for a synbiotic use to improve gastrointestinal 
health through modulating the gut microbiota. 
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Table S1 Impacts of filtrated supernatants obtained from feces (A), microbiota implemented in the 
SHIME® model without treatment (B) and microbiota implemented in the SHIME® model after 
prebiotic, metabolic, probiotic and synbiotic treatments (C) on virulence gene expression of E. coli 
O157:H7. 
 
AC: ascending colon; TC: transverse colon: DC: descending colon; Stabilization: period before starting the experiments and between each 
treatment; 3SL: prebiotic treatment with 3’-sialylactose; CFSM: metabolic treatment with cell free spent media obtained from culture of 
3’-sialyllactose and B. crudilactis FR/62/b/3; Bc: probiotic treatment with B. crudilactis FR/62/b/3; Bc+3SL: synbiotic treatment with 
3’-sialyllactose and B. crudilactis FR/62/b/3; ND: not determined. 
  
A) ler fliC luxS stx1 qseA
Feces 1 ND ND ND ND ND
Feces 2 1.6 -1.3 6.5 1.2 1.8
Feces 3a -1.3 1.1 4.3 -1.4 1.7
Feces 3b 1.6 1.4 5.3 1.0 2.2
B) ler fliC luxS stx1 qseA
AC TC DC AC TC DC AC TC DC AC TC DC AC TC DC
Run 1 -1.0 ± 0.5 0.1 ± 0.8 3.0 ± 0.3 -20.7 ± 9.9 -6.7  ±3.4 1.1 ± 1.1 0.1 ± 0.8 0.6 ± 0.5 0.9 ± 0.9 -1.9 ± 0.4 -1.5 ± 0.0 0.4 ± 0.4 2.1 ± 0.3 -0.1 ± 0.9 0.3 ± 0.3
Run 2 2.6 ± 0.6 3.2 ± 0.7 2.9 ± 0.6 1.7 ± 0.2 1.8 ± 0.1 1.6 ± 0.1 4.5 ± 1.5 3.9 ± 1.1 2.7  ±0.8 0.5 ± 0.8 1.2 ± 0.2 -0.6 ± 0.8 2.2 ± 0.2 2.1 ± 0.2 2.0 ± 0.2
Run 3 7.1 ± 4.9 4.4 ± 0.4 5.4 ± 2.3 0.6 ± 0.6 2.0 ± 0.5 1.3 ± 0.1 0.7 ± 1.6 2.0 ± 0.0 1.9 ± 2.0 -0.7 ± 2.1 -0.1 ± 0.0 -0.1 ± 1.2 0.9 ± 0.7 1.9 ± 0.1 2.2 ± 0.1
C) ler fliC luxS stx1 qseA
AC TC DC AC TC DC AC TC DC AC TC DC AC TC DC
3'SL
Run 1 1.1 -1.0 -2.6 -2.5 -6.3 -22.3 -2.0 -1.4 -2.2 1.5 6.1 -1.6 1.3 2.1 -1.7
Run 2 1.0 -1.2 1.2 1.3 1.0 1.7 1.5 -1.7 1.4 1.3 -1.5 1.2 1.7 -1.4 1.1
Run 3 -4.3 1.1 1.0 -1.5 1.2 -2.1 1.0 1.1 -1.7 -2.0 -9.0 -1.6 1.2 1.1 -1.7
CFSM
Run 1 -1.2 -1.6 1.2 2.3 -1.9 -6.4 -1.2 -1.1 1.1 -1.3 -1.1 1.7 -1.3 -1.1 -1.3
Run 2 3.2 2.9 1.7 -1.1 -1.1 -1.1 -1.6 1.2 1.9 1.4 1.2 1.2 1.0 1.3 1.1
Run 3 -3.9 1.2 1.0 1.2 1.0 1.8 -1.8 -2.0 -1.3 -2.7 -1.6 -1.1 -1.2 -1.5 1.5
Bc
Run 1 -3.4 -3.1 3.1 0.7 -20.3 3.1 -3.3 -2.0 -1.1 -1.3 1.2 -14.6 -3.4 1.1 1.5
Run 2 4.0 -3.6 -1.6 -1.8 -1.8 1.0 1.0 -1.7 -1.2 2.1 -1.2 -1.2 1.1 -1.6 1.0
Run 3 1.2 1.2 1.1 1.0 1.2 -1.1 1.0 1.4 -1.2 1.0 1.5 -1.1 -1.2 1.7 -1.5
Bc+3'SL
Run 1 2.1 1.3 ND 1.6 3.6 ND 35.2 3.5 ND 1.8 1.4 ND 2.9 3.3 ND
Run 2 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Run 3 1.0 1.3 -1.1 1.0 -2.0 -1.1 1.3 -3.3 1.6 -1.0 -1.4 -1.2 -1.0 1.3 -1.1
Figure S1 Impacts of filtrated supernatants obtained from feces (A), microbiota implemented in the SHIME® model without treatment (B) and microbiota implemented in the SHIME ®
model after prebiotic, metabolic, probiotic and synbiotic treatments (C) on virulence genes expression of E. coli O157:H7. 
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Table S2 Effects of prebiotic, metabolic, probiotic and synbiotic treatments on composition of 
microbiota implemented in the toddler SHIME® model during the first run. 
 
AC: ascending colon; TC: transverse colon; DC: descending colon; Stabilization: period before starting the experiments and between each 
treatment; 3SL: prebiotic treatment with 3’-sialylactose; CFSM: metabolic treatment with cell free spent media obtained from culture of 
3’-sialyllactose and B. crudilactis FR/62/b/3; Bc: probiotic treatment with B. crudilactis FR/62/b/3; Bc+3SL: synbiotic treatment with 
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Table S3 Effects of prebiotic, metabolic, probiotic and synbiotic treatments on composition of 
microbiota implemented in the toddler SHIME® model during the second run. 
 
AC: ascending colon; TC: transverse colon; DC: descending colon; Stabilization: period before starting the experiments and between each 
treatment; 3SL: prebiotic treatment with 3’-sialylactose; CFSM: metabolic treatment with cell free spent media obtained from culture of 
3’-sialyllactose and B. crudilactis FR/62/b/3; Bc: probiotic treatment with B. crudilactis FR/62/b/3; Bc+3SL: synbiotic treatment with 
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Table S4 Effects of prebiotic, metabolic, probiotic and synbiotic treatments on composition 
of microbiota implemented in the toddler SHIME® model during the third run. 
 
AC: ascending colon; TC: transverse colon; DC: descending colon; F1: first feces harvested from the third donor; F2: second feces harvested 
from the third donor; Stabilization: period before starting the experiments and between each treatment; 3SL: prebiotic treatment with 
3’-sialylactose; CFSM: metabolic treatment with cell free spent media obtained from culture of 3’-sialyllactose and B. crudilactis FR/62/b/3; 
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Ability of B. crudilactis FR/62/b/3 and 
B. mongoliense FR/49/f/2 to metabolize BMO 
and 3’SL 
 
Objective 1:  
Highlight the presence of the enzymes and transport systems involved in 
HMO/BMO metabolism in B. crudilactis LMG 23609 and B. mongoliense 
DSM 21395 genomes. 
 
B. mongoliense FR/49/f/2 and B. crudilatis FR/62/b/3 (also deposited as reference strain under the 
name LMG 23609) are both of bovine origin (Delcenserie et al., 2013). However, the B. mongoliense 
DSM 21395 reference strain has a glycobiome more sophisticated for digesting BMO compared to 
B. crudilactis LMG 23609, as determined using the CAZy database. According to this study, 
B. mongoliense DSM 21395 possesses many genes encoding enzymes belonging to the GH families 
involved in complex carbohydrate degradation, such as GH2 (β-galactosidase), GH3 (glucosidases), 
GH13 (amylases), GH20 (β-hexosaminidases), GH33 (α-sialidases), GH42 (β-galactosidases) and 
GH95 (α-fucosidases). All these genes are present in the B. crudilactis LMG 23609 genome too, 
except those encoding for GH20, GH95 and GH33, which are essential for HMO or BMO digestion 
(Milani et al., 2016). In addition, the transport system of B. mongoliense DSM 21395 seems more 
diversified than that of B. crudilactis LMG 23609. 
 
According to the CAZy database, B. mongoliense DSM 21395 can in theory digest most of the 
oligosaccharides found in BMO (Figure 25). This bifidobacterium metabolizes 3’SL using an 
extracellular α-sialidase but cannot internalize sialic acid, which is supposed to stay in the external 
environment. Then, lactose could be internalized using an ABC transporter and metabolized using a 
cytoplasmic β-galactosidase (Figure 25). According to the B. crudilactis LMG 23609 genome 
analysis, the BMO or 3’SL metabolism seems impossible without a previous cross-feeding step 
(Figure 25). Indeed, only the genes encoding for β-galactosidase have been identified, and the genome 
does not possess the genes encoding for α-sialidases or β-hexosaminidases, which are essential for 
complete BMO digestion. 
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Figure 25 Putative representations of the major molecular strategies in B. crudilactis LMG 23609 and 
B. mongoliense DSM 21395 for BMO utilization. 
 
HMO are mainly composed of type 1 components, such as LNB in LNT, whereas BMO are mainly 
composed of type 2 structures, such as LacNac in LNnT (Urashima et al., 2013). From analysis of the 
TCDB families, B. mongoliense DSM 21395 and B. crudilactis LMG 23609 might be able to transport 
LNB, a disaccharide associated with HMO. However, the very high E-values observed with 
transporters belonging to TCDB family 3.A.1.1.48 indicate a very low confidence index and suggest 
that another disaccharide close to LNB, such as LacNac, a BMO-associated disaccharide, could be 
internalized by B. mongoliense DSM 21395 or B. crudilactis LMG 23609 (Figure 23). Although this 
remains to be confirmed, this hypothesis would be more logical, because bifidobacteria of bovine 
origin are supposed to metabolize BMO in an easier way than HMO. 
 
In cow’s milk, the majority of BMO contain sialic acid, and fucose can be considered as non-present. 
In contrast, human milk is rich in fucosylated HMO, while few HMO are sialylated (Urashima et al., 
2013). For example, 2’FL is one of the most abundant HMO and contributes to infant microbiota 
shaping by improving the growth of beneficial bifidobacteria such as B. infantis (Thompson et al., 
2018). Interestingly, despite its bovine origin, the B. mongoliense DSM 21395 genome possesses 
putative fucosidase-encoding genes and could therefore be able to digest the majority of HMO (Figure 
23). This consolidates the hypothesis of Milani et al. (2014) who suggested bifidobacterium speciation 
by gene acquisition or loss from a common ancestor. 
 
 
















The phenotypic ability of bifidobacteria to grow on media supplemented with whey (rich in BMO) and 
3’SL has been tested in an attempt to partially answer previous question through the second objective. 
 
Objective 2: 
Determine if B. crudilactis FR/62/b/3 and B. mongoliense FR/49/f/2 are able 
to grow in the presence of whey (rich in BMO) and 3’SL, as the main 
source of carbohydrates. 
 
According to this work, the two strains are able to grow in media containing whey, rich in BMO, or 
3’SL, a major BMO. In addition, B. crudilactis FR/62/b/3 presented the best growth potential 
compared to B. bifidum BBA1, a bifidobacterial species associated with breastfed infant feces, 
particularly with whey or 3’SL instead of glucose.  
 
For all the bifidobacterial strains tested, the growth observed with media containing whey was higher 
than that observed with media containing 3’SL as the main source of carbohydrates. Indeed, in 
addition to BMO, whey is rich in lactose (FAO/OMS, 1998), a carbohydrate source easily consumed 
by bifidobacteria (Delcenserie et al., 2007).  
 
However, the important growth of B. crudilactis FR/62/b/3 observed with the medium containing a 
low quantity of 3’SL (0.85 g/L), as the main source of carbohydrates, was not expected. Genome 
analysis of B. crudilactis LMG 23609 indicated that this strain does not seem able to degrade 3’SL 
Perspectives: 
All data related to the genomic analysis of HMO or BMO utilization genes are predictions, and 
the metabolic pathways involving different transporters and enzymes have to be considered as 
putative. Therefore, other analyses would be of interest, such as: 
  -Expression studies using RT-qPCR targeting the genes corresponding to the different 
highlighted enzymes, such as sialidases or hexosaminidases, and allowing further understanding 
of the conditions in which those genes are expressed. 
  -Direct detection of the enzymes using proteomic analysis could also confirm the pathways 
highlighted using CAZy. 
  -The phenotypic ability of bifidobacteria to grow on different BMO-supplemented media. 
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without cross-feeding interaction. The hypothesis is that this growth could be due to the presence of 











The growth results presented in this study were considered as an indication of consumption and no 
conclusions can be made with these results alone. Indeed, the growth of B. mongoliense FR/49/f/2 
in medium containing BMO or 3’SL could be due to the presence of carbohydrate residues, 
including yeast extracts, present in the MRS medium used in previous steps. Therefore, the 
fermented media should be analyzed for the presence of metabolites, such as mono- or 
oligosaccharides, to fully understand BMO metabolism. 
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Virulence gene expression analysis 
 
Objective 3:  
Determine if CFSM obtained from medium supplemented with BMO and 
fermented by B. crudilactis FR/62/b/3 or B. mongoliense FR/49/f/2 contains 
metabolites able to modulate the virulence gene expression of E. coli 
O157:H7 and S. Typhimurium. 
 
According to the literature, the CFSM obtained from lactic acid bacteria or bifidobacteria contains 
metabolites which decrease the virulence gene expression of intestinal pathogens such as C. jejuni 
(Mundi et al., 2013), E. coli O157:H7 (Medellin-Peña et al., 2007) and S. enterica serotype 
Typhimurium (Bayoumi et al., 2012). In addition, CFSM obtained from medium supplemented with 
whey presents protective effects in EHEC-infected mice (Zeinhom et al., 2012). 
 
The same observations were globally observed according to in vitro analysis of E. coli O157:H7 
ATCC 43890 and S. Typhimurium ATCC 14028 gene expression.  
 
Regarding E. coli O157:H7, all or most of the virulence gene expression tested was decreased, 
excepted that of the fliC gene, after contact with CFSM obtained from a medium containing 3’SL or 
whey and fermented by B. crudilactis FR62/b/3 or B. mongoliense FR/49/f/2, respectively. 
Down-regulation of the fliC gene while other virulence genes are up-regulated has already been 
demonstrated in the literature (Carey et al., 2009; Mei et al., 2015; Singh et al., 2015). The fliC gene, 
not coded by the LEE operon, is not regulated in the same way as the other virulence genes involved 
in T3SS, especially the luxS gene (Kaper et al., 2004). This could explain why this “inverse” 
behaviour of the fliC gene was observed several times during the experiments. 
Interestingly, the same medium fermented by B. crudilactis FR/62/b/3 or B. mongoliense FR/49/f/2 
led to different virulence gene expression profiles. The hypothesis is that the metabolites produced by 
B. mongoliense FR/49/f/2 are different to those produced by B. crudilactis FR/62/b/3. This is in 
accordance with the genome analysis of these two bifidobacteria, which highlighted two different 
carbohydrate metabolic pathways using CAZy. 
 
Regarding S. Typhimurium, most of the virulence gene expression tested tended to be decreased after 
contact with CFSM obtained from a medium supplemented with 3’SL and fermented by 
B. mongoliense FR/49/f/2. 
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The hil and sopD genes are both involved in T3SS-1 and located in SP-1, contrary to the ssrB gene 
which is involved in T3SS-2 and located in SP-2 (Gart et al., 2016). In accordance with the literature, 
the hil and sopD genes systematically followed the same modulation. 
 
Then, the expression activity was tested in a gastrointestinal model, closer to in vivo conditions, but 
the previous results were not been confirmed. 
 
Interpretation of the modulation of virulence gene expression is very complex and has to be 
considered with caution, especially interpretation of the results obtained during the three experiments 
performed with the SHIME® model. The virulence gene expression of intestinal pathogens can be 
influenced by the presence of nutrients, which can interfere with QS mechanisms (Delcenserie et al., 
2012) as well as by the composition in SCFA mixes (Lackraj et al., 2016). As explained previously, 
some bioactive molecules issued from the metabolism of different bacteria are able to modulate the 
virulence gene expression of intestinal pathogens (Medellin-Peña et al., 2007; Bayoumi et al., 2012; 
Mundi et al., 2013). Therefore, the presence of some changing microbial populations in a highly 
nutritive medium, as observed in the SHIME® reactors, could interfere with gene expression and could 
explain why the results observed in the dynamic in vitro model did not confirm the results observed in 
the previous part of the study. 
 
Little is known about the exact nature of these metabolites. These bioactive molecules could be related 
to some carbohydrate residues, such as exopolysaccharides, if they are obtained from carbohydrate 
metabolism (Leroy and De Vuyst, 2016). According to the genome analysis of the two 
bifidobacterium strains, the carbohydrate residues obtained from BMO fermentation by 
B. mongoliense FR/49/f/2, such as sialic acid, glucose, galactose or GlcNAc, could be involved in this 
antivirulent effect. However, B. crudilactis FR/62/b/3 does not seem able to metabolize BMO, and the 
presence of such residues seems unlikely. 
 
These bioactive molecules could also originate from degradation of proteins, especially casein, present 
in high quantities in milk or whey. Probiotic bacteria, such as lactobacilli, are able to hydrolyze milk 
proteins during fermentation (Raveschot et al., 2020). For example, because of its specific cell 
envelope associated peptidases, Lactobacillus helveticus produces a large variety of bioactive peptides 
(BAP) from casein, such as the lactotripeptides isoleucyl-prolyl-proline and valyl-prolyl-proline 
(Raveschot et al., 2018). Bifidobacteria are also known to produce antimicrobial peptides, and more 
specifically bacteriocins, such as bifidine, bifidocine and bisine (Martinez et al., 2013). However, the 
results of this work suggest that the CFSM activity could be due to small peptides with an antivirulent 
effect without any antimicrobial impact, since the survival of the pathogen was not affected. 
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Because CFSM obtained from a medium without glucose and fermented by B. mongoliense FR/49/f/2 
or B. crudilactis FR/62/b/3 led to the down-regulation of all the E. coli O157:H7  or S. Typhimurium 
regulator or virulence genes tested, respectively, the activity of CFSM might be due to small peptides 
rather than glucidic residues. 
 
According to the results observed and the literature, these bioactive molecules could probably 
originate from protein degradation and could therefore be peptide residues. Tellez et al. (2012) 
demonstrated that bioactive components obtained from L. helveticus-fermented milk reduce 
Salmonella Enteritidis infection in mice and that bioactive fractions contain several peptide sequences. 
In a recent study, both exopolysaccharide-producing and non-producing strains of Lactococcus lactis 
subsp. cremoris JFR1 were able to down-regulate Salmonella virulence gene expression, meaning that 
these glycosidic metabolites cannot play a significant role (Zhang et al., 2016). In addition, the 
oligopeptide transport system of Salmonella seems essential for an antivirulence effect (Zhang et al., 
2019). Indeed, to be effective in vitro against Salmonella invasion into intestinal epithelial cells, milk 















The expression activity observed using RT-qPCR should be confirmed with: 
  -In vitro tests to evaluate the pathogen adhesion on intestinal cells, such as caco-2 cells or other 
cell lines. 
  -In vivo tests to evaluate the adhesion of pathogenic strains to intestinal epithelial cells. 
 
Identification of the nature of bioactive metabolites should also be investigated. The size and the 
nature (peptidic or other) of the bioactive metabolites could be confirmed by using techniques of 
chromatography associated with mass-spectrometry, enzymatic tests, mutant strains or other 
equivalent methods. 
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Challenges in the toddler SHIME® model 
 
Objective 4:  
Inoculate feces from young children in the ascending, transverse and 
descending colons of the SHIME® model, in order to reproduce the 
digestion process and a colonic environment.  
 
To date, the SHIME® model is the most complete in vitro system able to mimic both the upper and 
lower digestive tract compared to other models. For example, the PolyfermS model mimics only 
colons conditions, especially the ascending colon. The TIM-1 model reproduces the upper 
gastrointestinal tract and TIM-2 the lower gastrointestinal tract, but only in one reactor. However, TIM 
is able to reproduce peristaltic movements, while the SHIME® model simply pumps and stirs the food 
bolus. Contrary to SIMGI®, which also reproduces the entire gastrointestinal tract, mucin beads can be 
added in the SHIME® model to reproduce a mucosal microbiome (M-SHIME®) (Van den Abbeele et 
al., 2012, 2013a), as well as dialysis membranes mimicking the passive absorption process (Van de 
Wiele et al., 2015) as in the TIM. In addition, the absence of enterocytes or immune cells can be 
corrected by adding Caco-2 cells or macrophage cell line U937 (Venema et al., 2013). An HMITM 
module to study interactions with host cells during long-term incubation may also be incorporated 
(Marzorati et al., 2014).  
 
First of all, the proportion of SCFA (especially acetate, propionate and butyrate) allows confirmation 
of the stability and quality of the microbiota present. According to the literature, total SCFA 
concentrations in feces are between 50 and 150 mM (Rivière et al., 2016). In this study, the 
concentrations found in the reactors mimicking young children’s colons were in the same range as 
these data. This toddler gastrointestinal model was adapted from a dynamic adult model validated by 
Van den Abbeele et al. (2010), and for both models, the low concentrations of SCFA observed in the 
AC are explained by an acidic pH less favourable to bacterial growth and therefore to SCFA 
production (Van den Abbele et al., 2010). In in vivo conditions, the majority of the SCFA produced 
are absorbed (Hamer et al., 2008), and the high concentrations observed in the DC are probably due to 
the absence of absorption in this in vitro model and to an accumulation of SCFA, increasing from 
reactor to reactor (Cinquin et al., 2004; Van den Abbeele et al., 2010). 
 
Because of the age of the donors (between 1 and 2 years-old), the inoculated microbiota is different of 
those of neonates or young babies, and of course, from that of adults (Ottman et al., 2012). The SCFA 
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proportions measured in this in vitro system are between the normal values for infants and adults, 
suggesting that the toddler SHIME® model developed in this study shares both infant and adult 
characteristics. 
 
Specific quantification of the genus Bifidobacterium and an identification of the dominant 
bifidobacterium species were performed using qPCR targeting the hsp60 gene and a specific 
bifidobacterium 16S rRNA gene followed by sequencing, respectively. The presence of bifidobacteria 
in the reactor suggested that culture medium and the choice of the system parameters do not alter 
bifidobacteria growth, but identification of the dominant species lacked precision: indeed, the 
amplified gene could belong to another species present in a lower quantity. In addition, due to the low 
concentration of B. crudilactis FR/62/b/3 added to the system and the absence of a probe able to track 
it more specifically, this species was only identified once. 
 
The microbial environments developed in this toddler SHIME® model were well adapted to colon 
regions. As previously observed with the SHIME® model developed by Van den Abbeele et al. (2010), 
TC and DC were similar to each other. Conversely, richness observed in the AC was lower due to the 
environmental conditions, which are strongly different to the fecal conditions (pH, bile salts, nutrients, 
etc.). In addition, some bacteria more abundant in the small intestine, such as the genera Lactobacillus 
or Veillonella (Rajilić-Stojanović and de Vos, 2014), grew easily in the AC, suggesting that the 
environment reproduced in this reactor is close that of the human small intestine. 
 
The toddler SHIME® developed in this study was inoculated with feces from three different donors 
and the microbial populations detected by metagenetic analysis were not the same from one run to 
another. Interestingly, despite the different populations present, the SCFA concentrations were similar 
from one run to another, meaning that metabolic activity regarding SCFA profiles was similar for all 
microbiota implemented. 
 
High-throughput sequencing allows highlighting of the microorganisms present in high proportions in 
an environment, and some bacteria involved in biofilms formation were detected. Biofilms formation 
involved the genera Stenotrophomonas (run 1), Megasphera (runs 2 and 3) and Enterobacter (run 2). 
The majority of studies performing genetic analysis, such as DGGE, FISH or qPCR, target some 
specific populations (Cinquin et al., 2004, 2006; Van de Abbeele et al., 2010; Thevenot et al., 2013). 
This is probably why biofilm development in gastrointestinal models has not yet been described in the 
literature. This study is the first to mention their presence, which could be related to the use of high-
throughput sequencing analysis to identify microbiota. 
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Metagenetic analysis does not detect the populations present in low quantities. Therefore, the high 
proportions of bacteria involved in biofilm formation could hide the presence of minority populations. 
The use of a standardized inoculum without biofilm-forming bacteria could improve the repeatability 
of the results and limit biofilm formation. In addition, the use of a homogeneous inoculum could 
improve the repeatability of the experiments. 
 
As mentioned previously, colon region-specific microbial communities were able to develop in each 
compartment. However, DGGE analysis performed on the adult equivalent SHIME® model 
highlighted that the passage from an in vivo to an in vitro environment resulted in a shift of the 
microbiota, resulting in an increase of the Bacteroidetes/Firmicutes ratio. Moreover, Clostridium 
cluster IX (propionate producers) was enriched compared to Clostridium clusters IV and XIVa 
(butyrate producers), now classified as Ruminococcaceae and Lachnospiraceae families, respectively 
(Van den Abbeele et al., 2010). The high presence of bacteria involved in biofilm formation and 
highlighted by metagenetic analysis does not allow the calculation of a reliable 
Bacteroidetes/Firmicutes ratio. However, the model in this work probably suffers from this same shift, 
and the incorporation of a mucosal environment (M-SHIME®), as suggested by Van de Abbeele et al. 
(2012), could result in a better representation of the human intestinal microbial composition by 
increasing the Firmicutes representation. A toddler M-SHIME® model could allow colonization of 
Lactobacillus mucosae and Lactobacillus rhamnosus GG, in accordance with the in vivo conditions, 
and enrichment of Bacteroidetes and Proteobacteria phyla in the luminal content of the system (Van 
den Abbeele et al., 2012). The phylum Firmicutes preferentially colonizes the mucin layer with 
Clostridium cluster XIVa, accounting for almost 60% of the mucin-adherent microbiota. In the M-
SHIME® model, these butyrate-producing bacteria are mainly represented by Roseburia intestinalis 
and Eubacterium rectale (Van den Abbeele et al., 2013a). 
 
In addition, the incorporation of a mucosal environment could be favourable to the growth of mucosal 
bacteria involved in biofilm formation, such as Bacteroides (Macfarlane and Dillon, 2007), and could 
prevent unwanted bacteria biofilm formation by competition.  
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Objective 5:  
Evaluate the prebiotic (3’SL), probiotic (B. crudilactis FR/62/b/3), synbiotic 
(3’SL+B. crudilactis FR/62/b/3) and CFSM (metabolites) effects on the 
microbiota of young children implemented in the SHIME® model. 
 
According to our observations, the synbiotic combination of B. crudilactis FR/62/b/3 and 3’SL could 
be responsible for an interesting bifidogenic effect, probably due to a cross-feeding mechanism.  
 
In addition, the maintenance of Akkermansia muciniphila and Faecalibacterium prausnitzii, two 
promising species belonging to the new generation of probiotics (Patel and DuPont, 2015), was 
observed in the SHIME® model, especially after the synbiotic treatment. These results were observed 
only once during the first run and cannot be considered as significant. However, the potential growth 
or even maintenance of these two bacteria in the SHIME® system could highlight an interesting cross-
feeding process which could involve the carbohydrates and metabolites obtained from B. crudilactis 
FR/62/b/3 fermentation with or without 3’SL.  
 
This potential cross-feeding process associated with synbiotic treatment was also suggested by the 
increase of alpha-dispersion indices such as Chao1, reciprocal Simpson biodiversity and evenness 
indices. These highlighted cross-feeding phenomena are in accordance with analysis of the 
B. crudilactis LMG 23609 genome in which some genes involved in BMO degradation (β-
galactosidases), have been identified. However, their presence must be associated with a cross-feeding 






























The table 9 summarizes the different results observed in this work, as well as their corresponding 
limitations and perspectives. 
Perspectives: 
-Determine the proportions of the different bifidobacterial species present using high-throughput 
sequencing targeting bifidobacterial species. 
-Develop qPCR based on B. crudilactis FR/62/b/3 probe detection, in order to track more precisely 
the bifidobacteria of interest in this work. 
- Use a standardized inoculum to improve the repeatability of the results and limit biofilm 
formation. 
- Complete the results with other genetic analyses targeting some specific populations, such as 
DGGE, FISH or qPCR, to precisely follow the microbial population evolution. 
-Incorporate mucin beads in the SHIME® model (M-SHIME®) to reproduce a mucosal 
environment and to obtain bacterial populations proportions closer to those in in vivo conditions. 
-Test the synbiotic combination of B. mongoliense FR/49/f/2, containing a more sophisticated 
enzymatic pathway regarding BMO digestion, with 3’SL in the toddler SHIME® model. 
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Table 9 Results observed in this work and their corresponding limitations and perspectives. 
  
Chapter 4  Discussion & perspectives 
177 
B. crudilactis FR/62/b/3 and 
B. mongoliense FR/49/f/2 in the future 
 
 
The European Commission is very careful about the health claims attributed to potential probiotics. 
The only health claim authorized for probiotics concerns the yoghurt, which contains the starter 
microorganisms Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus. Indeed, 
probiotic bacteria found in yoghurt improve lactose digestibility, which is considered as a beneficial 
physiological effect for individuals with lactose maldigestion (EFSA, 2010). 
 
Finally, to be considered as probiotic, B. crudilactis FR/62/b/3 and B. mongoliense FR/49/f/2 strains 
will need further investigations. For example, in order to obtain the qualified presumption of safety 
(QPS) status, the whole genome sequencing of these strains should be analyzed in order to highlight or 
not some genes involved in antibioresistance or in virulence factor. In addition, a phenotypic testing 
based on minimum inhibitory concentration for different antimicrobials has to be carried out. 
Taxonomic identity, body of knowledge and safety will also have to be established (EFSA, 2018). 
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To conclude, this work contributes to improve the knowledges of HMO/BMO metabolism by 
B. crudilactis FR/62/b/3 and B. mongoliense FR/49/f/2, two strains of bovine origin. Their synbiotic 
combination with BMO, especially 3’SL, could result in the presence of bioactive metabolites able to 
decrease the virulence gene expression of intestinal pathogens. In addition, the synbiotic combination 
tested on the microbiota implemented in the toddler SHIME® model tended to a bifidogenic effect. 
These two bifidobacteria could be favorable to child health. However, B. mongoliense DSM 21395 
seems have a glycobiome more sophisticated for digesting HMO and BMO compared to B. crudilactis 
LMG 23609. 
 
Finally, the SHIME® model developed in this study is an adaptable and well-performing tool for 
studying the microbial interactions in a toddler microbiota, sharing both infant and adult microbiota 
properties. 
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